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Abstract 
 
Oculocerebrorenal syndrome of Lowe (OCRL) is caused by mutations in a 
phosphatidylinositol 5-phosphatase, OCRL1, and is believed to lead to an 
elevation of its preferred substrate, PI(4,5)P2. To date, much of the work on 
OCRL1 has centred on its role at Golgi and endosomal membranes. 
However, there is also evidence of plasma membrane activity for OCRL1, 
where its PI(4,5)P2 substrate is known to be highly abundant. PI(4,5)P2 
regulates a wide array of downstream cellular functions such as cytoskeletal 
dynamics, membrane trafficking and signalling. The tight regulation of 
PI(4,5)P2 levels and localisation, like other phosphoinositides, provides a 
framework upon which many of these cellular processes work. In this thesis, 
effects of OCRL1 loss have been tested through siRNA depletion of OCRL1, 
focussing where possible on multiple PI(4,5)P2-dependent mechanisms, and 
also focussing on cells forming polarised epithelia. Firstly, we have visualised 
the localisation of PI(4,5)P2 in living HeLa cells lacking OCRL1 through 
immunostaining for Annexin A2, which showed a marked translocation to the 
plasma membrane. This change in distribution of Annexin A2 suggested that 
OCRL1 depletion may have an effect on intracellular calcium dynamics as 
well as PI(4,5)P2 localisation. We also used a GFP-chimera of the well 
characterised PI(4,5)P2-binding pleckstrin homology domain of PLCδ1. This 
showed no difference in localisation upon OCRL1 depletion. As OCRL1 is 
highly enriched at the TGN, we fused the pleckstrin homology domain of 
PLCδ1 to a mutated pleckstrin homology domain of OSBP known to bind   3 
ARF1 at the TGN, to act as a coincidence detector for PI(4,5)P2 at the TGN. 
This construct also showed no reproducible effect of OCRL1 depletion.  
 
Secondly we tested the effect of loss of OCRL1 on cytosolic calcium levels. 
Using two phospholipase C (PLC) agonists, and a SERCA pump inhibitor, we 
found no consistent differences in calcium handling upon depletion of OCRL1. 
Thirdly, we have assessed the potential specialised role that OCRL1 has in 
polarised epithelial cells, which might relate to the clinical picture in Lowe 
Syndrome. We found that OCRL1 targets the tight junctions of immortalised 
lines and primary cells. Through co-immunoprecipitation, we found OCRL1 in 
complexes with the tight junction scaffold protein ZO-1. Most significantly, we 
found that depletion of OCRL1 in human polarised epithelial cell lines 
interfered with epithelial differentiation, reducing cell number and altering 
morphology, to produce large flat cells. We attribute this phenotype, stronger 
than any other so far described experimentally, to a defect in tight junction 
maturation.    4 
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1: Introduction 
 
Oculocerebrorenal disease of Lowe (OCRL), otherwise known as Lowe 
Syndrome, is an X-linked recessive disease that manifests in patients with in-
born bilateral cataract, mental retardation and a selective proximal 
tubulopathy. The renal disorder in Lowe Syndrome is characterised by low 
molecular weight proteinuria and hypercalciuria, which eventually progresses 
to renal failure, commonly in the second decade. The disease gene, OCRL1, 
was discovered in 1992; its transcript encodes an inositol polyphosphate 5-
phosphatase
1. Thus, OCRL likely arises from an inborn error in inositol lipid 
metabolism, and this is one of very few hereditary diseases that directly link 
phosphoinositides to disease. 
 
Phosphatidylinositol is an important cellular lipid, both as a key membrane 
constituent and as a participant in metabolic processes, a number of its 
metabolites being significant signalling molecules. Phosphatidylinositol is 
synthesised at the endoplasmic reticulum and is delivered to other 
membranes either by vesicular transport or via cytosolic phosphatidylinositol 
transfer proteins, where it can then be modified in a number of ways 
2. The 
inositol ring of phosphatidylinositol can be reversibly phosphorylated at 
positions D3, D4 and D5. The different combinations of which give rise to 
seven phosphoinositide isomers 
3. Interconversion of phosphoinositides 
through lipid kinase and lipid phosphatase activity occurs in a manner strictly 
regulated spatially and temporally.  
   24 
The resulting abundancies of different phosphoinositide at distinct sites within 
the cell (Figure 1.1) can result in the recruitment, and thereby activation, of a 
wide array of different proteins important in regulating a variety of cellular 
processes 
4-6. Phosphoinositide binding domains respond to phosphorylation 
events occurring at the membrane, and respond to the temporal and spatial 
regulation of phosphoinositide levels 
7. Many proteins demonstrated to play 
important roles in a wide range of cellular processes such as membrane 
trafficking, cell signalling and cytoskeletal organisation have phosphoinositide 
binding domains that drive their recruitment to sites of activity or enzyme 
substrates 
8, 9. The best examples of modular domains that bind 
phosphoinositides are the well-studied Pleckstrin homology (PH), Phox 
homology (PX) and epsin N-terminal homology (ENTH) domain families 
10. In 
order to visualise where these lipids accumulate within the cell, many of these 
domains have been isolated, characterised for their phosphoinositide 
preference and expressed in cells as green fluorescent protein (GFP) 
chimeras 
11. This method of detecting where certain phosphoinositides are 
localised within the cell has revealed a very highly ordered cellular map, with 
different classes of phosphoinositide accumulating at specific membranes 
(Figure 1.1). For example, the PH domain of oxysterol binding protein (OSBP) 
has been used as a coincidence detector of Golgi PI(4)P. PI(4)P generation at 
the Golgi coordinates many events, such as vesicular trafficking from the TGN 
to the plasma membrane and modification of key lipids such as 
glycosphingolipids . Wang et al. demonstrated the importance of Golgi PI(4)P 
generation through their studies on PI4KIIalpha 
12. By specifically generating 
PI(4)P at the Golgi, the cell creates a signal to recruit clathrin adaptor AP-1.   25 
Figure 1.1: Phosphoinositides and membrane identity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 
This diagram depicts a model whereby specific phosphoinositides 
preferentially accumulate at distinct organelles within the cell. For instance, 
the major pool of PI(4,5)P2 has been shown to be at the plasma membrane. 
However, there is also evidence of small pools of PI(4,5)P2 existing at 
different organelles, such as the Golgi and nucleus 
13, 14. PI(3)P has been 
shown to be enriched at early endosomes, and there is some evidence of 
= Early  
endosomes  
PI(3)P 
= Golgi/TGN 
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membrane 
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   PI(3,5)P2   26 
PI(3,5)P2 at the late endosome/lysosome 
15-18. Least convincingly fitting this 
model is PI(4)P. It has been shown that PI(4)P is highly enriched at the Golgi 
apparatus and plays multiple roles at this site 
19-21. However, there is some 
data showing that there is a pool of PI(4)P at the plasma membrane, 
presumably as a precursor to PI(4,5)P2 
22. It is thought that the enrichment of 
these lipids at different organelles aids the recruitment of proteins to their 
desired site. These lipids have been shown to have a wide variety of roles, 
varying from PLC signalling (PI(4,5)P2) to the release of vesicles from the 
TGN (PI(4)P), discussed below.   27 
 
This enzyme was shown to generate the majority of Golgi PI(4)P and without 
it, AP-1 fails to target the Golgi and AP-1 dependent post-Golgi events are 
inhibited. Another example of the importance of Golgi PI(4)P can be drawn 
from work carried out on the four phosphate adaptor protein-2 (FAPP-2). The 
PH domain of FAPP-2 has been used as a co-incidence detector for PI(4)P; 
when the ability of FAPP-2 PH to interact with phosphoinositides is disturbed, 
TGN to plasma membrane transport is inhibited 
23. The work with PI(4)P 
indicating it is more widely distributed than is commonly thought from 
simplistic assessment of results with a selected group of reporters, which are 
actually are more like co-incidence detectors, is a notion that is highly useful 
and applicable to PI(4,5)P2 as well. PI(4,5)P2 has classically been shown to 
be abundant at the plasma membrane through studies using the PH domain 
of phospholipase C delta (PLCδ-PH) 
22, 24, but it may be that it has a wider 
distribution when methods do not involve coincidence detection 
13. The 
importance of PI(4,5)P2 abundance at the plasma membrane is described in 
detail later in the introduction. However, this section provides two examples of 
the significance of plasma membrane PI(4,5)P2. Firstly, it has been found that 
PI(4,5)P2 is required for the early and late events in formation of endocytic 
coated vesicles 
25. Furthermore, many signal transduction events work via 
receptor mediated PLC hydrolysis of PI(4,5)P2. In a recent study, it was 
shown that IP3-mediated signalling cannot occur when PI(4,5)P2 is depleted 
from the plasma membrane 
26. This was achieved utilising an artificial system 
whereby a recombinant inositol 5-phosphatase is recruited to the plasma 
membrane.     28 
 
By contrast to 4-phosphorylated PIPs, phosphatidylinositol 3-phosphate 
(PI(3)P) has been demonstrated to be highly enriched at early endosomes 
and its levels and downstream signalling regulates proteins important in 
sorting endocytosed receptors from endosomes to lysosomes 
27. For 
example, PI(3)P-binding protein Hrs (hepatocyte growth factor regulated 
tyrosine kinase substrate) mediates endosomal sorting of growth factor 
receptors 
28. PI(3)P has also been shown to recruit a kinase that converts 
PI(3)P into PI(3,5)P2, named PIKfyve, an enzyme now shown to partake in 
multiple membrane trafficking pathways such as EGFR trafficking to the 
nucleus and exocytosis in neurosecretory cells 
29, 30. PI(3,4,5)P3 is present at 
very low levels in cells at rest. Upon many different stimuli, PI(3,4,5)P3 is 
generated at the plasma membrane through the actions of PI3K. PI(3,4,5)P3 
engages in a variety of processes at the plasma membrane  such as 
phagocytosis, regulated exocytosis, and cytoskeletal organisation 
6, 31. 
 
Responsibility of maintaining the identity and function of cellular membranes 
through the segregation of phosphoinositides falls on the shoulders of 
proteins able to modulate them; this can be through interconversion by 
phosphoinositide kinases and phosphatases, or by their hydrolysis through 
phospholipases 
4, 32-34. OCRL1 is a type-II inositol polyphosphate 5-
phosphatase 
35. The acronym OCRL stands for Oculocerebrorenal syndrome 
of Lowe, an X-linked disorder. Pathological mutations in the OCRL1 gene 
invariably cause almost complete absence of OCRL1 protein and an elevation 
of its preferred substrate, PI(4,5)P2 
36.    29 
 
OCRL1 has a central inositol 5-polyphosphate phosphatase domain that has 
been shown to be responsible for dephosphorylation of phosphoinositides and 
inositol phosphates at the D5 position of the myo-inositol ring 
37, 38. OCRL1 
belongs to a family of ten mammalian 5-phosphatases (Figure 1.2) (four 
members expressed in yeast) that have been shown to have a wide range of 
functions, such as synaptic vesicle re-cycling, hematopoietic cell function and 
insulin signalling 
33. In order to appreciate where OCRL1 fits within this 
enzyme family, knowledge of the cellular roles played by other 5-
phosphatases is required. A great amount of work has been carried out on 
other mammalian 5-phosphatases such as synaptojanin 1, synaptojanin 2, 
SHIP1 and SHIP2. 5-phosphatases identified more recently include SKIP and 
PIPP 
39, 40. However, there are many differences in function and activity, as 
well as differences in the expression pattern of this enzyme family. The full 
map of where these proteins act is not yet known, which causes difficulty in 
interpreting the level of redundancy between them. The clearest and most 
obvious level of redundancy can be found with studies comparing INPP5B 
and OCRL1. Knock-out INPP5B and OCRL1 mice are viable and have few 
abnormalities 
41. However, upon crossing mice deficient in OCRL1 to mice 
deficient in INPP5B, no live born mice were found. This demonstrates the high 
level of redundancy between these two proteins. The similarity between these 
proteins is discussed later. By definition, each member of this enzyme family 
contains a central conserved 5-phosphatase catalytic domain. The crystal 
structure of an archetypal 5-phosphatase has revealed the 5-phosphatases 
belong to the AP endonuclease family with a His/Asp active site pair 
33.    30 
 
Figure 1.2: The inositol polyphosphate 5-phosphatase family 
 
 
Legend 
This diagram depicts the similarities and differences in domain structure 
between the inositol polyphosphate 5-phosphatase proteins, with the shared 
5-phosphatase domain aligned to the centre. OCRL1 and INPP5B form a 
subfamily of 5-phosphatases with ASH and RhoGAP domains.
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OCRL1 and another 5-phosphatase, INPP5B, differ from other family 
members by having a carboxy-terminal domain homologous to Rho-GTPase 
activating proteins (Figure 1.2). This domain has been shown to have no 
GTPase activity, but does regulate the ability of OCRL1 to bind various small 
GTPases, notably Cdc42 and Rac1 GTPases and ADP-ribosylation factor 
(ARF) family members ARF1 and ARF6 
42, 43. A great number of the Rab 
family of small GTPases have also been shown to bind the OCRL1 linker 
region between the phosphatase domain and Rho-GAP homology domain 
44, 
45, now known to co-incide with the ASH (ASPM, SPD-2 and Hydin) domain. It 
is believed that binding to these small GTPases is the major driving factor in 
OCRL1 localisation to the trans-Golgi network (TGN) and the endosomal 
system 
44, 46. It has also been shown that OCRL1 translocates to the plasma 
membrane upon growth-factor stimulation in a Rac1-dependent manner 
47. 
Recently it has also been revealed that binding to GTP-locked Rab GTPases 
in vitro is sufficient to increase OCRL1 enzyme activity 
44. This suggests that 
OCRL1 recruitment to membranes containing these GTPases is synonymous 
with inositol polyphosphatase 5-phosphatase activation and is physiologically 
relevant to its function. These data suggest that the RhoGAP domain within 
OCRL1 is important in its recruitment to inositol polyphosphate 5-phosphatase 
substrates. These binding events may alter the conformation and activation of 
the full-length OCRL1 protein. The idea that overall protein structure is 
regulated by the ASH domain is supported by the observation that Lowe 
Syndrome patients express a wide spectrum of single amino-acid mutations 
within the ASH and Rho-GAP domains 
48-50. On either side of the central   32 
 
inositol polyphosphate 5-phosphatase domain of OCRL1 are two motifs that 
co-ordinate binding to proteins important in clathrin-mediated endocytosis and 
membrane trafficking. These two short motifs within OCRL1, by single letter 
amino acid code: LIDLE and FEDNF, have been shown to mediate binding of 
OCRL1 to clathrin heavy-chain and the clathrin adaptor protein-2 (AP-2), 
respectively (Figure 1.3). Not only does OCRL1 bind these molecules but it 
has also been demonstrated in vitro to facilitate the formation of clathrin cages 
51, 52. Alternative splicing in an exon adjacent to the LIDLE motif of OCRL1 
gives rise to two (one short and one long) isoforms of OCRL1. These isoforms 
arise due to tissue-specific splicing and differ by the presence or absence of a 
stretch of eight amino acids (EDSFLEKE), immediately downstream of the 
LIDLE motif. Both isoforms are expressed in all tissues, with the short isoform 
of OCRL1 the more abundant of the two 
53. The only exception to this arises 
in the brain, where only the long isoform is expressed. The significance of 
alternative splicing of OCRL1 and potential differences in the clathrin binding 
activity of each isoform has not yet been elucidated. INPP5B does not have 
clathrin binding motifs, but contains the same carboxy-terminal domains as 
OCRL1, such as the ASH and RhoGAP homology domain. INPP5B, unlike 
OCRL1, does however contain a carboxy-terminal CAAX box allowing it to be 
prenylated, thus increasing its affinity for membranes (Figure 1.3). However, 
the differences between OCRL1 and INPP5B proteins may not be functionally 
significant, as there is some evidence that the reason why Lowe syndrome 
affects only a few tissues is that INPP5B can compensate for it. This    33 
Figure 1.3: Schematic of OCRL1 and INPP5B domain organisation 
 
   
 
 
 
 
 
Legend 
OCRL1 and INPP5B differ from the other eight 5-phosphatases by their 
carboxy-terminal domains with homology to Rho-GAPs. These domains do 
not have any GAP activity for GTPases. Nevertheless, this domain in OCRL1 
facilitates binding to Rac1, Arf1, Arf6, and Cdc42 to a lesser extent, not being 
specific for the active forms 
42, 43, 54. The homologous domain in Inpp5b has 
not been studied in detail. The ASH domain in both proteins has been shown 
to facilitate binding to multiple Rab GTPases 
44. The overlap in specificity 
directs both phosphatases to early endosomes and the Golgi 
52, 55. The ASH 
and RhoGAP domains together of both OCRL1 and INPP5B bind to the 
endocytic adaptor APPL1 
54. OCRL1 also has two motifs that interact with 
clathrin heavy chain (LIDLE and LIDIA), and one that binds to AP-2 (FEDNF), 
all these being absent from INPP5B 
52. An NMR structure has been reported 
for the extreme amino-terminal of OCRL1 by Prof. P de Camilli (Personal 
communication). This region apparently folds into a PH-like fold, but there is 
no electro-positive pocket, so binding to PIPs is highly unlikely. 
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mechanism is suggested by the work of Prof. R Nussbaum constructing a 
mouse model of Lowe Syndrome. While single knock-out of INPP5B or 
OCRL1 is viable, double INPP5B and OCRL1 knock-out in mice is lethal. This 
suggests that INPP5B complements the loss of OCRL1 in the mouse. To 
explain why INPP5B does not complement OCRL1 loss in humans, analysis 
of murine and human INPP5B reveals that the two genes differ in structure. 
There is alternative splicing at exon 7 of the murine INPP5B gene, leading to 
increased transcripts (though truncated at the 5’ end). For this reason, work is 
currently being undertaken to “humanise” the 5-phosphatase pathway in mice 
by placing human INPP5B onto an INPP5B knock-out background and 
crossing this mutant with the OCRL1 knock-out mouse (personal 
communication, Prof. R Nussbaum). 
 
Recently, data has shown that OCRL1 is recruited to late-stage, endocytic 
clathrin-coated pits and binds the Rab5 effector APPL1, on peripheral early 
endosomes 
54. Bioinformatics studies predicted that OCRL1 contained an 
ASH domain in-between its RhoGAP and 5-phosphatase domains 
56. This 
prediction has now been validated through structural studies of the interaction 
of OCRL1 with APPL1, involving the first determination of an ASH domain 
structure. The ASH domain was shown to have a super-immunoglobulin-like 
fold, similar to VAP. This interaction is mediated by the ASH and RhoGAP 
domains of OCRL1 and is abolished by described disease mutations 
50, 54. 
This study suggested that the interaction between OCRL1 and APPL1 
provided links with protein networks that may be dysfunctional in Lowe 
Syndrome. The PTB domain of APPL1 binds directly cell surface receptors,   35 
including DCC (deleted in colon cancer), adiponectin, FSH receptor, and TrkA 
57-60. It is possible that OCRL1 loss of function could affect one or many 
signalling pathways downstream of these receptors. For instance, activation 
of TrkA results in the generation of PI(3,4,5)P3 and the activation of AKT
61. 
Interestingly, AKT has been found to be a binding partner of megalin, a 
protein shown to be less abundant in Lowe Syndrome patient urine 
62. It has 
been suggested before that abnormal recycling of megalin to the plasma 
membrane may be responsible for the abnormal protein reabsorption and 
proximal tubulopathy observed in Lowe Syndrome patients 
63. Furthermore, it 
has been suggested that abnormal TrkA (and other aforementioned receptors 
expressed in the brain) trafficking underlies the CNS defects exhibited by 
Lowe Syndrome patients. However attractive these models may be, it must be 
added that although OCRL1 translocates to clathrin-coated pits at the 
plasma membrane, this group observed no defect in endocytosis upon 
OCRL1 depletion in this studies. (Personal communication, Prof. P. de 
Camilli) 
 
The confirmed localisations and binding partners of OCRL1 implicate a role in 
the regulation of membrane traffic, something of which was demonstrated by 
Choudhury et al. in 2005. In this study, defective trafficking of shiga toxin 
(STxB) from early endosomes to the TGN in cells over-expressing OCRL1 or 
a 5-phosphatase domain deletion mutant form of OCRL1 was demonstrated. 
OCRL1 depletion by RNAi results in redistribution of CI-MPR and TGN46, 
TGN-resident proteins, to early endosomes supporting the theory that OCRL1 
regulates vesicular membrane traffic 
52. Whether this partial redistribution of   36 
markers is PI(4,5)P2 dependent or independent is unclear. It is possible that 
the function of some membrane trafficking proteins may be regulated by 
changes in phosphoinositide levels due to OCRL1 loss. For instance, if Golgi 
PI(4)P is less abundant upon OCRL1 loss, it is possible that the previously 
described effects of loss of PI4KIIα function could be reproduced 
12. This 
general theory may prove to be true if OCRL1 activity is targeted to Golgi 
pools of phosphoinositides. 
 
However, loss of OCRL1 may affect the normal function of proteins through 
PI(4,5)P2-independent mechanisms, such as scaffolding of other proteins, 
including small GTPases. The activity of proteins integral in regulation of 
TGN-to-endosome vesicular trafficking may potentially be altered by OCRL1 
depletion. Trafficking of STxB is regulated by Rab6 
64. It is possible that 
OCRL1 plays pivotal roles in the availability of Rab6, suggested by the finding 
that STxB trafficking is perturbed by over-expression of OCRL1 
52. This may 
be a general mechanism for all small GTPases that bind OCRL1. Overall, 
effects may be a result of both PI(4,5)P2-dependent and PI(4,5)P2-
independent mechanisms.  
 
PI(4,5)P2- dependent mechanisms have been suggested to be responsible 
for an altered actin phenotype in Lowe Syndrome patient fibroblasts. As 
previously suggested, upon loss of OCRL1 function, PI(4,5)P2 may become 
elevated at sites OCRL1 is normally resident. PI(4,5)P2 has been shown to 
have dramatic effects upon the regulation of proteins instrumental in the 
organisation of the actin cytoskeleton such as gelsolin and proflin 
65. This   37 
raises the possibility that dysregulation of PI(4,5)P2 levels at internal sites 
within the cell may be responsible for the actin phenotype in Lowe Syndrome 
patient cells. Fibroblasts from Lowe Syndrome patients have increased 
punctate actin staining that colocalises with actin-modulating proteins 
previously shown to bind or be activated by PI(4,5)P2. This punctate pattern 
of actin is concomitant with a loss of actin stress-fibres 
66.  
 
Whether PI(4,5)P2 accumulates at internal membranes after OCRL1 
depletion is uncertain. The potential to generate PI(4,5)P2 at internal 
membranes is suggested by studies that show PI(4)P5K activity is present in 
isolated Golgi membrane fractions 
67. Furthermore, PI(4)P5Ks can be 
stimulated through ARF activity, linking levels of PI(4,5)P2 with vesicular 
trafficking 
68. However, the presence of PI(4,5)P2 at these internal 
membranes has not been shown directly, apart from one study by Watt et al. 
in 2002 (discussed later) 
13. There is an important question in analysing the 
cellular role of OCRL1: is it possible to accurately visualise the 
phosphoinositides with which it interacts and creates? The nature of the lipid 
molecule creates a problem; there is no perfect tool available to enable direct 
visualisation of endogenous lipids within the cell. This means that visualisation 
of subcellular sites of lipids is limited to the affinity and accuracy of fluorescent 
probes that can bind them. For example, GFP chimeras of the PH domain of 
PLCδ are used to visualise PI(4,5)P2, a phosphoinositide known to be highly 
abundant at the plasma membrane 
11, 69. However, the localisation of PLCδ-
PH-GFP to the plasma membrane is due to PI(4,5)P2 head-group specific 
interactions in combination with an affinity for anionic environments at the   38 
plasma membrane
70, 71. This leads to confusion in interpreting the PLCδ-PH-
GFP signal; localisation at the plasma membrane is not wholly driven by 
PI(4,5)P2 levels. The general affinity of PLCδ-PH-GFP for the plasma 
membrane means that visualising potential sites of PI(4,5)P2 elevation at the 
Golgi apparatus or endosomes upon loss of OCRL1 may not be possible, 
although previous work in yeast by Stefan et al. in 2002 demonstrated 
increases in PI(4,5)P2 upon inactivation of the cell’s complement of 
synaptojanins, leaving no 5-phosphatase activity 
72. PI(4,5)P2 accumulated in 
intracellular compartments, reported through use of 2xPLCδ-PH fused to 
GFP. Interestingly, this study also revealed cellular phenotypes similar to 
those demonstrated in Lowe Syndrome patient fibroblasts and OCRL1 
depleted cells. Synaptojanin-like protein inactivation led to a loss of 
organisation of the actin cytoskeleton and impaired clathrin mediated 
membrane traffic 
72. Loss of OCRL1 function and inactivation of the inositol 
polyphosphate 5-phosphatase domain of the synaptojanin-like proteins lead to 
similar cellular phenotypes. This suggests that a common PI(4,5)P2 
mechanism is in place and warrants further investigation. As referred to earlier 
in this section, evidence of low levels PI(4,5)P2 at internal membranes has 
been demonstrated through immuno-electron microscopical analysis of on-
section labelling with PLCδ-PH 
13. In this study, PLCδ-PH labelling of ultra thin 
cell sections verified the high abundance of PI(4,5)P2 at the plasma 
membrane. In addition to this, but to a lesser extent, PLCδ-PH was also 
detected on the Golgi stack, endosomes and in the nucleus. Potentially, this 
low level of PI(4,5)P2 on internal membranes is increased upon loss of   39 
OCRL1 function. This shows that under some circumstances PLCδ-PH can 
detect PI(4,5)P2 on internal membranes. 
 
OCRL1 and calcium handling 
An alternative way of analysing the downstream effects of OCRL1 loss is by 
looking at the localisation of proteins that are known to either bind to or be 
activated by PI(4,5)P2. OCRL1 loss or depletion increases the substrate of 
members of the phospholipase C (PLC) family. This suggests there may be 
an effect upon second messengers downstream of it, namely inositol(1,4,5)-
trisphosphate (IP3), 1,2-diacylglycerol (DAG) and calcium. Annexin A2 is a 
phospholipid binding protein known to share OCRL1 binding partners such as 
Rac1 and clathrin adaptor AP-2 
73, 74. Annexin A2 also binds PI(4,5)P2 and 
membranes in a calcium-dependent manner 
75-77. These reports and the 
endosomal localisation of Annexin A2 suggest that it may have an important 
relationship with OCRL1. For these reasons, we have investigated Annexin 
A2 localisation upon OCRL1 depletion, with the hypothesis that Annexin A2 
would translocate to sites of PI(4,5)P2 elevation in the presence of a 
hypothesised elevation in cytosolic calcium. A similar translocation of Annexin 
A2 occurs upon inactivation of the proton-chloride antiporter CLCN5, which 
makes it a candidate for an active participant in Lowe’s syndrome 
78.  
 
The link between OCRL1 and CLCN5 was first established because 
mutations in CLCN5 lead to a condition known as Dent’s Disease, which 
shares a very similar selective renal tubulopathy with Lowe Syndrome 
79. The 
similarity in the pathology of these patients is supported further by the finding   40 
that 20% of patients with the Dent’s phenotype have mutations in OCRL1, not 
in CLCN5. These data are suggestive of a single, shared pathophysiological 
mechanism in both CLCN5 -/- and OCRL1 -/- patients, and it is therefore 
plausible that Annexin A2 has a role in Lowe Syndrome 
80.  
 
From the above, it might be hypothesised that OCRL1 depletion has an effect 
on the PLC pathway. The hydrolysis of PI(4,5)P2 to second-messengers IP3 
and DAG by members of the PLC family triggers the release of intracellular 
calcium stores and the recruitment of protein kinase C (PKC) to the plasma 
membrane, respectively 
81, 82. There are many possible effects that OCRL1 
depletion may have on this process. Firstly, raised PI(4,5)P2 levels may 
cause an increase in the speed and amount of calcium release, by providing 
increased substrate availability for members of the PLC family. The Golgi 
apparatus has been shown to be a bona fide calcium store and can liberate 
calcium upon IP3 stimulation through endogenous IP3 receptors 
83, 84. If 
OCRL1 depletion leads to an elevation of PI(4,5)P2 at the Golgi, local PLC 
mediated PI(4,5)P2 hydrolysis may occur at this site 
83. This may affect the 
responsiveness of Golgi calcium stores. Other evidence for a potential 
increase in IP3 responses upon OCRL1 can be drawn from work carried out 
with synaptojanin-1. Over-expression of the synaptojanin-1 inositol 
polyphosphate 5-phosphatase domain has an inhibitory effect on calcium 
store release in response to ATP. This inhibition of calcium signalling 
coincided with GFP-PLCδ-PH being less associated with the plasma 
membrane 
85. In a similar study, rapid translocation of an inositol 
polyphosphate 5-phosphatase, closely related to OCRL1, to the plasma   41 
membrane caused significant differences in calcium handling in COS-7 cells 
with rapid termination of calcium signals in the cytoplasm 
26. This was shown 
to be due to interference with the sustained generation of IP3, rather than a 
block of capacitative calcium entry. These data led to the hypothesis that 
when the opposite situation arises, as in Lowe Syndrome, with depletion of 
proteins with inositol polyphosphate 5-phosphatase activity, there may be an 
increase in IP3 responses. 
 
Alternatively, there are well-described mechanisms by which depletion of 
OCRL1 may have a negative impact on calcium signalling. Studies have 
shown that PI(4,5)P2 inhibits the IP3 receptor. This raises the possibility that 
increased PI(4,5)P2 at sites apposing the IP3 receptor may inhibit the PLC 
signalling pathway 
86. In addition, PI(4,5)P2 has been shown to have positive 
and negative roles in many different channels and pumps integral to calcium 
signalling 
87. The overall sum effect of these interactions is hard to predict, but 
worth investigating further. 
 
OCRL1 and intercellular junctions 
As described earlier in the introduction, phosphoinositides build up in a 
specific spatial and temporal manner. This particular arrangement controls 
many cellular processes, such as aforementioned membrane trafficking and 
signal transduction. Phosphoinositides also regulate the formation and 
function of many different intercellular junctions. There is also a clear cross-
talk between these processes, for instance, regulation of membrane trafficking 
can affect the formation of the tight junction, and recruitment of effector   42 
proteins to the tight junction can affect certain signalling cascades. The 
complex regulation of these different processes is in some part controlled 
through generation and destruction of different phosphoinositides.  
 
To date, cell biological studies of OCRL1 have tended to use non-polarised 
cells, most frequently fibroblasts 
44, 52, 54. However, Lowe Syndrome is a 
disease that manifests itself in polarised cell types such as epithelia and cells 
of the CNS. The key difference between polarised and non-polarised cell 
types is the presence of intercellular junctions. Because regulation of 
phosphoinositides is closely related to many aspects of intercellular junction 
activity, we believed that the inability to find a phenotype for OCRL1 loss 
might be a consequence of studying non-polarised cell types. For these 
reasons we felt a study of OCRL1 in polarised cell types was warranted to 
determine if there is a role for OCRL1 at intercellular junctions. 
Junction biogenesis and maintenance 
Eukaryotic cells have evolved to interact with one another through many 
different specialised junctions, the most studied and understood being 
adherens, tight and gap junctions. These junctions control a wide range of 
cellular processes such as cellular differentiation, signal transduction, 
apoptosis and proliferation 
88, 89. Gap junctions are specialised channels that 
connect the cytoplasm of two cells and allow various molecules and ions, 
such as IP3 and calcium, to pass in a regulated manner between cells 
90, 91. 
Gap junctions are composed of and defined by their structure: 6 homo- or 
heterotypic connexins are incorporated into connexons (or hemichannels), 
one provided by each neighbouring cell, which connect across the intercellular   43 
space. These channels are important in cellular events such as electrical and 
metabolic coupling between cells, adhesion and tumor suppression 
91. Gap 
junctions can be linked to the pathological effects of OCRL1 loss in humans, 
as gap junction dysregulation can lead to cataract formation 
92. Adherens 
junctions are a specialised apical bridge between two epithelial cells, normally 
basally located in relation to the tight junction. They are defined by the 
presence of proteins such as cadherins and catenins and are thought to 
function as a bridge between the actin cytoskeleton and intercellular junctions 
93. Again, these junctions are integral to adhesion between cells and also 
provide the platform for signalling pathways and formation of other types of 
junction 
88. The other main type of junction between epithelial cells is the tight 
junction. These junctions form a physical barrier to diffusion of fluid and 
macromolecules and also function to couple cells together, and so can be 
used to define epithelia as leaky or tight, a definition based on the number of 
tight junction strands and ability to restrict fluid movement. These independent 
strands form a complex network that seals the apical membrane and blocks 
passage of solutes between cells. Proteins such as occludins and claudins 
characterise the tight junction. These proteins, like adherens junction proteins, 
also link the actin cytoskeleton between cells 
93. An important function of both 
tight and adherens junctions is to act as physical barriers within the 
membrane. These junctions serve to restrict the lateral movement of proteins 
within the membrane. This process of compartmentalisation along the apical-
basolateral plane of the membrane is integral to cellular functions such as 
endocytosis, exocytosis and cell signalling.  
   44 
Intercellular junction formation in mammalian epithelia occurs in a strict 
spatio-temporal manner. As cells make contact with one another, a “primordial 
adherens junction” is formed. Beneath the membrane, this structure is 
supported by filamentous F-actin, which later develops into a peripheral F-
actin ring that plays a supportive and restrictive role, discussed in the later 
section entitled “Epithelial polarisation and the actin cytoskeleton”. After the 
formation of the primordial adherens junction, F-actin polymerisation occurs 
alongside the development of the tight junction, apical to the adherens 
junction 
94-96. These two types of junction then go on to mature fully and 
separately; this junctional maturation is supported by the underlying actin 
cytoskeleton and is aided by delivery of junctional components through 
vesicular trafficking (discussed later in the section entitled “Membrane 
trafficking”).  
 
Upon maturation of these junctions however, the proteins are not stable and 
inert but continuously remodelled and active in many processes such as cell 
signalling and cell division, discussed in later sections. A few recent papers 
have highlighted the continuous and dynamic nature of junctional proteins 
harnessed the ability of fluorescence-recovery after photobleaching (FRAP) to 
investigate the movement of proteins in and out of the membrane. One of 
these studies, looking at the movement of three tight junction proteins, ZO-1, 
occludin and claudin-1, revealed that each had very different stabilities at the 
membrane 
97. Striking results show that approximately 70% of occludin is 
motile within the plane of the plasma membrane, and nearly 70% of ZO-1 
moves dynamically between plasma membrane pools and intracellular pools.   45 
However, 76% of claudin-1 is stable within the plasma membrane. These data 
revealed that the tight junction complex is rapidly and continuously remodelled 
in an energy-dependent manner, even when epithelia and intercellular 
junctions are “fully matured”. These data challenged the previously thought 
model of static, scaffold like-junctions. Furthermore, each protein analysed 
had a different mechanism of exchange at the tight junction, highlighting the 
dynamic and specific nature of junctional remodelling, even at time-points 
previously thought to be quite stable.  
Epithelial polarisation and the actin cytoskeleton. 
 
The cell cytoskeleton plays key roles in junction formation and the resultant 
polarisation of cells. The characteristic tall cuboidal shaping of polarised cells, 
displaying distinct apical and basolateral membranes, occurs partly as a result 
of cytoskeletal rearrangements. There are distinct differences and changes in 
cytoskeletal elements that occur during intercellular junction formation. The 
cell contains three main kinds of cytoskeletal filaments, which are 
microfilaments (e.g. actin), intermediate filaments (e.g. vimentin/keratin), and 
microtubules (e.g. α-tubulin). These cytoskeletal filaments provide the cell 
with structure and shape. Of these, actin microfilaments have been linked to 
OCRL1 cell biology, but to-date only in non-polarised skin fibroblasts from 
Lowe Syndrome patients. In one of these studies, it was shown that Lowe 
Syndrome fibroblasts show a much-reduced number of actin stress fibers or 
bundles and some small punctate vesicular actin at perinuclear regions of the 
cell 
66. Also, in a recent study by our group and that of Prof, SE Moss, we 
have shown that this “vesicular” actin takes the form of an actin “rocket” or   46 
“comet”, an elongated, arborescent form of actin that propels a vesicle 
through the cytoplasm. Actin rockets form in Lowe Syndrome patient 
fibroblasts at rest 
98, 99, which is a sign of increased actin polymerisation. The 
presence of actin rockets in Lowe Syndrome fibroblasts might be caused by 
increased PI(4,5)P2, and so, possibly ties in with OCRL1 loss 
100.  
 
Actin has key roles in junction formation and also in the maturation of epithelia 
from large flat cells to tall cuboidal cells 
101. The polarisation of epithelia is 
thought to occur in a specific sequence of events. At early stages of 
polarisation, it is thought that actin is recruited to junctions in order to restrict 
movement of proteins out of and within the plane of the membrane. By doing 
so, the specific spatial (namely apical to basolateral) ordering of junctional 
components is established. In the later stages of polarisation, peripheral 
circular actin bundles play a supportive, protective and active role in cell 
shape and are co-incident with cell-cell junctions. 
  
There are two very good examples of the importance of actin at cell-cell 
contacts in polarised cell types. The first is demonstrated by a mammalian 
study showing two distinct pools of filamentous actin that are dynamically 
altered upon cell-cell adhesion: a continuous line of junctional actin and 
peripheral thin bundles 
102. These two types of actin filaments differ in their 
actin dynamics, mode of formation and have distinct roles in the polarisation 
process. This “two-pool” theory has recently been corroborated in a different 
model, looking at epithelial development in Drosophila embryogenesis. In this 
recent study, the relationship between E-cadherin and actin was assessed   47 
103. At intercellular contacts, cells concentrate E-cadherin and in 
perijunctional regions F-actin is accumulated. However, there is a different 
level of complexity in that E-cadherin is not distributed uniformly in cell–cell 
contacts. E-cadherin is shown to concentrate in discrete spots or clusters 
thought to be “spot-adherens” junctions. Using FRAP and photoactivation 
techniques, clustered E-cadherin was shown to be much more stable than 
the E-cadherin found at perijunctional regions of the cell. Like the earlier 
study described, there seemed to be a similar “two-pool” mechanism in 
place, where different forms of actin may differentially regulate different 
pools of junctional components such as E-cadherin. It was found that the 
clustered E-cadherin was stable despite perijunctional actin disruption with 
injected latrunculin A, which inhibits actin filament assembly, or in mutant 
flies that have a fragmented junctional actin network. Interestingly, 
latrunculin A treatment caused this clustered E-cadherin to become much 
more mobile within the membrane. In contrast, lateral mobility of E-cadherin 
was decreased through expression of proteins that promote actin 
assembly, such as Wiscott-Aldrich Syndrome protein (WASP), a protein that 
is regulated by PI(4,5)P2. These findings suggest a model whereby a 
dynamic pool of junctional actin restricts the movement of stable cadherin 
clusters. It seems that there is a relatively stable pool of actin filaments in 
close proximity to the E-cadherin clusters as well as a dynamic pool at 
intercellular contacts. This evidence adds weight to the view that different 
pools of actin differentially control specific maturational events junctions.  
   48 
In sum, OCRL1 loss has a dramatic effect on the actin cytoskeleton in non-
polarised fibroblast cells. There is added complexity within the actin 
cytoskeleton of polarised cells. This means that a previously unseen effect 
of OCRL1 loss may be revealed in a polarised cell type. Furthermore, 
OCRL1 contains a Rho-GAP homology domain at its carboxy-terminus, 
known to bind Cdc42 and Rac1. The role of the Rho GTPase family and the 
actin cytoskeleton is well characterised. OCRL1 binding to Cdc42 and/or 
Rac1 may lead to unanticipated changes in the way they regulate actin at 
intercellular contacts. For example, studies in MDCK cells using 
constitutively active and dominant negative mutants of Rho, Cdc42 and 
Rac1 revealed that these proteins have a high potential to interfere with 
specific functions localised to the tight junction 
104, 105. Clathrin-dependent 
endocytosis (which involves OCRL1) is highly dependent upon dynamic 
changes in actin polymerisation at the plasma membrane. If OCRL1 had a 
specific role at junctions, it is possible that OCRL1 partakes in clathrin-
mediated endocytosis of junctional proteins, which would not be observed 
in non-polarised cells. In support of this, adherens and tight junction 
proteins such as E-cadherin and occludin are internalised in a clathrin-
dependent manner 
106. These findings suggest that an investigation of 
OCRL1 and the actin cytoskeleton in polarised cells is warranted. 
 
Membrane trafficking in polarised cells 
To maintain the functionally and structurally different plasma membranes in a 
polarised cell, junctional and polarity proteins must be trafficked selectively to   49 
their correct and desired sites. The maintenance of apico-basolateral polarity 
requires the activity of membrane trafficking proteins to sort proteins from 
endocytic and biosynthetic origin 
88.  
 
Of the many classes and types of proteins important in membrane trafficking, 
one of the largest and most important is the Rab family of small GTPases 
107, 
108. A recent study has shown that OCRL1 has extremely broad binding 
specificity for the Rab GTPases 
45. Of the many Rab proteins that bind 
OCRL1, there is some evidence that two specific Rab GTPases are vital to 
trafficking of junctional proteins to the plasma membrane. Rab 8 has been 
shown to play an in vivo role in the localisation of apical membrane and 
junction proteins 
109, 110. Another member of the Rab GTPase family, Rab 13 
has been shown to localise to the tight junction 
111. Interestingly endogenous 
Rab 13 localises to intracellular vesicles in non-polarised CHO cells. 
However, when in polarised cell types such as Caco-2 and LLC-PK1, the 
protein is very specifically localised to the apical plasma membrane, at the 
level of the tight junction as shown by strong colocalisation with ZO-1. In this 
same study, the junctional localisation of Rab 13 was also confirmed in frozen 
intestinal sections from mouse 
112.  
 
While Rab 13 has a role outside polarisation, regulating membrane trafficking 
of proteins between the TGN and endosomes in MDCK cells, it was shown 
that Rab 13 mutants inhibit specific surface delivery of cargo proteins to apical 
and basolateral membranes 
113. Moreover, upon over-expression of dominant-
active Rab 13, not only is the structure of the tight junction affected, but   50 
functional read-outs of tight junctional integrity such as trans-epithelial 
resistance and measurement of fence function are greatly disturbed 
111. This 
causes a delay in tight junction formation, which the authors propose to be 
due to impaired endocytic recycling of tight junction proteins such as claudin-1 
and occludin. These data are verified by work showing that Rab 13 mediates 
the continuous trafficking of occludin in and out of the membrane 
114. This was 
shown by partial colocalisation of vesicular, endocytosed occludin with 
endogenous Rab 13. Furthermore, this study showed that over-expression of 
constitutively active Rab 13 caused the specific and striking movement of 
occludin to intracellular vesicles.  
 
Another example of the importance of membrane trafficking proteins in 
junction formation can be drawn from a study assessing the roles of 
JRAB/MICAL-L2 in adherens and tight junction formation. JRAB/MICAL-L2 is 
a cytoplasmic protein that binds to both Rab 8 and Rab 13 and regulates the 
endocytic recycling of tight junction proteins occludin and claudin-1 
115. 
Interestingly, depletion of JRAB/MICAL-L2 and expression of its Rab 13 
binding domain inhibited traffic of occludin and claudin-1, but also traffic of 
adherens junction protein E-cadherin 
109. Knockdown of Rab 8 also caused 
impaired trafficking of E-cadherin in this study. Given the theory that the 
polarised tissues affected by OCRL1 loss (lens, kidney, neurons/glia) are 
uncompensated for by its homologue INPP5B, one extremely interesting 
observation is that OCRL1, but not INPP5B, binds Rab 1 4, which regulates 
specific apical targetting in polarised cell types 
44, 55, 116. The difference in Rab 
binding may be important, despite the hypothesis that OCRL1 and INPP5B   51 
are redundant (discussed above), as this latter hypothesis has yet to be 
tested fully. Altogether, these findings provide possible molecular pathways by 
which OCRL1 might regulate junctional activities. 
 
The trafficking of proteins to their desired locations serves to place them at 
their sites of activity. Previous studies, discussed above, describe how altered 
activity of Rab 13 causes a plethora of defects in tight junction assembly and 
function. Interestingly, this happens due to a cross talk between membrane 
trafficking and signal transduction. Constitutively active Rab 13 causes the 
inhibition of VASP phosphorylation by protein kinase A (PKA) in polarised cell 
types 
117. This is thought to be due to Rab-GTP binding to VASP, and perhaps 
leading to it being sequestered away from the tight junction. Interestingly, 
restoration of tight junction structure was achieved upon stimulation of PKA 
signalling by forskolin, emphasising the importance of trafficking and activity 
of signalling proteins in tight junction function. The importance of cell 
signalling at the junction is the topic of the next section. 
 
Cell signalling derived from cell-cell junctions 
The cytoplasmic face of intercellular junction complexes provides a scaffold 
by which cell-cell interaction and related activities at junctions feed back to 
many different signalling pathways that regulate cellular processes such as 
cell differentiation and proliferation 
88, 118. Due to the multitude of different 
pathways downstream of intercellular junctions, this section will concern itself 
with signalling to and from tight junctions, and will suggest the most likely 
pathways within which OCRL1 may function.    52 
 
OCRL1 is a phosphatidylinositol polyphosphate 5-phosphatase, with a 
preference for dephosphorylating PI(4,5)P2 
119. Apart from its roles in 
recruiting proteins to its sites of existence, PI(4,5)P2 is also a signalling lipid. 
PI(4,5)P2 can be converted into two second messengers, inositol (1,4,5)-
triphosphate and phosphatidylinositol (3,4,5) triphosphate, through the actions 
of phospholipase C (PLC) and phosphatidylinositol 3-kinase (PI3K), 
respectively. These second messengers have been shown to be important to 
the function, maintenance and structure of tight junctions. Given the 
localisation of these lipids to junctions, and that enzymes that act upon them, 
such as PLCβ3, bind to junctional proteins, there are many avenues to 
investigate 
120. For instance, the tight junction protein ZO-1 is a scaffolding 
protein for Gα12 
121. Through binding to the SH3 domain of ZO-1, Gα12 may 
co-ordinate signalling events downstream of the tight junction such as PLCε 
hydrolysis of PI(4,5)P2 
122. If levels of PI(4,5)P2 at tight junctions are 
regulated by OCRL1, downstream effects such as the barrier function and 
viability of tight junctions may be affected. This is discussed further in the 
section, “Intercellular junctions and phosphoinositides”  
 
As mentioned earlier, there are a wide number of signalling proteins that are 
linked to OCRL1 function by virtue of their ability to bind APPL1 
58-61. It has 
been shown that changes in phosphoinositide levels or localisation affect the 
formation of junctions and the cell polarisation process 
123. If OCRL1 
contributes to the strictly controlled apico-basolateral segregation of 
phosphoinositides, either PI(4,5)P2 or PI(3,4,5)P3, then it may play a role in   53 
cell polarisation. It is also possible that in a polarised context, the ability of 
OCRL1 to dephosphorylate PI(3,4,5)P3 may become significant 
119. Finally, 
loss of OCRL1 may also affect, directly or indirectly, the shuttling of APPL1 in 
and out of the nucleus. If this were to occur, a pathway that regulates 
proliferation via APPL1 and Rab 5 may become dysregulated 
124 . 
 
Intercellular junctions and phosphoinositides 
Several aspects of junction formation and regulation may feasibly require 
OCRL1. The potential ability of OCRL1 to dephosphorylate PI(4,5)P2 at 
intercellular junctions has many possible outcomes. One study has shown 
PI(4,5)P2 is important in gap junction communication 
120. PI(4,5)P2 is highly 
enriched at the plasma membrane. Through use of a novel regulated system, 
in which a 5-phosphatase domain highly homologous to the OCRL1 5-
phosphatase domain is forcibly driven to the plasma membrane, the functions 
of PI(4,5)P2 at gap junctions was investigated. Using this system, it was found 
that depletion of PI(4,5)P2 was sufficient to close connexin 43 channels. 
However, when PI(4,5)P2 levels were restored through overexpression of 
PI(4)P5-K, this effect was attenuated. Furthermore, overexpression of 
PI(4)P5-K alone, reduced closure of connexin 43 channels. These data are 
supported by the fact that PI(4)P5-Kγ localises to adherens junctions in A431 
epithelial cells 
125. Worthy of note, PI(4)P5-Kγ localisation to the junction, 
much like the previously described localisation of Rab 13, only occurs in 
polarised cell types, but is vesicular and cytoplasmic in non-polarised cell 
types. This work demonstrated a key role for levels of PI(4,5)P2 in the gating   54 
of connexin channels. However, these findings were rather crude, in that they 
force the event of PI(4,5)P2 generation or depletion.  
 
The physiological significance of these studies was inferred when it was 
shown that connexin 43 binds to the tight junction protein ZO-1, bringing with 
it the PI(4,5)P2 lipase, PLCβ3. PLCβ3, when activated through stimulation of 
Gαq, inhibited gap junction communication 
120. Interestingly, knock-down of 
ZO-1 mediated defects in gap junction communication, but had no effect on 
agonist induced calcium responses. This result may suggest that the 
interaction between ZO-1 and PLCβ3 is not significant to levels of PI(4,5)P2 
at the junction, but simply an effect upon gross connexin 43 biology. The 
authors propose that this complex represents an endogenous system of 
regulating PI(4,5)P2 levels at gap and presumably tight junctions. Although 
the effect of PI(4,5)P2 depletion, through a number of methods, was shown to 
inhibit gap junction communication, the significance of PI(4,5)P2 depletion 
upon tight junction read-outs was not assessed. However, evidence for a role 
for PLCβ at tight junctions can be drawn from a study by Ward et al., where 
the activity of PLCβ is shown to be directly linked to the permeability function 
of tight junctions in MDCK cells 
126. In this study, it was shown that the activity 
of PLCβ causes changes in the underlying actin cytoskeleton and that this 
modulation altered the permeability of tight junctions. Given that ZO-1 also co-
ordinates and binds actin, the existence of this complex is highly possible. 
This change in the actin cytoskeleton may alter other properties of the tight 
junction as well. A previously mentioned study in Caco-2 cells supports this 
theory, in demonstrating that PLCγ activity is the component that confers   55 
EGF-mediated protection of tight junctions treated with acetaldehyde 
127. This 
activity was closely related to association of F-actin at junctional interfaces. 
The roles of PI(4,5)P2 activity and its effects on the actin cytoskeleton, in 
concert with proteins such as WASP, profilin, GAP43, MARCKS and Rac1 are 
well documented 
100, 128-130. Should OCRL1 be key to formation and function 
of this complex, or even located within it, another potential method for removal 
of PI(4,5)P2, and its many downstream functions including closure of gap 
junctions can be envisaged.  
 
There is also pre-existing evidence for another inositol 5-phosphatase, SHIP-
1, in regulation of cell-cell junctions. SHIP-1 functions as a 5-phosphatase to 
PI(3,4,5)P3, the product of PI3K activity. Overexpression of SHIP-1 in MDCK 
cells leads to a phenotype that resembles an epithelial to mesenchymal 
transition (EMT) 
131. During EMT, epithelial cells lose contact with one another 
in a monolayer and adopt more motile and independent behaviour, much 
unlike the nature of epithelial cells. Cells overexpressing SHIP-1 lost cortical 
actin, developed stress fibers and became highly motile. Upon over-
expression of a phosphatase-null mutant of SHIP-1, these phenotypes were 
not observed. However HGF stimulation, which induces EMT-like behaviour in 
normal, untransfected MDCK cells, did not cause EMT expressing this 
mutant. This is another piece of work that is highly suggestive of a role for 
phosphoinositides at intercellular junctions.  
 
Other junctional proteins, especially those containing PDZ domains, have 
strong links to phosphoinositides. Two studies, one looking at syntenin and   56 
the other, looking at Par proteins and other PDZ containing proteins reveal 
that PDZ domains have a high affinity for phosphoinositides 
132, 133. 
Interestingly, many PDZ domains, including at least one in each of ZO-1, Par 
3 and syntenins bind PIPs. In a recent paper by Wu et al., these domains are 
suggested to be phosphoinositide signalling integrators 
132. Much like 
pleckstrin homology domains, PDZ domains seem to be modules that 
recognise a combination of phosphoinositide and protein. However, the high 
occurrence of PDZ domains in junctional proteins is suggestive that 
phosphoinositides are integral to their function 
134. This is further highlighted 
by an experiment where the second PDZ domain of Par3, which binds 
phosphoinositides, is shown to be required for epithelial cell polarisation. In a 
very neat model, it is shown that Par3 also binds to PTEN through its third 
PDZ domain. By doing so, Par 3 integrates the signalling action of PTEN 
activity on PI(3,4,5)P3 to generate PI(4,5)P2, thus facilitating its binding to the 
membrane 
132. Syntenins are interesting examples of junctional proteins with 
PDZ domains that bind to PI(4,5)P2. Syntenin-1 interaction with PI(4,5)P2 has 
been shown to be important in receptor cargo recycling whereas syntenin-2 
has been found to play a role in organisation and localisation of PI(4,5)P2 to 
nuclear speckles 
21, 133.  
 
Many proteins, designated to be junctional in localisation, actually shuttle 
between the nucleus and junction 
135. It is now well established that PI(4,5)P2 
exists in nuclear speckles within the nucleus, at sites involved in pre-mRNA 
processing 
14, 136. In addition to syntenin-2, ZO-1 and ZO-2 have also been 
found to target nuclear speckles and their PDZ domains have been shown to   57 
interact with phosphoinositides 
132, 137, 138. The full physiological extent of 
nuclear PI(4,5)P2 has not yet been elucidated, however for a long time 
nuclear speckles and the PI(4,5)P2 were thought to regulate the expression of 
specific mRNAs 
139. This has been verified recently through regulation of a 
poly(A) polymerase, Star PAP 
140. Nuclear speckles containing PI(4,5)P2 
have previously been found to co-localise with pre-mRNA splicing factors, but 
the significance of this colocalisation had not been found. The existence of 
nuclear PLCβ has also been established and characterised. So far, only 
SHIP-2 has been found to be localised to nuclear speckles, but it is not clear if 
this is the only 5-phosphatase active on nuclear PI(4,5)P2 
141.  
 
One of the most recent and important findings was that of Martin-Belmonte 
and colleagues, in which they demonstrate the importance of segregation of 
PI(4,5)P2 and PI(3,4,5)P3 between apical and basal membranes, 
respectively, in 3D MDCK culture 
123. Previous work had shown the necessity 
of PI(3,4,5)P3 in formation of the basolateral plasma membrane, but now it 
seems that this concentration of basolateral PI(3,4,5)P2 is only important 
relative to apical PI(4,5)P2 
142. Phosphoinositide segregation is brought about 
through specific recruitment of PI(3,4,5)P3 3-phosphatase, PTEN, to apical 
membranes. PTEN recruitment causes the generation and concentration of 
PI(4,5)P2 at apical membranes, which in turn recruits Annexin A2, a calcium 
and PI(4,5)P2 binding protein with actin polymerisation activity. Annexin A2 
recruits the RhoGTPase Cdc42 to the apical membrane, where presumably 
both proteins act in concert to facilitate the subapical actin remodelling 
required for lumen formation characteristic of MDCK 3D cysts 
123.   58 
Furthermore, apical localisation of Cdc42 brings aPKC/Par6 to the apical 
surface, establishing the polarity of the MDCK cyst. This paper highlights that 
PI(4,5)P2, the preferred substrate of OCRL1, is a key determinant of the 
apical plasma membrane. Interestingly, the segregation of phosphoinositides 
seems to be a conserved model for polarity between species, as regulated 
PTEN activity and localisation is also shown to be required for apical 
membrane morphogenesis in Drosophila photoreceptor epithelial cells 
143. 
Furthermore, the demonstration of apical to basolateral segregation of 
PI(4,5)P2 and PI(3,4,5)P2 adds to the view that phosphoinositides are general 
determinants of membrane identity. Should OCRL1 play a role in reducing the 
levels of PI(4,5)P2 at either the apical or basolateral membrane at key stages 
of cyst formation, a phenotype related to the organisation of junctions and 
epithelial polarity may become apparent upon OCRL1 loss. This may occur 
through increased levels of PI(4,5)P2 at either membrane, causing 
mistargetting of PI(4,5)P2-binding proteins. On the other hand, the excess 
PI(4,5)P2 may be converted to PI(3,4,5)P3 by PI3K family members at 
aberrant sites, perhaps uncompensated by PTEN activity. Testing for a role 
for OCRL1 in this model system would be quite appealing if evidence for 
OCRL1 at junctions were to be found. 
 
This thesis comprises of three chapters of results. In Chapter 3, I will present 
data from experiments testing changes in PI(4,5)P2 upon OCRL1 depletion. 
To do this, we have created a construct that seeks to target PLCδ-PH to 
internal membranes, and possibly redistributes from the plasma membrane to 
intracellular sites of PI(4,5)P2 elevation. We have also investigated whether   59 
endogenous Annexin A2, a known PI(4,5)P2 binding protein, translocates 
upon OCRL1 depletion. In Chapter 4, data will be presented from work 
assessing the effect of depletion of OCRL1 on the PLC pathway and 
intracellular calcium handling. Finally, in Chapter 5 work on OCRL1 in 
polarised cells will be presented. In this chapter we provide evidence for a 
potential new site for OCRL1 activity- intercellular junctions, and a novel 
binding partner, tight junction protein zona occludens 1 (ZO1).    60 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2:  
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2: Materials and Methods 
 
Materials and antibodies 
 
All materials were obtained from Sigma unless otherwise stated. Sheep 
polyclonal antibody against OCRL1 was a kind gift from Dr. Martin Lowe. 
Rabbit anti-ZO-1 was a kind gift from Prof. Karl Matter. Mouse anti-E-cadherin 
was a kind gift from Dr. Patric Turowski. Transferrin-alexa 555, donkey anti-
sheep HRP, mouse anti-sheep CY2, mouse anti-sheep CY3 and mouse 
antibody to EEA1 were kind gifts from Dr. Clare Futter. Anti-Annexin A2, 
donkey anti-mouse CY3, TRITC- and FITC-phalloidin were a kind gift from 
Prof. Stephen Moss. Sheep polyclonal anti-TGN46 was a kind gift of Dr. Vas 
Ponnambolam. 
 
Molecular biology 
 
Plasmids: EGFP-OCRL1 (Isoform b, 893 amino acids), EGFP-INPP5B (a kind 
gift from Dr. Martin Lowe), GFP-AKT-PH, GFP-Grp1-PH (a kind gift from Dr. 
Tamas Balla).  
 
GFP-POP consisted of the CMV immediate early promoter, followed by GFP, 
the first 175 amino acids of rat PLC∂1 which include its PH domain, a linker 
(GAGARS) then the PH domain of human OSBP (residues 87-185) carrying 
R109E and R110E mutations and followed by KNS*. POP was derived from a   62 
similar construct containing two copies of the mutated PH domain of OSBP 
(pTL352, ref 
144), replacing the last 150 base pairs of GFP and first of these 
PH domains with the analogous sequence from GFP-PLC∂ PH (pTL335 ref 
144) from a PCR product using CAAAATACTCCAATTGGCG (19mer 5’3’, 
within GFP) and GGGAAGATCTAGCTCCTGCACCCTGGATGTTGAGCTCC-
TTC (43mer 3’5’, coding for linker and the last 19 base pairs of the PLC∂1 
PH domain). The PCR product was digested with Mfe1 and Bgl2, inserted 
between these sites in the vector, and checked by sequencing. 
 
OCRL1 amino-terminus-GFP consisted of the first CMV immediate early 
promoter, followed by GFP, and then the first 501 amino acids of OCRL1 
which include its PH-like domain and half of the inositol 5-phosphatase 
domain. This construct was created through digestion of GFP-OCRL1 (a gift 
from Dr. Martin Lowe) with restriction enzymes EcoRI and SmaI.  
 
OCRL1 carboxy-terminus-GFP consisted of the first CMV immediate early 
promoter, followed by GFP, and then the amino acids 501 to 893 of OCRL1 
which include half of the inositol 5-phosphatase domain, ASH domain and 
RhoGAP homology domain. This construct was created through digestion of 
GFP-OCRL1 (gift from Dr. Martin Lowe) with restriction enzymes EcoRI and 
BspEI, followed by addition of Klenow enzyme and dNTPs to the restriction 
mixture, to fill-in the over-hanging sticky-ends.  
 
GFP-POP with a PHO5 promotor was created for visualisation within yeast. 
This was created by digestion of PHO5>GFP-Scs2/VAP chimera
145 with MfeI   63 
and Sac2 and insertion of POP sequence from CMV>GFP-POP, also 
digested with MfeI and Sac2. 
 
Mammalian cell culture and transfection 
 
HeLa, Caco-2, MDCK and primary porcine retinal epithelial cells were grown 
at 37ºC and 5% CO2 in DMEM containing 10% foetal calf serum (FCS), 
100µg/ml streptomycin and 100µg/ml penicillin (regular medium). HLE-B3 
cells were grown at 37ºC and 5% CO2 in MEMα containing 20% FCS 
supplemented with 2mM glutamine, 100µg/ml streptomycin and 100µg/ml 
penicillin. Lowe Syndrome patient skin fibroblasts, designated Lowe B and 
Lowe 2 were a kind gift from Dr. William O’Brien, University of Texas Medical 
Branch . Lowe B and Lowe 2 cells were cultured at 37ºC and 5% CO2 in 
DMEM containing 20% foetal calf serum (FCS), 100µg/ml streptomycin and 
100µg/ml penicillin. 
 
For visualisation of GFP-tagged constructs, cells at 70-80% confluence were 
transfected with 0.4µg plasmid DNA in 35mm glass bottom dishes (MatTek 
Corporation) with 10µl Lipofectamine 2000 (Invitrogen). DNA/lipofectamine 
complexes were made in serum-free conditions and incubated with cells in 
2ml regular medium. After 6 hours of incubation, cells were washed with PBS 
and replaced in regular medium overnight. GFP-tagged constructs were 
analysed 24 hours after transfection.  
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Yeast cell culture 
Wild-type or deletion strains were obtained from freezer stocks of the yeast 
deletion collection (Mat a, based on parental strain BY4741). Yeast were 
grown overnight at 30 °C and on the day of experiment, split back to log 
phase of growth then examined with a confocal microscope system (AOBS 
SP2; Leica) at room temperature (63x NA 1.4 objective) using LCS software 
(Leica) for acquisition. 
RNAi interference 
 
Cells were transfected according to manufacturer’s instructions. Briefly, non-
targetting, Allstars negative control siRNA (Catalogue number 1027281, 
Qiagen), Annexin A11 siRNA sequence CUGCCGAAUGCCGUUCCUA 
(Qiagen), which has shown to be defective (Dr. Rebecca Longbottom, UCL 
Institute of Ophthalmology, personal communication) or pooled OCRL1 siRNA 
sequences CUUUCCGGUACCUUCGUUCUU, AAAGCCUUAGUCUUCUUC-
GUU, UUUGAUGAGACCCUCCCGCUU, UAUCGACACUGAUCCUUUCUU 
(SmartPool, Dharmacon) were made into complexes with 5µl Oligofectamine 
(Invitrogen) in serum-free medium. Oligofectamine/siRNA complexes were 
added to cells grown to 40-50% confluence in 2ml regular medium minus 
penicillin/streptomycin on 35mm glass bottom dishes (MatTek Corporation). 
Cells were treated twice with siRNA, at 24 hours and 48 hours then left for a 
further 24 hours in regular medium to recover. Cells treated with siRNA for 
calcium experiments were treated only once with siRNA, at 24 hours. Final 
siRNA concentrations were 100nM and cells were analysed either 48 hours 
(in some calcium experiments) or otherwise 72 hours post-transfection.   65 
 
Percoll based sub-cellular fractionation 
 
Cells grown to approximately 90-100% confluence in 35mm tissue culture 
dishes were washed twice with HBSS followed by trypsinisation and re-
suspension in complete medium. Cells were centrifuged at 100 x g and 
resuspended in 1ml homogenisation buffer (10mM HEPES, 200mM sucrose, 
3mM imidazole, pH 7.2). Cells were homogenised by passing the samples 
through a ball-bearing homogeniser set with a clearance of 10µM x 20 times. 
An in situ gradient was formed by mixing the 1ml homogenate with 5ml 36% 
Percoll solution in homogenisation buffer to form an average density of 
1.08g/ml. Samples were centrifuged at 50,000 x g for 90 minutes in a S80 
AT3-0051 rotor (Sorvall RC M150 GX). The resulting gradient was then split 
into 6 x 1ml aliquots. Triton X-100 (final 1%) and EGTA (5mM) was added to 
each aliquot and mixed. Samples were centrifuged at 100,000 x g for 120 
minutes and the supernatant removed. Protein in the supernatant was 
precipitated by addition of an equal volume of acetone and left on ice for 10 
minutes. Samples were then centrifuged at 16,000 x g at 4ºC. The resulting 
supernatant was aspirated and precipitated protein was re-suspended in 
boiled 2x sample buffer. 
 
Immunoprecipitation 
 
Cells were washed three times in PBS. In cases where DSP was used to 
cross-link proteins, cells were incubated for 30 mins in 1mM DSP in cross-  66 
linking solution (10mM triethanolamine, 250mM sucrose, 2mM CaCl2, pH 7.4) 
at room temperature. Cells were then washed three times for 15 mins in 
blocking solution (10mM triethanolamine, 250mM sucrose, 2mM CaCl2, 50mM 
ethanolamine, pH 7.4) at room temperature. Cells were then scraped, 
centrifuged at 1,000 x g and re-suspended in 250µl lysis buffer (10mM 
HEPES, 142.5 mM KCl, 0.2% NP-40, 2.5mM sodium pyrophosphate, 1mM β-
glycerol phosphate, 1mM sodium orthovanadate, 100µM CaCl2, pH 7.4). In 
the case of immunoprecipitations performed without DSP, cells were lysed 
directly after three washes in PBS. All lysis steps and subsequent washes 
were performed in the presence of protease inhibitor cocktail (Sigma). Lysates 
were then incubated with pre-clearing Protein G beads in lysis buffer and left 
to rotate for 30 mins at 4°C. After three washes in lysis buffer, the washed 
beads were centrifuged at 7,500 x g and pre-cleared lysates were added to 
beads pre-coated (overnight) with stated antibodies. Lysate and bead mixes 
were then placed on a rotator and incubated at 4°C for two hours. Lysate and 
bead mixes were then centrifuged at 7,500 x g and the supernatants were 
saved. Beads used for the immunoprecipitation were then washed and 
centrifuged at 7,500 x g six times. After washing steps, sample buffer was 
added to the beads. 2x sample buffer was also added to supernatants (1:1). 
Bead and supernatant samples were then boiled for ten minutes and stored at 
-20°. 
Sample preparation and SDS-PAGE and Western blotting 
 
For studies of Annexin A2 secretion, cells were placed in serum-free 
conditions for 24 hours. Medium was collected and precipitated with 150µl   67 
TCA for 15 minutes at 4°C, centrifugation at 16,000 x g for 5 minutes and two 
ice-cold washes with acetone. Excess acetone was then evaporated at 95°C 
and resuspended in 50µl 2x sample buffer. Cells were washed twice with 
HBSS and then incubated for 2 minutes with 5mM EGTA in PBS at 4ºC to 
liberate Annexin A2 adhering to the extracellular surface and then subjected 
to TCA precipitation as above. Whole cell lysates were prepared by addition 
of boiling 2x sample buffer in the presence of protease inhibitors directly to 
plates washed once with PBS. Samples were run on 10% acrylamide minigels 
for 90 minutes at 150V at 4ºC. Proteins were transferred by wet blotting for 45 
mins at 300 Amps to PVDF membranes, blocked in 1x PBS in 0.05% 
Tween20 supplemented with 5% powdered milk (Marvel) and incubated either 
with mouse anti-Human α-tubulin, rabbit anti-Human ZO1, sheep anti-Human 
OCRL1, mouse anti-Human β-actin or mouse anti-Human Annexin A2 primary 
antibodies (dilutions in range 1 in 1000 to 5000). For ZO-1 Western blots, 
SDS-PAGE gels were transferred to nitrocellulose through wet blotting for 3 
hours at 350 Amps at 4ºC. Nitrocellulose membranes were then treated with 
Amidon Black solution for 5 minutes and destained in 20% methanol/7.5% 
acetic acid. Primary antibody incubations were for one hour at room 
temperature or overnight at 4ºC. PVDF membranes were then washed with 
PBS/Tween20 three times before a one hour incubation at room temperature 
with relevant HRP-conjugated secondary antibodies raised in Goat (Dako). 
After 6 washes with PBS/Tween20, PVDF membranes were visualised with 
ECL (Amersham Biosciences) using Fuji medical x-ray film. 
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Labelling of early endosomes 
 
Cells were grown to 50% confluence in 2ml regular medium minus 
penicillin/streptomycin on 35mm glass bottom dishes (MatTek Corporation). 
On the day of experiment, cells were washed once with PBS, placed in 
serum-free medium for one hour and fed 5ng transferrin conjugated to alexa-
555 for 45 minutes, before one wash with PBS and fixation with freshly-made 
4% paraformaldehyde (PFA).  
 
Immunofluorescence microscopy 
 
Cells were first washed with PBS and subsequently either fixed with 4% PFA 
at room temperature for 20 mins or with methanol for 5 mins at -20ºC. After 
fixation with methanol, cells were washed three times with PBS and then left 
in PBS for 15 minutes. Cells fixed by 4% PFA were then permeabilised by 
0.2% Triton X-100 in PBS. Blocking of the cells was carried out in PBS in the 
presence of 0.5mg/ml bovine serum albumin and 0.2% Triton X-100 for 20 
minutes. Primary antibodies were incubated with the cells in PBS in the 
presence of 0.2% Triton X-100 overnight and washed three times. Secondary 
antibodies (Invitrogen, unless stated) were then incubated in PBS plus 0.2% 
Triton X-100 and cells were washed three times, before one wash with water 
and mounting in Vectashield (Vector Laboratories, Inc) for imaging on a 
confocal microscopy system (AOBS SP2; Leica) at room temperature (63x NA 
1.4 objective) using LCS software (Leica) for acquisition.   69 
 
Calcium imaging 
 
Cells at approximately 90-100% confluence in 96 well plates were washed 
twice in regular extracellular media (ECM) containing 121mM NaCl, 5.4 KCl, 
0.8mM MgCl2, 1.8mM CaCl2, 6mM NaHCO3, 5.5mM D-glucose and 25mM 
Hepes (pH7.3). Cells were then loaded in the dark with 2µM Fluo-4 dye in the 
presence of pluronic acid (0.1%) for 45 minutes. Cells were washed twice and 
left in ECM at room temperature. Either 10µM or 100µM histamine (final 
concentrations) made up in regular ECM or regular ECM alone was added to 
cells. Changes in calcium levels reported through Fluo-4 intensity were then 
recorded using a high-throughput 96-well plate fluorescence reader, FLIPR 
(Molecular Devices, USA). After 10 minutes stimulation, 1µM thapsigargin 
(final concentration) in calcium free ECM plus 10mM BAPTA, or calcium free 
ECM plus 10mM BAPTA alone was added to cells and imaged using FLIPR 
for a further 5 minutes. Data were then normalised based upon baseline 
fluorescence values of Fluo-4. Subsequent analysis was then performed 
using Microsoft Excel spreadsheets, mean values calculated and error bars 
represent standard deviations of 3 or 4 replicates. Data are expressed in 
arbitrary units. 
 
Calcium switch assay and TER measurement 
 
HCE cells were washed three times in PBS and then treated with trypsin-
EDTA for 30 minutes, to break apart the majority of cell-cell junctions. Cells   70 
were then re-suspended in regular DMEM (containing 10% FBS, 100µg/ml 
streptomycin and 100µg/ml penicillin) and incubated at room-temperature for 
15 minutes. Cells were then centrifuged at 1,000 x g for 5 minutes and 
supernatants were removed carefully. Cells were then resuspended in low 
calcium Sigma Spinner culture medium (containing 2mM L-glutamine, 1mM 
Na-pyruvate and 10% dialysed FCS (Sigma)). Cells were then re-centrifuged 
and re-suspended in fresh Sigma Spinner culture medium and plated in 
excess, onto an 8-well ECIS 8W10E slide. After cells had become adherent to 
the bottom of the wells, excess cells were removed through careful aspiration 
and Sigma Spinner culture media was exchanged for fresh medium. Cells 
were then left in this low calcium media overnight at 37ºC. The next day, the 
low calcium medium was removed and regular DMEM was added. After 15 
minutes, measurement of the impedance and TER across the HCE monolayer 
was started and carried out for 6 hours. 
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3: OCRL1 and regulation of PI(4,5)P2 localisation 
 
PI(4,5)P2 is most abundant at the plasma membrane. Much of the work 
carried out with regard to PI(4,5)P2 has focussed upon its wide range of roles 
that it coordinates from the cell periphery, such as regulation of membrane 
trafficking, the actin cytoskeleton and membrane channels. However, there 
are reports in the literature that provide support for a role of PI(4,5)P2 on 
internal membranes such as the TGN, even though such reports are rare and 
experiments to support this are technically difficult for many different reasons 
13, 72. These reports do however suggest that there is a physiologically 
relevant pool of PI(4,5)P2 on internal membranes, and one hypothesis is that 
OCRL1 plays a pivotal role in maintaining low levels of PI(4,5)P2 at some of 
these sites. Should an increased pool of PI(4,5)P2 at internal membranes 
occur upon depletion of OCRL1, it is important to know specifically to which 
membranes OCRL1 is targeted. For this reason, experiments were carried out 
to re-confirm the specific subcellular localisation of OCRL1 in HeLa cells, in 
particular studying its targeting to early endosomes, by co-localisation of 
OCRL1 with fluorescently-tagged transferrin fed to HeLa cells over a period of 
forty-five minutes. The punctate pattern of internalised transferrin revealed 
significant regions of co-localisation with OCRL1 (Figure 3.1.1, white arrows). 
Targeting of OCRL1 to early endosomes was further confirmed by 
immunofluorescence studies, however there was only limited colocalisation of 
OCRL1 with EEA1. This suggests that OCRL1 is present on only a specific 
subset of early endosomes (Figure 3.1.2). Apart from endosomes, OCRL1   73 
has been predominantly localised to the TGN
42, 52, 146. We confirmed these 
data by comparing the localisation of OCRL1 with the resident TGN 
glycoprotein TGN46. Strong perinuclear localisation of TGN46 and OCRL1 
was found in HeLa cells (Figure 3.1.3). These results are supported by recent 
data showing that OCRL1 is targeted to these sites by its ability to bind 
members of the Rab GTPase family that are known to localise to the TGN and 
endosomes 
52. In fact, a large scale screen revealed that OCRL1 has an 
extremely broad Rab binding specificity, binding a total of 16 Rab GTPases 
that target to these sites 
45.   74 
3.1: Confirmation of subcellular localisation of OCRL1 in HeLa cells 
Figure 3.1.1: Colocalisation of OCRL1 with transferrin 
 
 
Figure 3.1.1 legend: OCRL1-EGFP positive puncta co-localise with 
internalised transferrin, indicating that OCRL1 is localised to early 
endosomes. HeLa cells were transfected with 0.4µg OCRL1-EGFP 24 hours 
prior to feeding with transferrin-alexa555 (a gift from Dr. Clare Futter, UCL) for 
45 minutes. Top panel: left: OCRL1-EGFP; middle: Transferrin-alexa 555; 
right: Overlay – OCRL1 green, Transferrin red, co-localisation yellow. Bottom 
panel: enlarged images of the boxed area indicated in the top panel. Arrows 
highlight regions of co-localisation. Single confocal sections. (Scale bar 10µm) 
.
OCRL1-EGFP  Transferrin (Red)  Overlay   75 
 
Figure 3.1.2: OCRL1 is targeted to early endosomes 
 
 
     OCRL-EGFP               EEA1                      DAPI                    Overlay 
 
Figure 3.1.2. legend: OCRL1-EGFP positive puncta co-localise with 
antibodies specific to early endosome antigen 1 (EEA1), indicating that 
OCRL1 is localised to early endosomes. HeLa cells were transfected with 
0.4µg OCRL1-EGFP 24 hours prior to fixation and immunostaining. Top 
panel: left: OCRL1-EGFP; second: EEA1 immunostain; third: DAPI stain; 
right: overlay - OCRL1 green, EEA1 red, co-localisation yellow, DAPI blue. 
Bottom panel: enlarged image of boxed area indicated in top panel. Arrows 
highlight regions of co-localisation. Single confocal sections. (Scale bar 10µm) 
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Figure 3.1.3: OCRL1 protein is targeted to the TGN 
 
 
Figure 3.1.3. legend: OCRL1-EGFP positive puncta co-localise with 
antibodies specific to TGN46, indicating that OCRL1 is localised to the trans-
Golgi network. HeLa cells were transfected with 0.4µg OCRL1-EGFP 24 
hours prior to fixation and immunostaining. Top panel: left: OCRL1-EGFP; 
second: TGN46 immunostain; third: DAPI stain; right: Overlay – OCRL1 
green, TGN46 red, co-localisation yellow. Bottom panel: zoom image of white 
box indicated in top panel. Single confocal sections. (Scale bar 10µm) 
OCRL-EGFP  TGN46 (Red)  DAPI (Blue)  Overlay   77 
 
3.2: Effect of OCRL depletion on Annexin A2 distribution 
 
The discovery that some patients with Dent’s disease, a renal proximal 
tubulopathy without central nervous or ocular phenotypes, have mutations in 
OCRL1 suggests that there may be a common mechanism between the 
disorders 
80. Recent data has shown that in cells with inactive CLCN5, the 
proton/chloride antiporter mutated in Dent’s Disease, Annexin A2 translocates 
from the cytosol to the plasma membrane 
78. Translocation of Annexin A2 
coincided with it being detected at the extracellular face of the plasma 
membrane. This discovery was interpreted to indicate that extracellular 
Annexin A2 might nucleate calcium oxalate deposition, a known mechanism 
for nephrocalcinosis and nephrolithiasis, which are common to both Dent’s 
disease and Lowe syndrome.  
 
These discoveries provide a potential link between the two disorders, in that 
cells derived from Lowe Syndrome patients contain elevated levels of 
PI(4,5)P2, a known calcium-enhanced binding partner of Annexin A2 
36, 147. 
The potential links between OCRL1 and Annexin A2 are further supported by 
the shared targeting of both proteins to sites within the endosomal trafficking 
pathway and shared binding partners such as Rac1 and clathrin-adaptor AP-2 
73, 74. Annexin A2 is also proposed to be important in central nervous system 
function and lens differentiation 
148, 149. For the above reasons, the effect of 
OCRL1 depletion upon the localisation of Annexin A2 was investigated. 
   78 
OCRL1 can be efficiently depleted from both HeLa and HLE-B3 cells. In a 
representative experiment (taken from three separate experiments) depletion 
of 60% OCRL1 from HeLa cells (Figure 3.2.1) was associated with a striking 
translocation of Annexin A2 from the cytosol to limiting membranes (Figure 
3.2.2). Annexin A2 seems to accumulate at the plasma membrane to a higher 
degree in cells depleted of OCRL1, is less prevalent in the cytosol and is 
possibly present more on internal membranes. This membrane pool is likely to 
be a small percentage of the overall amount of Annexin A2, which is a very 
highly expressed protein in epithelial and endothelial cells, at an estimated 
0.5% of total cellular protein in most transformed cell lines such as HeLa cells 
(Professor Stephen Moss, personal communication). In order to achieve these 
results cells had to be fixed in methanol, which tends to not preserve the 
cytoplasm. Fixation in paraformaldehyde did not show the same effect, 
possibly due to better preservation of the cytoplasm. 
 
A more physiologically relevant cell line to study in which to study the effects 
of OCRL1 depletion is HLE-B3, a cell line derived from human lens 
epithelium, a tissue known to be severely affected in Lowe Syndrome 
150. A 
similar effect was produced in HLE-B3 cells, again showing an increased 
general re-distribution of Annexin A2 to the plasma membrane from the 
cytosol, and some cells display accumulations on internal membranes and 
vesicles (Figure 3.2.3). The redistribution of Annexin A2 to membranes upon 
OCRL1 depletion was present in every cell. This observation was 
unanticipated as depletion of OCRL1 was not 100%. This observation is   79 
suggestive of an increase in intercellular calcium handling. This is discussed 
in detail in Chapter 6.  
 
To confirm these findings further, a biochemical analysis of Annexin A2 
redistribution upon OCRL1 depletion from HeLa cells was undertaken. 
Analysis by Western blot shows that total Annexin A2 levels are unchanged 
upon OCRL1 depletion (data not shown). This indicates that the higher 
prevalence of Annexin A2 at membranes is not due to an up-regulation of 
Annexin A2 expression, but a translocation event. This was confirmed by 
fractionation of HeLa cells on Percoll gradients, which separate membranes 
and cellular material based on density. Percoll fractionation of OCRL1 
depleted HeLa cells revealed increased of Annexin A2 in dense membrane 
fractions, in comparison to mock oligofectamine treated controls (Figure 
3.2.4). This result is in agreement with the redistirubution of Annexin A2 to 
membranes in OCRL1 depleted cells (Figures 3.2.2 & 3).  
 
Annexin A2 has also been reported to be secreted in some cellular 
environments 
151. The tendency for Annexin A2 to accumulate at membranes 
suggested that upon OCRL1 depletion, Annexin A2 may translocate across 
the membrane as it does in cells lacking CLCN5 function, and even be 
secreted. Incubation of cells with 5mM EGTA, a calcium chelator, strips 
calcium binding proteins from the cell surface. Upon this treatment, data 
indicate that Annexin A2 levels at the extracellular face of the plasma 
membrane after OCRL1 siRNA treatment are unaffected, in comparison with 
mock oligofectamine treated HeLa cells (Figure 3.2.4., first lane). The   80 
appearance of a band positive for Annexin A2 in a lane that was left blank 
suggests that over-flow from either EGTA-stripped membranes or fraction one 
occurred. This means that the redistribution of Annexin A2 to the extracellular 
face of the membrane cannot be fully determined from the current data 
(Figure 3.2.4). However, a much clearer effect was that Annexin A2 was 
found to be elevated in the medium of cells treated with OCRL1 siRNA, 
showing that Annexin A2 is lost from these cells (Figure 3.2.5). Here, the 
tubulin control shows that the recovered Annexin A2 is not associated with 
cells. This is consistent with the finding that Annexin A2 is shed from cells in 
exosomes 
152.  
 
Overall these results show that depletion of OCRL1 leads to translocation of 
Annexin A2 from the cytoplasm to the plasma membrane, which it crosses. 
The mechanism by which this event occurs has not yet been fully 
investigated.   81 
Figure 3.2.1: OCRL1 can be efficiently depleted from cells upon siRNA 
transfection 
 
 
Figure 3.2.1. legend: HeLa and HLE-B3 cells were treated with OCRL1 
siRNA or oligofectamine alone 72 hours prior to analysis of OCRL1 and α-
tubulin expression levels by Western Blot. AIDA densitometry reveals that 
relative OCRL1 expression is reduced by 60% in comparison to mock 
oligofectamine control. The effect of OCRL1 siRNA in HLE-B3 is not 
statistically relevant due to a loss of HLE-B3 cell viability upon treatment with 
siRNA.  
   82 
 
Figure 3.2.2: Immunofluorescence studies reveal that Annexin A2 is re-
distributed upon OCRL1 depletion in epithelial cell line, HeLa 
 
 
          OCRL1                 Annexin A2                  DAPI 
 
Figure 3.2.2. legend: HeLa cells were treated with oligofectamine alone (1
st 
and 2
nd rows) or OCRL1 siRNA (3
rd and 4
th rows). 72 hours later cells were 
fixed with methanol at -20ºC for 5 minutes, and immunostained with 
antibodies specific to OCRL1 (left column), Annexin A2 (middle column) and 
Oligofectamine  
 
Oligofectamine  
(2x magnification) 
  
OCRL1 siRNA       
OCRL1 siRNA       
(2x magnification) 
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stained with DAPI (right column). The bottom two rows are zoomed images 
from the top rows. White arrows highlight internal membranes positive for 
Annexin A2. Single confocal sections. (Scale bar 10µm). 
 
The effect of OCRL1 depletion with siRNA on the OCRL1 immunostain seems 
to be very weak, especially when compared to western blot analyses, which 
show an approximate 60% reduction in protein levels. This discrepancy is due 
to high background staining by this batch of immunoaffinity purified OCRL1 
primary antibody, which is associated with the appearance of three non-
specific bands on Western blots.    84 
 
Figure 3.2.3: Effect of OCRL1 depletion on Annexin A2 distribution in 
human lens epithelial cell line, HLE-B3 
 
      OCRL1          Annexin A2            DAPI              Overlay 
Figure 3.2.3. legend: HLE-B3 cells were treated 72 hours prior to fixation 
with methanol at 20ºC with mock oligofectamine (top panel) or OCRL1 siRNA 
(bottom panel) and immunostained with antibodies specific to OCRL1 and 
Annexin A2. Nuclei were stained with DAPI. White arrows indicate sites of 
Annexin A2 accumulation at internal membranes. Single confocal sections. 
 
In a similar fashion to Figure 3.2.2., there is only a small change in the 
OCRL1 immunostain upon depletion of OCRL1. (Scale bar 10µm). 
 
Oligofectamine 
Oligofectamine 
(2x magnification) 
 
OCRL1 siRNA 
(2x magnification) 
 
OCRL1 siRNA 
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Figure 3.2.4: Percoll fractionation to examine Annexin A2 re-distribution 
upon OCRL1 depletion from HeLa cells 
 
 
Figure 3.2.4. legend: HeLa cells were treated with either oligofectamine or 
OCRL1 siRNA for 72 hours. Cells were washed twice with HBSS and were 
incubated for 2 minutes with 5mM EGTA, a calcium chelator that served to 
strip Annexin A2 from the extracellular plasma membrane. From these EGTA 
treated cells, lysates were prepared and separated by Percoll density gradient 
centrifugation. The EGTA stripped solution and each fraction were then 
precipitated with TCA and probed by Western Blot for Annexin A2.  
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Figure 3.2.5: Annexin A2 is found in the extracellular medium upon 
OCRL1 depletion from HeLa cells 
 
 
 
Figure 3.2.5. legend: HeLa cells were treated with either OCRL1 siRNA or 
oligofectamine alone for 72 hours. Cells were placed in serum-free medium at 
48 hours and medium was removed and precipitated after 72 hours. 
Precipitates were then analysed for Annexin A2 and α-tubulin levels by 
Western blot. The tubulin blot demonstrates that the precipitates did not 
include dead cells. A similar result was obtained in two experiments. 
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3.3: Effect of OCRL1 depletion on the localisation of different 
phosphoinositides using PH domains 
 
The preferred substrate of OCRL1 has been reported to be PI(4,5)P2 and 
accordingly PI(4,5)P2 levels are elevated in cells lacking expression of 
OCRL1 
36, 38. However, the location within cells of this PI(4,5)P2 is unknown. 
There are reports of PI(4,5)P2 pools residing at other sites in the cell other 
than the plasma membrane, such as the nucleus, and within Golgi stacks 
13. 
The increased levels of PI(4,5)P2 raise another interesting possibility, that 
there is an impact on levels of other phosphoinositides. For example, a loss of 
PI(4,5)P2 5-phosphatase activity as a result of OCRL1 depletion may lead to 
a reduction in PI(4)P or an elevation in PI(3,4,5)P3 levels. Again these 
changes may coincide with a change in the normal distribution of these 
phosphoinositides within the cell. To address this possibility, analysis of living 
cells transiently expressing GFP-PH domain chimeras specific to different 
phosphoinositides was undertaken. A plethora of phosphoinositide binding 
domains have been discovered, some of which bind one particular 
phosphoinositide. One such domain is the PH domain of PLCδ1, which 
recognises PI(4,5)P2 with high specificity. Another PH domain, that of 
oxysterol binding protein (OSBP) recognises a pool of PI(4)P that resides at 
the Golgi apparatus. These domains were expressed as GFP fusions in HeLa 
cells, and showed the expected distributions (Figure 3.3.1). 
 
Previous results showing a re-distribution of Annexin A2 to the plasma 
membrane and intracellular compartments suggested that PI(4,5)P2 may   88 
accumulate at these sites upon OCRL1 depletion (Figure 3.2.2). In yeast, 
intracellular pools of PI(4,5)P2 are tightly regulated by the activity of proteins 
belonging to the synaptojanin family, which are able to dephosphorylate the 
phosphoinositide at the 5’ position of the myo-inositol ring. Upon inactivation 
of multiple synaptojanin-like proteins in yeast, PI(4,5)P2 accumulates at 
internal membranes 
72. Other evidence of the presence of PI(4,5)P2 at 
internal membranes comes from an immuno-electron microscopic study using 
the purified PH domain of PLCδ . This method was effective in showing that 
PI(4,5)P2 is greatly concentrated at the plasma membrane, but is also present 
at lower levels in the Golgi, endosomes and also the nucleus 
13.  
 
OCRL1 is localised to the TGN and endosomes and therefore PI(4,5)P2 may 
be at these sites at low levels in normal cells, and accumulate there upon 
OCRL1 depletion. Classically, the localisation of PI(4,5)P2 is reported in living 
cells using a GFP chimera of the PH domain of PLCδ1. The localisation of 
GFP-PLCδ-PH upon OCRL1 depletion in HeLa cells was therefore analysed. 
The localisation of GFP-PLCδ-PH in mock transfected cells reveals a plasma 
membrane distribution thought to be driven principally by the high abundance 
of PI(4,5)P2 at this membrane (Figure 3.3.2., top panel). Upon RNAi mediated 
depletion of OCRL1, no significant difference in the localisation of GFP-PLCδ-
PH was observed with the majority of cells showing a purely plasma 
membrane accumulation. However in a subset of the cells, GFP-PLCδ-PH 
showed signs of accumulating at intracellular sites within the cell (Figure 
3.3.2., bottom panel). Given that the PLCδ1-PH domain has other factors 
driving its accumulation at the plasma membrane such as anionic charge this   89 
observation suggests that PI(4,5)P2 might be accumulating on internal 
membranes in cells lacking OCRL1 
71.  
 
Despite claims that the PLCδ1-PH domain localises to the plasma membrane 
based on its affinity for PI(4,5)P2 alone, there are other, non-phosphoinositide 
dependent mechanisms, such as an affinity for anionic charge that play a part 
in targeting to the plasma membrane 
71. Therefore, the signal of PI(4,5)P2 as 
reported by PLCδ-PH is contaminated by non-phosphoinositide, plasma 
membrane-specific factors. For this reason, we investigated whether a fusion 
of PLCδ-PH to a protein loosely targeted to an intracellular site within the cell 
(here the TGN) may reveal previously unobserved PI(4,5)P2. We have 
created a construct that expresses a mutant version of the OSBP PH domain 
fused to PLCδ-GFP. In previous work by Levine and Munro in 1998 and 2002, 
it was shown that the PH domain of OSBP binds tightly to the TGN 
144, 153. 
This is also shown in Figure 3.3.1 (right panel). This interaction was shown to 
be dependent on a phosphoinositide determinant and a protein determinant, 
now thought to be Arf1
23. Upon mutation of two critical arginine residues to 
glutamic acid residues, the ability of OSBP-PH (RR->EE) to localise to the 
TGN is greatly reduced due to a loss of phosphoinositide binding ability 
144, 
although there is weak targeting that is still detected using a dimeric construct 
with two PH domains in tandem. 
 
By fusing the mutated OSBP-PH domain to GFP-PLCδ-PH, the weak Golgi 
targeting may be sufficient to allow PI(4,5)P2 at the Golgi to compete with 
PI(4,5)P2 at the plasma membrane for binding to the PLCδ-PH, and so detect   90 
PI(4,5)P2 at the TGN in living cells. This fusion protein (given the acronym 
GFP-POP, from PLC∂-OSBP[EE] PH dimer) may be more likely to report 
intracellular accumulations of PI(4,5)P2, which potentially arise upon OCRL1 
depletion. Alternatively, if OCRL1 depletion causes PI(4,5)P2 accumulation at 
the plasma membrane, redistribution of GFP-POP from intracellular sites to 
the plasma membrane may occur. Therefore, analysis of the abundance of 
GFP-POP at the plasma membrane, the cytosol and intracellular 
compartments, was carried out to detect potential changes in sub-cellular 
PI(4,5)P2 accumulation with knockdown of OCRL1. 
 
In mock siRNA treated HeLa cells, GFP-POP exhibited a largely plasma 
membrane and cytosolic localisation with weak intracellular accumulations 
sometimes observed (Figure 3.3.3., top panel). Upon depletion of OCRL1 with 
siRNA a redistribution of GFP-POP from the cytosol and plasma membrane to 
intracellular sites was suggested upon initial analysis (Figure 3.3.3., bottom 
panel,). Strong accumulation of GFP-POP at perinuclear sites within OCRL1 
siRNA-treated HeLa cells was not seen as readily in cells treated with mock 
siRNA, although some punctate distribution of GFP-POP was seen. Further 
characterisation based on the ratio of GFP-POP localisation between the 
plasma membrane, cytosol and internal membrane compartments upon 
OCRL1 depletion was required and three separate experiments revealed a 
statistically significant difference (Figure 3.3.4).  
 
However, upon assessment of a large number of cells, different clones of 
HeLa cells and further categorisation of the strength of accumulations of GFP-  91 
POP on internal membranes, these results were irreproducible. We began to 
find that a higher percentage of control siRNA treated cells exhibited strong 
accumulations on internal membranes, and the significance of the initial set of 
results was reduced. We decided to further characterise whether there were 
any undesired effects of over-expression of GFP-POP in these cells. 
Immunofluorescent studies of control and OCRL1 siRNA treated cells 
transiently expressing GFP-POP revealed that over-expression caused strong 
relocalisation of endogenous OCRL1 to a perinuclear site (Figure 3.3.5). 
Furthermore, in control siRNA and OCRL1 siRNA treated cells the localisation 
and possibly the detectable levels of TGN46, a protein highly enriched at the 
trans-Golgi network was adversely affected (Figure 3.3.6). In GFP-POP 
expressing cells, the normal perinuclear distribution of TGN46 was lost and a 
much lower level of fluorescence was detected. This result is similar to, 
though less strong than, the effect of over-expressing GFP-OSBP-PH on 
TGN46 and indicates that the GFP-POP construct is binding to and thereby 
sequestering, ARF1 on the TGN, leading to dispersal of that organelle 
23, 153. 
  
It is possible that loss of OCRL1 has effects on levels and localisations of 
phosphoinositides other than PI(4,5)P2. Increases in PI(4,5)P2 may reflect a 
decrease in PI(4)P. Also, since PI(4,5)P2 is the substrate for PI3K family 
members and OCRL1 can dephosphorylate PI(3,4,5)P3, there may be an 
increase in PI(3,4,5)P3 levels. Further studies were carried out analysing the 
distribution of a GFP chimera of the AKT-PH domain often used to report 
PI(3,4,5)P3 
11, 154. However, no significant changes in GFP-AKT-PH or GFP-
Grp1-PH localisation upon OCRL1 depletion were observed (Figure 3.3.7). It   92 
is worth bearing in mind that differences in GFP-AKT-PH or GFP-Grp1-PH 
localisation may only be achieved upon stimulating cells to synthesise 
PI(3,4,5)P3, for example with platelet-derived growth factor, PDGF 
155.   93 
 
Figure 3.3.1: Use of PH domains to visualise two different 
phosphorylated phosphoinositide populations 
 
 
                 GFP-PLCδ-PH                                   GFP-OSBP-PH 
Figure 3.3.1. legend: HeLa cells transiently expressing GFP-PLCδ-PH and 
GFP-OSBP-PH. HeLa cells were transfected with DNA encoding either 
expressing GFP-PLCδ-PH (left panel) GFP-OSBP-PH (right panel), 24 hours 
prior to analysis by confocal microscopy. Single confocal sections. Scale bar 
(10µm).   94 
 
Figure 3.3.2: Effect of OCRL1 depletion on intracellular localisation of 
GFP-PLCδ-PH in living HeLa cells 
 
     
 
     
 
Figure 3.3.2. legend: HeLa cells expressing GFP-PLCδ-PH. Cells were 
treated with either mock siRNA (top panel) or OCRL1 siRNA (bottom panel), 
48 hours prior to analysis by confocal microscopy, and transfected with GFP-
PLCδ-PH 24 hours prior to imaging. Single confocal sections. Scale bar 
(10µm). 
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Figure 3.3.3: Effect of OCRL1 depletion on intracellular localisation of 
GFP- POP in living HeLa cells 
 
 
 
Figure 3.3.3. legend: Representative images of living HeLa cells transiently 
expressing GFP-POP for 24 hours after either mock siRNA (top panel) or 
OCRL1 siRNA (bottom panel) treatment for 48 hours. Single confocal 
sections. Scale bar (10µm). 
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Figure 3.3.4: Quantification of change in localisation of GFP-POP upon 
OCRL1 depletion 
   
Figure 3.3.4 legend: Three separate categories were coded based on 
accumulation of GFP-POP at internal membranes. These categories were: 
none, weak and strong internal membrane accumulation. Three separate 
experiments were performed; control siRNA (n=70) and OCRL1 siRNA (n=70) 
treated cells were coded to be indistinguishable, and assigned to these 
categories by a third party. *p=<0.05. **p=<0.02.  97 
 
Figure 3.3.5: OCRL1 localisation in HeLa cells over-expressing GFP-POP 
 
                           OCRL1                                       GFP-POP 
Figure 3.3.5 legend: Control siRNA treated HeLa cells were transiently 
transfected with DNA encoding GFP-POP. After 24 hours of over-expression, 
cells were fixed with 4% paraformaldehyde, permeabilised and blocked in 
1mg/ml BSA and stained for OCRL1. The lower two panels are enlarged 
images taken from the white boxes in the upper panels. Single confocal 
sections. Scale bar (10µm). 
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Figure 3.3.6: TGN46 localisation in HeLa cells over-expressing GFP-POP 
 
                       GFP-POP                                            TGN46 
Figure 3.3.6 legend: Control siRNA treated HeLa cells were transiently 
transfected with DNA encoding GFP-POP. After 24 hours of over-expression, 
cells were fixed with 4% paraformaldehyde, permeabilised and blocked in 
1mg/ml BSA and stained for TGN46. The lower two panels are enlarged 
images taken from the white boxes in the upper panels. Single confocal 
sections. Scale bar (10µm). 
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Figure 3.3.7: PI(3,4,5)P3 localisation in HeLa cells over-expressing PH 
domains of GFP-AKT or GFP-Grp1 upon OCRL1 depletion 
 
 
     
     
                Control siRNA                             OCRL1 siRNA 
 
Figure 3.3.7 legend: HeLa cells were treated with non-targetting, negative 
control siRNA or OCRL1 siRNA for 72 hours. Cells were transiently 
transfected with DNA encoding GFP-tagged PH domains of AKT (top row) or 
Grp1 (bottom row) after 48 hours of siRNA treatment. After 24 hours of over-
expression, living cells visualised using a Leica confocal microscope at room 
temperature. No differences were seen with either construct. Single confocal 
sections. Scale bar (10µm). 
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3.4: PI(4,5)P2 localisation studies in Saccharomyces Cerevisiae 
 
In a previous study in yeast it was shown that the PLCδ-PH domain can target 
internal membranes upon inactivation of multiple members of the synaptojanin 
family 
72. These data provide evidence that PI(4,5)P2 can accumulate at 
internal membranes in yeast mutants. The results achieved in this thesis with 
GFP-POP in mammalian cells (Figure 3.3.2) suggested that our novel 
construct may be able to visualise changes in PI(4,5)P2 levels and 
localisation in yeast. In the aforementioned study, only upon inactivation of the 
entire complement of synaptojanin-like family members did GFP-PLCδ-PHx2 
accumulate at internal membranes.  
 
S.cerevisiae do not express OCRL1, however the synaptojanin family proteins 
share the same highly conserved inositol polyphosphate 5-phosphatase 
domain 
33, 156. Given the suggested propensity of GFP-POP in the OCRL1 
RNAi experiments to bind PI(4,5)P2 on internal membranes, we decided to 
compare GFP-POP with GFP-PLCδ-PH in wild-type yeast and mutants with 
single deletion of either Inpp51, Inpp52, Inpp53 or Inpp54. We decided to test 
whether POP detects a previously unappreciated internal pool of PI(4,5)P2 in 
the single deletion mutants.  
 
Upon comparison of GFP-PLCδ-PH and GFP-POP in wildtype yeast, two 
clear differences were observed (Figure 3.4.1). Firstly, the expression levels 
of GFP-POP were much lower than that of GFP-PLCδ-PH. Fluorescence   101 
levels varied a great amount between cells within an experiment, as the 
expression vector used produces a variable copy number. However, on 
average, expression levels of GFP-PLCδ-PH in yeast were much higher than 
GFP-POP cells. Secondly, a clearer localisation to the cell periphery above 
the cytoplasmic background was reproducibly seen for GFP-POP in 
comparison to GFP-PLCδ-PH. Interestingly, in some of the yeast, an internal 
GFP-POP positive punctum was visible, in close proximity but not adjoining, 
the nucleus and vacuole. 
 
It is well known that yeast contain a higher level of inositol phosphates in 
comparison to mammalian cells, which would compete for the GFP-PLCδ-PH 
interaction with PI(4,5)P2. For this reason, a dimer of the PLCδ-PH domain is 
often used for visualisation of PI(4,5)P2 in yeast 
72, 144. One factor not 
considered originally in the design of POP, is that in theory this novel hetero-
dimeric construct would bind, in addition to the desired sites of co-incidence, 
any membrane receptors of both PH domains. The increased plasma 
membrane targeting of POP over PLCδ-PH may be caused by additional, yet 
weak, affinity of mutant OSBP-PH for the plasma membrane. This is likely to 
be because of a residual interaction by mutant OSBP-PH with anionic 
phospholipids such as phosphatidic acid (Dr. Tim Levine, unpublished 
observation). 
 
Upon deletion of each synaptojanin homologue, GFP-POP localisation to the 
plasma membrane was diminished (Figure 3.4.2). Given that the majority of 
PI(4,5)P2 resides at the plasma membrane, this result was surprising. The   102 
most plausible explanation for this is that loss of plasma membrane targeting 
of GFP-POP is due to increased cytosolic I(1,4,5)P3, with increased 
phospholipase C action occurring when PI(4,5)P2 is turned over less by 
phosphatases. To test this, we decided to look at PLC1 deletion mutants. In 
yeast there is only one PLC family member, therefore these yeast are unable 
to hydrolyse PI(4,5)P2 to I(1,4,5)P3 and (1,2)-diacylglycerol. Due to the loss 
of I(1,4,5)P3 formed from PI(4,5)P2 hydrolysis, and possibly an increase in 
plasma membrane PI(4,5)P2, we expected to see an increase in the plasma 
membrane targeting of GFP-POP and GFP-PLCδ-PH. As expected, the 
plasma membrane localisation of GFP-POP was enhanced in ∆plc1 yeast, in 
comparison to wildtype yeast (Figure 3.4.3, top and bottom right panels). 
However, the localisation and intensity of GFP-PLCδ-PH in wildtype and 
mutant yeast seemed to be very comparable (Figure 3.4.3, top and bottom left 
panels). This result suggested that GFP-POP may be better than GFP-PLCδ-
PH as a reporter for PI(4,5)P2 in yeast. 
 
To further this study we would like to look at double ∆plc1/∆inp51-54 yeast 
expressing GFP-PLCδ-PH or GFP-POP: if our hypothesis is correct then it 
may be that deletion of PLC1 recovers plasma membrane recruitment of 
GFP-POP. 
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Figure 3.4.1: Comparison of GFP-POP and GFP-PLCδ-PH in wildtype 
S.cerevisiae 
 
 
                          GFP-PLCδ-PH                            GFP-POP 
Figure 3.4.1 legend: GFP-tagged proteins (PLCδ-PH and POP) were 
visualised in live wild-type cells growing in log phase at 30°C. Confocal 
images of cells were taken immediately after plating onto a glass slide and 
spread gently by application of a coverslip. Images from the top row have 
been enlarged and are shown in the bottom row. Single confocal sections. 
Scale bar (10µm).   104 
 
Figure 3.4.2: Effect of deletion of synaptojanin-like proteins in yeast on 
localisation of GFP-POP 
 
 
 
(2x 
magnification) 
Δinpp51  Δinpp52 
Δinpp53  Δinpp54 
Δinpp51  Δinpp52 
Δinpp53  Δinpp54   105 
Figure 3.4.2 legend: GFP-POP was visualised in wild-type and mutant yeast 
(synaptojanin-like family member deleted is labelled in the top right hand 
corner) growing in log phase at 30°C. Confocal images of cells were taken 
immediately after plating onto a glass slide and spread gently by application of 
a coverslip. Images from the top two rows have been enlarged and are shown 
in the bottom two rows. Single confocal sections. Scale bar (10µm). 
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Figure 3.4.3: Effect of PLC1 deletion on localisation of GFP-PLCδ-PH 
and GFP-POP 
 
 Δplc1/ GFP-PLC-PH   Δplc1/ GFP-POP-PH 
 Δplc1/ GFP-PLC-PH   Δplc1/ GFP-POP-PH 
(2x 
magnification) 
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Figure 3.4.3 legend: GFP-tagged proteins (PLCδ-PH and POP) were 
visualised in live wild-type and PLC1 delete cells growing in log phase at 
30°C. Confocal images of cells were taken immediately after plating onto a 
glass slide and spread gently by application of a coverslip. Images from the 
top two rows have been enlarged and are shown in the bottom two rows. 
Single confocal sections. Scale bar (10µm). 
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4: OCRL1 and calcium signalling 
 
Cells taken from Lowe Syndrome patients have elevated levels of PI(4,5)P2 
36. Regulation of the level and localisation of PI(4,5)2 is integral to many cell 
signalling pathways. Upon stimulation of G-protein mediated PLC family 
members, PI(4,5)P2 is readily hydrolysed to IP3 and DAG. The IP3 generated 
from this event causes the release of calcium stores into the cytosol, through 
the IP3 receptor 
157. IP3-sensitive calcium stores include organelles such as 
the endoplasmic reticulum and Golgi apparatus, the latter of which OCRL1 
localises to.  
 
If OCRL1 5-phosphatase activity regulates a signalling pool of PI(4,5)P2, cells 
without OCRL1 may exhibit a difference in intracellular calcium handling. It is 
possible that elevated PI(4,5)P2 levels as a result of OCRL1 loss has a 
knock-on effect on the speed and magnitude of calcium store release, through 
an increase in substrate availability for PLC family members. It is also 
possible that OCRL1 functions to dampen the IP3 signal by 
dephosphorylating IP3 to inositol(1,4)-bisphosphate (IP2). This means that 
IP3 may persist in the cytosol of a cell lacking OCRL1, which may change the 
kinetics of calcium levels in the cytosol. In support of this hypothesis, inositol 
polyphosphate 5-phosphatases specific to PI(4,5)P2 have been shown to 
have very important roles in calcium signalling 
26, 85. 
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Furthermore, our previous results are intricately linked to this hypothesis. We 
have demonstrated a change in localisation of Annexin A2 upon OCRL1 
depletion. Previous work has shown that Annexin A2 binding to PI(4,5)P2 is 
enhanced by the presence of calcium. Therefore the altered distribution of 
Annexin A2 upon OCRL1 loss may be due to a change in calcium levels as 
well as PI(4,5)P2 levels and localisation. Also, it is possible that Annexin A2 
redistribution corresponds to a functional role, tightly linked to regulation of 
intracellular calcium levels. Annexin A2 has been shown to be an effective 
inhibitor of G-protein mediated PLC activation 
158. Therefore Annexin A2 
redistribution may represent a homeostatic inhibition of uncontrolled IP3-
mediated calcium signalling in OCRL1 depleted cells. 
 
All these ideas suggest that OCRL1 plays a negative role in calcium signalling 
by keeping PI(4,5)P2 and IP3 levels down. Conversely, loss of OCRL1 
function may lead to a reduction in the ability of the cell to release calcium 
stores upon stimulation. It has been shown that PI(4,5)P2 has an inhibitory 
effect upon the IP3 receptor 
86. Therefore, should PI(4,5)P2 levels be elevated 
at sites containing the IP3 receptor, or increased PI(4,5)P2 levels at the 
plasma membrane be in apposition to internal membranes containing the IP3 
receptor, an inhibition of calcium signalling would be anticipated. This 
suggests that OCRL1 might play a positive role in calcium signalling in the 
cell. Only upon PLC stimulation and subsequent hydrolysis of PI(4,5)P2 would 
this inhibition be relieved, with IP3 competing with PI(4,5)P2 for the IP3 
receptor. IP3 has a much greater binding affinity than PI(4,5)P2 for the IP3 
receptor and would therefore have the dominating interaction upon IP3   111 
generation. Many other receptors and channels important in calcium signalling 
have been shown to be affected by PI(4,5)P2 and it was felt a study of 
OCRL1 and calcium signalling was warranted 
87.  
 
Histamine and ATP are known stimuli for G-protein coupled PLC activation 
and can be used for analysis of the IP3-sensitive calcium response. To 
investigate the effect of OCRL1 depletion upon calcium signalling in HeLa 
cells, two different concentrations of histamine were used: one submaximal 
dose (10µM) and one maximal dose (100µM). In comparison to mock siRNA 
treated HeLa cells, a greater increase in intracellular calcium levels was 
observed upon stimulation with both concentrations of histamine after 48 
hours and 72 hours treatment with OCRL1 siRNA (Figure 4.1.1 and Figure 
4.1.3, filled bars). Little or no difference was observed in the kinetics of 
calcium levels in the cytosol, with peaks of calcium levels being achieved 
within the same time-frame, regardless of cell treatment (Figure 4.1.2 and 
Figure 4.1.4).  
 
Treatment of cells with a sarco/endoplasmic reticulum calcium ATPase 
(SERCA) pump inhibitor, thapsigargin, causes the release of intracellular 
stored calcium. Histamine treatment of cells was followed by application of 
thapsigargin, in order to deplete residual levels of calcium in stores. A higher 
calcium concentration in the cytosol was observed in OCRL1 depleted cells in 
comparison with mock siRNA treated cells after treatment with thapsigargin 
(striped bars; Figure 4.1.1 and Figure 4.1.3). This indicated that it was 
possible that total store calcium was elevated in OCRL1 siRNA treated cells,   112 
or an increase in the store-operated calcium influx pathway through the 
plasma membrane. To test these findings further, cells were treated with 
thapsigargin alone as a measure of IP3-independent changes in cytosolic 
calcium. Clear differences in cytosolic calcium levels between mock siRNA 
treated and OCRL1 siRNA treated cells were observed, with OCRL1 depleted 
cells comparatively showing an approximate 2-fold increase in cytosolic 
calcium (Figures 4.2.1-4.2.2). This result indicates one of two things; either 
total store calcium in cells depleted of OCRL1 is higher, leading to higher 
levels of calcium release into the cytosol, or more calcium is entering the cell 
from the extracellular medium upon thapsigargin treatment, through 
capacitative calcium entry. The two phases of calcium elevation are 
representative of the initial IP3-dependent release of calcium stores, and then 
a second wave representative of store-operated calcium entry. These data 
suggest that the increased level of cytosolic calcium in OCRL1 RNAi treated 
cells upon thapsigargin alone suggests that the differences observed upon 
histamine treatment between control and OCRL1 siRNA treated cells (Figures 
4.1.1-.4.1.4) may not be IP3-dependent, but due to increases in total store 
calcium or calcium entry from the extracellular medium.  
 
To test these theories, we analysed calcium signalling in these cells in the 
presence of an extracellular calcium chelator, BAPTA. Upon stimulation with 
thapsigargin in the presence of BAPTA, we found that there was no difference 
to the change in cytoplasmic calcium between control siRNA and OCRL1 
siRNA treated cells (Figure 4.3.1, left hand pair of bars). Thapsigargin 
treatment causes the ER stores of calcium to become depleted into the   113 
cytoplasm. Upon calcium entry into the cytoplasm, different channels become 
activated, such as plasma membrane calcium ATPases (PMCAs) and store-
operated calcium channels (SOCs). In this experiment, upon ER calcium 
release, the cell extrudes cytoplasmic calcium through the plasma membrane, 
where it is chelated by the BAPTA in the extracellular medium. This process 
activates and primes SOCs at the plasma membrane, but no calcium can 
enter the cell through the plasma membrane, as it has been buffered out. 
However, upon addition of excess calcium to the extracellular medium, we 
can monitor the calcium entry back through the plasma membrane. We 
hypothesised that OCRL1 may alter levels of PI(4,5)P2 at the plasma 
membrane, where it may regulate plasma membrane SOCs. Upon re-addition 
of calcium to the extracellular medium, we saw a rapid rise in cytosolic 
calcium in both populations of cells, indicative of calcium entry through 
plasma membrane channels. We observed that cells depleted of OCRL1 
allowed more calcium to enter from the extracellular medium (Figure 4.3.1, 
right hand pair of bars). This elevated level of calcium was maintained and 
formed a sustained plateau, in a similar pattern to control siRNA treated cells. 
It is noteworthy that the shape of both graphs was very similar, the difference 
being the amplitude of response to re-addition of calcium (Figure 4.3.2). 
 
In previous studies, OCRL1 has been shown to translocate to the plasma 
membrane, either to plasma membrane clathrin coated pits, or to membrane 
ruffles upon growth factor treatment. The latter study suggested that OCRL1 
moves to the plasma membrane upon certain stimuli that evoke calcium 
signalling (namely EGF treatment), perhaps in order to reduce PI(4,5)P2   114 
levels or pools, to switch off the PLC/IP3 signalling cascade. For this reason, 
we decided to look at whether OCRL1 changes its distribution upon histamine 
treatment. We found that OCRL1 translocated to the plasma membrane and 
distributed itself in a non-linear pattern of punctate dots as soon as one 
minute after histamine treatment. Furthermore, this localisation to the plasma 
membrane became stronger as time passed, and was particularly prominent 
at later time points such as ten minutes, and even as long as one hour post-
stimulation (Figure 4.4). OCRL1 localisation to the plasma membrane in the 
time period of one minute to ten minutes was of particular importance, as this 
is the period after histamine stimulation in which levels of calcium in the 
cytosol begin to reduce. This is the period in which OCRL1 depleted cells 
display a higher level of calcium in the cytosol. Given our theory that 
increased calcium levels in the cytosol of OCRL1 depleted cells seems to be 
due to flow from the extracellular medium, this observation seems to fit in with 
the kinetics of the calcium measurements. It seems that OCRL1 may 
translocate to the plasma membrane after stimulation in order to regulate 
capacitative calcium entry and turn off IP3 generation. 
 
To further our findings that OCRL1 loss affects calcium signalling, we decided 
to look at skin fibroblasts taken from two different Lowe Syndrome patients 
(these cells were designated the names, Lowe B and Lowe 2). These cells 
may provide more meaningful insights into the effect of OCRL1 in calcium 
signalling, as RNAi treatment only looks at short-term, transient downstream 
consequences of OCRL1 loss. We found that these fibroblasts responded 
best to ATP rather than histamine and assessed responses of the these cells   115 
to three difference doses of ATP, 10µM, 50µM and 100µM. Unfortunately 
there seemed to be no consistency between Lowe B and Lowe 2 cells, 
however both were consistently different from control skin fibroblasts. 
 
At the lowest dose of 10µM ATP there were clear differences in the way Lowe 
Syndrome fibroblasts responded in comparison to contol traces. (Figure 
4.5.1). Control fibroblast traces show cytosolic calcium levels rapidly reaching 
a peak within the first minute of stimulation. Calcium levels then fall rapidly, 
traces displaying a plateau at 200 seconds, indicative of capacitative calcium 
entry, and finally fall down to base level again 600 seconds post stimulation. 
(Figure 4.5.1, red line trace) However, the initial response of Lowe B cells to 
10µM ATP is much less in amplitude and speed. (Figure 4.5.1, green line 
trace) Lowe B fibroblasts only reach approximately half the peak calcium level 
of control fibroblasts and much slower, at 300 seconds (Figure 4.5.2). The 
cytosolic calcium level then fails to drop back down to zero during the 20 
minute period of measurement. In comparison, the response of Lowe 2 cells 
is very different to both Lowe B and control fibroblast responses. Lowe 2 
fibroblasts achieve a peak calcium level in the cytosol within the first minute 
post stimulation, a little higher than control fibroblasts, however this level is 
only slightly reduced in the time period after. A very high calcium level is 
maintained in the cytosol, indicating that either the cell is failing to pump out 
calcium from the cytosol, or is allowing too much calcium to enter through 
plasma membrane channels. The failure of Lowe Syndrome fibroblasts to 
reduce cytosolic calcium back down to resting levels is clearly observed when 
comparing control, Lowe B and Lowe 2 calcium levels at the 600 second time   116 
point (Figure 4.5.2, light grey bars). Whereas control fibroblast calcium levels 
are nearly back down to resting levels, Lowe B levels are a bit higher and 
Lowe 2 levels are significantly raised, remaining so even up to 20 minutes 
post stimulation.  
 
This trend was reproducible with a higher dose of 50µM ATP (Figures 4.5.3 
and 4.5.4). Again, within one minute, peak levels of calcium in the cytosol 
were observed in control and Lowe 2 cells, with Lowe 2 displaying a slightly 
higher peak calcium level than control fibroblasts. However, Lowe B cells 
exhibited a much lower average calcium level and in a much slower fashion, 
reaching its peak at approximately 300 seconds post stimulation. (Figure 
4.5.3). Like responses to 10µM ATP, Lowe 2 cells maintained a significantly 
high level of cytosolic calcium in comparison to control cells, clearly observed 
when comparing calcium levels at the 600 second time point (Figure 4.5.4, 
light grey bars) . Again, when looking at the final values 20 minutes post-
stimulation, control responses are back down to basal values, whereas Lowe 
B and Lowe 2 cells maintain a higher level of cytosolic calcium.  
 
At a maximal dose of 100µM ATP, we saw the strongest responses, however 
the pattern of differences between Lowe Syndrome fibroblasts and control 
fibroblasts was slightly different (Figures 4.5.5 and 4.5.6). Again, sharp 
responses to ATP were seen with control and Lowe 2 fibroblasts, both 
peaking within one minute. However the highest peak calcium level was 
observed with control fibroblasts, suggesting that a dose of 10-50µM ATP is 
maximal for Lowe 2 fibroblasts, perhaps representing a heightened sensitivity   117 
to agonist in Lowe 2 fibroblasts. A much-weakened response was observed 
with Lowe B fibroblasts, with low peak calcium levels and an average line 
trace that at some time-points dipped lower than resting values (Figure 4.5.5). 
Again, a very high level of cytosolic calcium was maintained in Lowe 2 
fibroblasts up to 20 minutes post stimulation, whereas control and Lowe B 
fibroblast cytosolic calcium returned back to resting levels. This again has 
been shown by plotting calcium levels of the three cell types at the 600 
second time-point post stimulation with a ATP. It is noteworthy that in wild-
type cells the shape of calcium response was very similar at every 
concentration of ATP stimulation. However, these characteristic sharp peaks, 
troughs and returns to basal levels were unseen in Lowe Syndrome 
fibroblasts. In Lowe Syndrome fibroblasts, acute peaks of cytosolic calcium 
upon ATP stimulation were not observed. Interestingly, if calcium levels were 
elevated above basal levels upon ATP stimulation, it was persistent within the 
cytoplasm. This is suggestive of a failure to extrude calcium out of the cell, or 
buffer it back into internal organelles such as the ER, Golgi or lysosomes. 
 
To further elucidate the mechanism of the differences observed between 
Lowe Syndrome fibroblasts and control fibroblasts, we assessed the 
responses of these cells to an IP3-independent stimulus for calcium release, 
thapsigargin. (Figures 4.5.7 and 4.5.8). Control and Lowe 2 responses to 
thapsigargin were very similar, with a peak calcium level in the cytosol 
observed within 2 minutes and then slowly reducing as time passed (Figure 
4.5.7, red and blue line traces, respectively). Interestingly, the response of 
Lowe B to thapsigargin was the most intriguing (Figure 4.5.7, green line   118 
trace). Given the poor responses of Lowe B cells to ATP, a weak response to 
thapsigargin may have been expected. Surprisingly, the initial response to 
thapsigargin was very similar to control and Lowe 2 fibroblasts and as time 
passed, the level of cytosolic calcium continued to rise, producing a second 
peak in cytosolic calcium which is maintained all the way through to the final 
time point measured at 20 minutes post stimulation. This difference is clearly 
observed when plotting the cytosolic calcium levels at the 600 second time 
point (Figure 4.5.8, grey bars), with a significantly higher value in Lowe B 
cells. Furthermore, when comparing the peak calcium level to the 600 second 
time point in all measurements, we notice a consistent reduction in the ratio 
between the two. Beneath each graph of response kinetics, the ratio of peak 
to 600 second time points is consistently lower with loss of OCRL1 activity, be 
it through OCRL1 depletion or in Lowe Syndrome patient fibroblasts. This 
suggests that cells lacking OCRL1 either fail to buffer out the initial increase in 
cytoplasmic calcium through efflux mechanisms, and/or a sustained, 
unregulated level of SOC entry. 
 
These data show that Lowe Syndrome cells handle calcium levels very 
differently to control fibroblasts. Taking data from responses to thapsigargin, 
Lowe B cells contain a similar level of store calcium to Lowe 2 and control 
fibroblasts (Figures 4.5.7-4.5.8). However, at later time points when 
capacitative calcium entry occurs, the cytosolic calcium level is higher and 
maintained at this level. However Lowe B cells respond in a much weaker 
fashion to extracellular agonist in comparison to other cells, suggesting that 
the signalling pathway to calcium store release may have been attenuated in   119 
some manner, perhaps by downregulating the receptor for ATP. The reason 
for this downregulation could be suggested from the observed heightened 
ATP responses to Lowe 2 cells (Figure 4.5.1-4.5.6, blue line traces), which 
seem to have a heightened sensitivity to ATP leading to greater calcium 
responses in comparison to control traces. It may be possible that the way in 
which cells from Lowe Syndrome patients have adapted to OCRL1 loss 
affects the severity of their condition. Hypersensitive calcium responses to 
agonist would be highly detrimental to many physiological processes, 
however without details of the patients these cells have been taken from, 
these results cannot be tallied to the severity of Lowe Syndrome. It may be 
the case that there is so much variability that we need to test a higher number 
of different cell lines, from control and Lowe Syndrome patients, in order to 
obtain a typical phenotype.   120 
 
4.1: Effect of OCRL1 depletion on calcium signalling in HeLa cells 
Figure 4.1.1. Relative changes in Fluo-4 fluorescence after application of 
10µM histamine and 1µM thapsigargin 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
Mock 48 hours 72 hours
Cell Treatment
R
e
l
a
t
i
v
e
 
c
h
a
n
g
e
 
i
n
 
F
l
u
o
-
4
 
f
l
u
o
r
e
s
c
e
n
c
e
 
p
o
s
t
-
s
t
i
m
u
l
a
t
i
o
n
Histamine response Thapsigargin response
 
Figure 4.1.1 legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were stimulated with 10µM histamine and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Each bar is representative of 3 wells. All data are expressed as 
relative arbitrary values, normalised against basal Fluo-4 fluorescence before 
stimulation. Error bars are standard deviations.   121 
 
Figure 4.1.2. Kinetics of relative change in Fluo-4 fluorescence after 
application of 10µM histamine and 1µM thapsigargin 
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Figure 4.1.2. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were stimulated with 10µM histamine and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Two examples of each cell treatment are represented on the 
graph, choice was made based on highest basal Fluo-4 fluorescence. All data 
are expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation.  
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Figure 4.1.3. Relative changes in Fluo-4 fluorescence after application of 
100µM histamine and 1µM thapsigargin 
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Figure 4.1.3. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were stimulated with 100µM histamine and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Each bar is representative of 3 wells. All data are expressed as 
relative arbitrary values, normalised against basal Fluo-4 fluorescence before 
stimulation. Error bars are standard deviations. * T-tests comparing siRNA 
treated cells with controls produce p values < 0.05. 
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Figure 4.1.4. Kinetics of relative change in Fluo-4 fluorescence after 
application of 100µM histamine and 1µM thapsigargin 
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Figure 4.1.4. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were stimulated with 100µM histamine and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Two examples of each cell treatment are represented on the 
graph, choice was made based on highest basal Fluo-4 fluorescence. All data 
are expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation.   124 
 
4.2: Effect of OCRL1 loss on total store calcium in HeLa cells 
Figure 4.2.1. Measurement of total store calcium by cell response to 
thapsigargin alone 
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Figure 4.2.1. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were mock stimulated with buffer and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Each bar is representative of 3 wells. All data are expressed as 
relative arbitrary values, normalised against basal Fluo-4 fluorescence before 
stimulation. Error bars are standard deviations. * T-tests comparing siRNA 
treated cells with controls produce p values < 0.05.
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Figure 4.2.2. Kinetics of total store calcium release 
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Treatment  Peak/Plateau 
ratio 
Control siRNA  0.87 
OCRL1 siRNA (48)  0.64 
OCRL1 siRNA (72)  0.53 
 
Figure 5.2.2. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 48 or 72 hours. Cells were loaded with Fluo-4 AM 45 
minutes prior to stimulation. Cells were mock stimulated with buffer and 
imaged for 10 minutes. After 10 minutes cells were then stimulated with 1 µM 
thapsigargin and imaged for 5 minutes. All experiments were done at room 
temperature. Two examples of each cell treatment are represented on the 
graph, choice was made based on highest basal Fluo-4 fluorescence. All data 
are expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation.  126 
 
4.3: Elucidating the origin of elevated cytosolic calcium in OCRL1 
depleted cells 
Figure 4.3.1: Measurement of cytosolic calcium after thapsigargin 
treatment and calcium add-back in calcium-free conditions  
 
 
Figure 4.3.1. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 72 hours. Cells were loaded with Fluo-4 AM 45 minutes 
prior to stimulation. Cells were stimulated with 1 µM thapsigargin, in the 
presence of 10mM BAPTA and imaged for 10 minutes. After 10 minutes, 
regular extracellular medium with 50mM CaCl2, was applied to cells and 
monitored for 5 minutes. All experiments were done at room temperature. 
Three examples of each cell treatment are represented on the graph. All data 
are expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation.    127 
Figure 4.3.2: Kinetics of change of Fluo-4 fluorescence after 
thapsigargin treatment and calcium add-back in calcium-free conditions 
 
 
Figure 4.3.2. legend: HeLa cells were treated with mock siRNA for 72 hours 
or OCRL1 siRNA for 72 hours. Cells were loaded with Fluo-4 AM 45 minutes 
prior to stimulation. Cells were stimulated with 1 µM thapsigargin, in the 
presence of 20mM BAPTA and imaged for 10 minutes. The reduction in 
fluorescence upon application of BAPTA represents the chelation of free 
calcium. After 10 minutes, regular extracellular medium with 50mM CaCl2, 
was applied to cells and monitored for 5 minutes. All experiments were done 
at room temperature. Three examples of each cell treatment are represented 
on the graph. All data are expressed as relative arbitrary values, normalised 
against basal Fluo-4 fluorescence before stimulation.    128 
 
4.4: OCRL1 localisation after histamine treatment 
Figure 4.4: Localisation of GFP-OCRL1 upon histamine stimulation 
 
 
              1 minute                              10 minutes                                  1 hour 
 
Figure 4.4 legend: HeLa cells were transfected with 0.4µg GFP-OCRL1 DNA 
using lipofectamine, grown for 16 hours and treated with 100µM histamine for 
either 1 minute (left panel), 10 minutes (middle panel) or 1 hour (right panel). 
Cells were then fixed using 4% PFA and visualised using a Leica confocal 
microscope. All experiments were undertaken at room temperature. Single 
confocal sections. Scale bar (10µm). 
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4.5: Calcium signalling in Lowe Syndrome patient skin fibroblasts 
 
Figure 4.5.1: Response of Lowe Syndrome fibroblasts to 10µM ATP  
 
Cell type  Peak/600 sec 
ratio 
Control  3.42 
Lowe B  1.8 
Lowe 2  1.17 
 
Figure 4.5.1. legend: Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 10µM ATP and imaged 
for 20 minutes. All experiments were done at room temperature. Line traces 
represent six independent tests on the graph. All data are expressed as 
relative arbitrary values, normalised against basal Fluo-4 fluorescence before 
stimulation and with mock stimulated cell responses deleted from final values.   130 
 
Figure 4.5.2: Analysis of response of Lowe Syndrome fibroblasts to 
10µM ATP 
 
 
 
Figure 4.5.2. legend:. Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 10µM ATP and imaged 
for 20 minutes. All experiments were done at room temperature. Data are 
plotted for the peak calcium level in the cytosol (dark grey bars) and level of 
calcium at the 600 second time-point post stimulation (light grey bars). These 
data are representative of six independent experiments. All data are 
expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation and with mock stimulated cell responses 
deleted from final values. Error bars are standard deviations.   131 
 
Figure 4.5.3: Response of Lowe Syndrome fibroblasts to 50µM ATP  
 
Cell type  Peak/600 sec 
ratio 
Control  4.8 
Lowe B  1.83 
Lowe 2  1.41 
 
Figure 4.5.3. legend: Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 50µM ATP and imaged 
for 20 minutes. All experiments were done at room temperature. Line traces 
represent six independent tests on the graph. All data are expressed as 
relative arbitrary values, normalised against basal Fluo-4 fluorescence before 
stimulation and with mock stimulated cell responses deleted from final values. 
Error bars are standard deviations.   132 
 
Figure 4.5.4: Analysis of response of Lowe Syndrome fibroblasts to 
50µM ATP  
 
 
Figure 4.5.4. legend:. Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 50µM ATP and imaged 
for 20 minutes. All experiments were done at room temperature. Data are 
plotted for the peak calcium level in the cytosol (dark grey bars) and level of 
calcium at the 600 second time-point post stimulation (light grey bars). These 
data are representative of six independent experiments. All data are 
expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation and with mock stimulated cell responses 
deleted from final values. Error bars are standard deviations.   133 
 
Figure 4.5.5: Response of Lowe Syndrome fibroblasts to 100µM ATP  
 
Cell type  Peak/600 sec 
ratio 
Control  5.44 
Lowe B  2 
Lowe 2  2.06 
 
Figure 4.5.5. legend: Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 100µM ATP and 
imaged for 20 minutes. All experiments were done at room temperature. Line 
traces represent six independent tests on the graph. All data are expressed 
as relative arbitrary values, normalised against basal Fluo-4 fluorescence 
before stimulation and with mock stimulated cell responses deleted from final 
values. Error bars are standard deviations.   134 
 
Figure 4.5.6: Analysis of response of Lowe Syndrome fibroblasts to 
100µM ATP  
 
 
Figure 4.5.6. legend:. Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 100µM ATP and 
imaged for 20 minutes. All experiments were done at room temperature. Data 
are plotted for the peak calcium level in the cytosol (dark grey bars) and level 
of calcium at the 600 second time-point post stimulation (light grey bars). 
These data are representative of six independent experiments. All data are 
expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation and with mock stimulated cell responses 
deleted from final values. Error bars are standard deviations.   135 
 
Figure 4.5.7: Response of Lowe Syndrome fibroblasts to thapsigargin  
 
Cell type  Peak/600 sec 
ratio 
Control  1.48 
Lowe B  1.06 
Lowe 2  1.45 
 
Figure 4.5.7. legend: Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 1µM thapsigargin and 
imaged for 20 minutes. All experiments were done at room temperature. Line 
traces represent six independent tests on the graph. All data are expressed 
as relative arbitrary values, normalised against basal Fluo-4 fluorescence 
before stimulation and with mock stimulated cell responses deleted from final 
values. Error bars are standard deviations.   136 
 
Figure 4.5.8: Analysis of response of Lowe Syndrome fibroblasts to 
thapsigargin  
 
 
 
Figure 4.5.8. legend:. Fibroblasts were plated at 100% confluence one day 
before experiments. Cells were loaded with Fluo-4 AM 45 minutes prior to 
stimulation. Cells were mock stimulated with buffer or 100µM ATP and 
imaged for 20 minutes. All experiments were done at room temperature. Data 
are plotted for the peak calcium level in the cytosol (dark grey bars) and level 
of calcium at the 600 second time-point post stimulation (light grey bars). 
These data are representative of six independent experiments. All data are 
expressed as relative arbitrary values, normalised against basal Fluo-4 
fluorescence before stimulation and with mock stimulated cell responses 
deleted from final values. Error bars are standard deviations.   137 
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5: OCRL1 and polarised cells 
 
Oculocerebrorenal syndrome of Lowe manifests itself in dysfunction of a very 
few cell types, the most affected being neurons and/or glia, lens cells 
(epithelial and fiber cells) and renal proximal tubular epithelial cells. Thus the 
symptoms suffered by Lowe Syndrome patients arise from the dysfunction of 
polarised cells. These cells, upon contacting one another, form distinct apical 
and basolateral domains connected through three major types of intercellular 
junction: gap junctions, adherens junctions and tight junctions. Intercellular 
junctions regulate and are regulated by a wide array of cellular processes, 
such as cell signalling, membrane trafficking, transcription and apoptosis 
88, 89, 
135. Furthermore, all three of these types of junction have been shown to be 
regulated, in part, by the levels and localisation of phosphoinositides, and so 
might be affected by loss of OCRL1. 
 
We set upon testing whether the subcellular localisation of OCRL1 in a 
polarised cell type matches that observed in non-polarised cell lines such as 
HeLa and COS-7 
52. Most of our experiments used two well-characterised 
polarised cell lines to assess the role of OCRL1: Caco-2 and Madin-Darby 
canine kidney (MDCK) cells. The Caco-2 epithelial cell line is derived from a 
human colonic adenocarcinoma and upon reaching confluency forms a tightly 
packed monolayer complete with each of the three aforementioned types of 
cell-cell junction. These desired cellular properties are also present in the 
MDCK cell line. MDCK cells form a much more regular cobblestone-patterned 
epithelial monolayer. However, due to the canine origin of these cells, any   139 
experiments with them on OCRL1 must be treated with caution. Recent 
studies showed that the OCRL1 knockout mouse does not develop the 
phenotype observed in humans 
41. A current theory for this lack of phenotype 
is that other species compensate for OCRL1 loss with an alternatively spliced 
version of INPP5B, as discussed in the introduction of this thesis. Thus at this 
stage it is not clear which (if any) non-human species are likely to reproduce 
the salient features of Lowe Syndrome upon loss of OCRL1. For this reason 
we used the Caco-2 cell line in the majority of our work. 
 
Intercellular junction formation occurs in a specific temporal manner. Initiation 
of cell-cell contact leads to the formation of a primordial, “spot-like” adherens 
junction, a platform upon which cell polarisation and other types of 
intercellular junction form 
94-96. These primordial junctions then fuse with one 
another, through interaction with F-actin filaments to form “belt-like” adherens 
junctions 
101, 159. This process occurs alongside the formation of tight 
junctions, apical to the newly forming “belt-like” adherens junction. These two 
junctions then go on to mature separately, using a great number of proteins 
involved in actin reorganisation, membrane trafficking and signal transduction 
88, 103, 109, 111, 112, 114, 121. Therefore, to carry out a full and thorough investigation 
of a possible role for OCRL1 at intercellular junctions it was important to look 
at more than one time point during junction formation. For this reason we 
undertook a time-course experiment, fixing cells at different confluencies in 
order to assess OCRL1 localisation at different stages of intercellular junction 
maturation.  
   140 
In Caco-2 cells, a limited and weak co-localisation of OCRL1 and ZO-1 was 
observed when cells were plated at low confluency. (Figure 5.1.1), and was 
quantified using line-scan analysis (Figure 5.1.2). This showed that relatively 
low proportion of total OCRL1 at cell-cell junctions in Caco-2 cells was 
present specifically at the level of the tight junction. The majority of OCRL1 
still localised to the cytoplasm and internal membranes, as in non-polarised 
cells such as HeLa and COS-7. The partial co-localisation with ZO-1 was lost 
upon allowing cells to grow to a greater density (Figure 5.1.3). This suggests 
that the junctional recruitment of OCRL1 only occurs at early time points in the 
maturation of the epithelial monolayer. The level of junctional and plasma 
membrane localised OCRL1 was clearer when looking at MDCK cells growing 
at very low densities (Figure 5.1.4). There were a great number of cells with 
endogenous OCRL1 localised to intercellular junctions, however in some 
instances it was also highly abundant at parts of the plasma membrane 
making no contact with other cells (Figures 5.1.4, white arrows). Interestingly, 
a high level of fluorescence was detected in the nucleus. Furthermore, in a 
similar fashion to that observed in Caco-2 cells, the junctional recruitment of 
OCRL1 reduced with increased cell density (Figure 5.1.5).  
 
We decided to further the investigation of OCRL1 localisation in polarised 
cells by looking at OCRL1 distribution in primary cells. Using primary porcine 
retinal pigment epithelial cells (harvested by Jennifer Williams, UCL), we 
found a very similar localisation to that seen in MDCK cells, with OCRL1 
highly abundant in the nucleus and the plasma membrane (Figure 5.1.6). In a 
similar fashion to the staining pattern of OCRL1 in MDCK cells, plasma   141 
membrane staining of OCRL1 in primary porcine retinal pigment epithelial 
cells was highly, but not fully, co-incident with cell-cell junctions.  
 
These results show that OCRL1 in polarised epithelial cells localises to tight 
junctions, with some cell types also showing nuclear targeting. Both these 
sites, the plasma membrane and nucleus, have been shown to contain high 
levels of PI(4,5)P2. These data place OCRL1 at locations within the cell that 
contain its preferred substrate and suggest that recruitment to tight junctions 
is temporally regulated in a manner related to epithelial maturation.  
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5.1: Subcellular localisation of OCRL1 in polarised cell types 
Figure 5.1.1: OCRL1 localisation in Caco-2 cells at low density 
 
 
   
OCRL1                    ZO-1 
Figure 5.1.1 legend: Cells were plated onto 35mm tissue culture plastic 
dishes and allowed to grow to low density (40% confluency). Cells were then 
fixed with 4% paraformaldehyde, permeabilised, blocked and processed for 
OCRL1 and ZO-1 immunostaining. Images were then taken with a Leica 
confocal microscope. The top pair of images represent the staining of OCRL1 
and ZO-1 in Caco-2 cells. Regions of colocalisation between OCRL1 and ZO-
1 have been highlighted in the bottom pair of images, by overlaying orange 
lines. Single confocal sections. Scale bar (10µm).   143 
 
Figure 5.1.2: Line-scan analysis of Figure 5.1A showing ZO-1 
colocalisation with OCRL1 
 
 
 
 
Figure 5.1.2 legend: Image processing of Figure 5.1.1. This graph shows the 
mean of 12 line scans (± s.e.m.) of OCRL1 fluorescence measured 30 pixels 
either side of cell junctions highlighted in orange in Figure 5.1.1.   144 
 
Figure 5.1.3: Loss of specific junctional localisation of OCRL1 upon 
growth to medium density 
 
 
                                      OCRL1                           ZO-1 
Figure 5.1.3 legend: Cells were plated onto 35mm tissue culture plastic 
dishes and allowed to grow to medium density (70% confluency). Cells were 
then fixed with 4% paraformaldehyde, permeabilised, blocked and processed 
for OCRL1 and ZO-1 immunostaining. Images were then taken with a Leica 
confocal microscope. Image consists of 3 compressed confocal sections in 
the plane of the tight junction.   145 
Figure 5.1.4: Localisation of OCRL1 in MDCK cells grown at low density 
 
 
OCRL1                ZO-1 
   
OCRL1 
Figure 5.1.4 legend: Cells plated onto 35mm tissue culture dishes and 
allowed to grow to low density (40% confluency). Cells were then fixed with 
4% PFA, permeabilised, blocked and processed for OCRL1 and ZO-1 
immunostaining. Single sections were then taken with a Leica confocal 
microscope. Upper panels show colocalisation of OCRL1 and ZO-1 staining. 
OCRL1 also shows a strong nuclear localisation in MDCK cells. The bottom 
panel shows immunofluorescence of MDCK cells, stained with OCRL1 
specific antibody only, demonstrating that the junctional localisation seen is 
not an artefact of cross-reaction of antibodies. Arrows indicate plasma 
membrane staining of OCRL1 at non-contacting cell edges. Scale bar (10µm)   146 
Figure 5.1.5: Loss of ZO-1 colocalisation with OCRL1 in MDCK cells 
grown to medium density 
 
 
      
                           OCRL1                                                 ZO1 
 
Figure 5.1.5 legend: Cells were plated onto 35mm tissue culture plastic 
dishes and allowed to grow to medium density (70% confluency). Cells were 
then fixed with 4% paraformaldehyde, permeabilised, blocked and processed 
for OCRL1 and ZO-1 immunostaining. Three confocal sections were then 
taken with a Leica confocal microscope. Scale bar (10µm).   147 
Figure 5.1.6: Localisation of OCRL1 in primary porcine retinal pigment 
epithelial cells 
 
 
    
                                   OCRL1                                 ZO1 
 
Figure 5.1.6 legend: Cells were plated onto 35mm tissue culture plastic 
dishes and allowed to grow to full confluency (100% coverage on the dish). 
Cells were then fixed with 4% paraformaldehyde, permeabilised, blocked and 
processed for OCRL1 and ZO-1 immunostaining. Images were then taken 
with a Leica confocal microscope. Image comprises of three compressed 
confocal sections. Scale bar (10µm). 
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5.2: Over-expression studies 
 
We transfected these polarised cell types with GFP-tagged OCRL1, to see 
whether over-expressed OCRL1 matches the observed endogenous 
localisation of OCRL1. Caco-2 and MDCK cells expressing OCRL1-GFP 
partially colocalised with ZO-1 at the tight junction (Figure 5.2.1). However it 
did not match the endogenous localisation of OCRL1 observed in Figures 
5.1.1-.6. Interestingly the perinuclear distribution of OCRL1 normally seen in 
non-polarised cells was more evident upon over-expression. This may 
represent a mechanism where increased levels of OCRL1 are kept away from 
the plasma membrane to prevent undesired cellular effects. Interestingly there 
were examples where overexpression of OCRL1 led to pleiomorphic effects, 
with the formation of multinucleate cell syncytia, as observed by ZO-1 
immunostaining and DNA staining (Figure 5.2.2). Within these syncytia, we 
observed some ZO-1 in a punctate vesicular distribution (Figure 5.2.2, white 
arrows), however at this stage the significance of this is unclear.  
 
We decided to elucidate which determinants within OCRL1 target tight 
junctions. To do so, we expressed GFP-tagged chimeras of the amino- and 
carboxy-terminal halves of OCRL1 (as shown in Figure 5.2.3). We first 
expressed these proteins in HeLa cells and observed their localisations. The 
amino-terminal half of OCRL1 was cytoplasmic (Figure 5.2.4, left panel). 
However, the carboxy-terminus of OCRL1 localised strongly to internal 
membranes, and interestingly also entered the nucleus (Figure 5.2.4, right   149 
panel). Regarding the punctate targeting, the pattern was consistent with 
targeting to TGN and/or endosomes, but a double labelling experiment has 
not been performed. Regarding the nuclear localisation of GFP-OCRL1-
carboxy terminus, this has been found before with the expression of a GFP-
tagged chimera of the Rho-GAP domain of OCRL1 
42. In that study, GFP-
OCRL1-RhoGAP displayed a highly nuclear and cytoplasmic localisation. 
However, upon activation of RhoGTPases Cdc42 and Rac1 (known binding 
partners of OCRL1) GFP-OCRL1-RhoGAP moved into plasma membrane 
ruffles.  
 
Taking into consideration the past finding that the RhoGAP homology domain 
of OCRL1 has the propensity to move to the plasma membrane, our 
hypothesis was that the carboxy-terminus of OCRL1 would mediate the 
junctional localisation of OCRL1. To test this, we over-expressed each half of 
OCRL1 in Caco-2 cells. The GFP-OCRL1-amino-terminus was again 
cytoplasmic, and was limited to the basal cytoplasm of the cell (Figure 5.2.5). 
In contrast, a low proportion of GFP-OCRL1-carboxy terminus was seen at 
intercellular junctions (Figure 5.2.6). This maps the ability of OCRL1 to target 
intercellular junctions to the carboxy-terminal half. This, alongside the 
RhoGAP domain study by Faucherre et al. in 2003, suggests that OCRL1 has 
the propensity to move to the plasma membrane/intercellular junction in a 
stimulus dependent manner, perhaps through modulation of RhoGTPase 
proteins. Intercellular junction formation and function is known to be highly 
dependent on the activation of specific Rho GTPases such as Rho, Rac1 and 
Cdc42 
104, 105, 160-162.   150 
 
These data suggest that OCRL1 may be recruited to sites where its preferred 
substrate, PI(4,5)P2, exists. Other studies looking at lipid phosphatase activity 
show that OCRL1 is more active when in complex with Rab GTPases, 
perhaps through changes in the configuration of OCRL1 structure 
44. This 
work demonstrated that OCRL1 activity is controlled and regulated through 
specific recruitment. It may be possible that this proposed mechanism applies 
to OCRL1 activity at intercellular junctions. Much like the specific recruitment 
of OCRL1 to clathrin-coated pits at the plasma membrane during endocytosis, 
OCRL1 may be temporally recruited to junctions and activated to reduce 
PI(4,5)P2 levels. 
54. 
 
The closely related homologue of OCRL1, INPP5B, is the only other inositol 
polyphosphate 5-phosphatase containing a RhoGAP homology domain in the 
human genome. Interestingly, previous studies have shown an effect of 
INPP5B loss on adherens junctions in sertoli cells, suggesting a role for this 
protein at intercellular junctions 
163. Given that INPP5B shares 45% homology 
with OCRL1, and its suggested compensatory role in the mouse model of 
OCRL1, we decided to look at GFP-tagged INPP5B in Caco-2 cells 
41. Upon 
transfection we found that INPP5B also weakly targets tight junctions, as 
shown by colocalisation with tight junction marker ZO-1 (Figure 5.2.7). This 
indicates that OCRL1 and INPP5B may have similar functions at intercellular 
junctions. This supports a theory that Lowe Syndrome arises not because of 
differences in the functions of OCRL1 and INPP5B but relatively different 
levels of INPP5B and OCRL1 transcript. If there were a difference in the ratio   151 
of INPP5B to OCRL1 transcript in polarised cells, in comparison to non-
polarised cells, this theory would be validated.   152 
Figure 5.2.1: Localisation of GFP tagged OCRL1 in MDCK and Caco-2 
cells 
     
                              OCRL1-EGFP                      ZO-1 
Figure 5.2.1 legend: Cells were plated onto 35mm tissue culture plastic 
dishes at medium density (70% confluency). Cells were transfected with 
0.4µg GFP-OCRL1 DNA and left for 24 hours. Cells were fixed with 4% PFA, 
permeabilised, blocked and processed for ZO-1 immunostaining. Images 
were then taken with a Leica confocal microscope. White arrows indicate sites 
where OCRL1 co-localises with ZO-1. Single confocal sections. Scale bar 
(10µm). MDCK above, Caco-2 apical section middle, Caco-2 basal section 
below. 
MDCK 
Caco-2 
Apical 
Basal    153 
Figure 5.2.2: Over-expression of OCRL1 can lead to polynuclear 
syncytia 
 
 
Figure 5.2.2 legend: Cells were transfected with 0.4µg GFP-OCRL1 DNA 
and left for 24 hours. Cells were then fixed with 4% paraformaldehyde, 
permeabilised and processed for ZO-1 immunostaining. Images were then 
taken with a Leica confocal microscope. Top and middle rows: GFP-OCRL1 
(left panel), ZO-1 (right panel). Bottom row: Nuclear DAPI stain (left panel), 
overlay image of pseudocoloured images of GFP-OCRL1 and DAPI (right 
panel). Arrows indicate punctate ZO-1 inside GFP-OCRL1 positive syncytia. 
Single confocal sections. Scale bar (10µm).   154 
Figure 5.2.3: Diagram of domain structure of OCRL1 and division for 
GFP-tagging of N- and C-termini 
 
 
 
Figure 5.2.3 legend: The diagram above depicts where the division of 
OCRL1 into two termini was made. The 5-phosphatase domain was split in 
half at amino-acid number 501. The amino-terminal half consists of OCRL1 
residues 1-501 and contains motifs capable of binding AP-2 and clathrin. The 
carboxyl-terminal half consists of OCRL1 residues 501-901, and contains the 
ASH and RhoGAP domains, with its linker region, parts of OCRL1 sequence 
that can bind the proteins listed below the picture.   155 
Figure 5.2.4: Localisation of GFP-tagged N- and C-terminal OCRL1 in 
HeLa cells 
 
 
                      GFP-OCRL1 N-term              GFP-OCRL1 C-term 
 
Figure 5.2.4 legend: Cells were plated onto 35mm tissue culture dishes and 
transfected with 0.4µg either GFP-OCRL1 amino-terminal or carboxy-terminal 
DNA. After 24 hours of over-expression, live cells were then imaged with a 
Leica confocal microscope. Single confocal sections. Scale bar (10µm). 
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Figure 5.2.5: Localisation of GFP N-terminal OCRL1 in Caco-2 cells 
   
   
   
  GFP-OCRL1 N-term                       ZO-1           
 
Figure 5.2.5 legend: Cells were transfected with 0.4µg GFP-OCRL1 amino-
terminal DNA and left for 24 hours. Cells were then fixed with 4% 
paraformaldehyde, permeabilised and processed for ZO-1 immunostaining. 
Single sections were then taken with a Leica confocal microscope. Images 
are from different confocal sections of the same group of cells. Scale bar 
(10µm)
Apical 
zone 
Medial 
zone 
Basal 
zone   157 
 
Figure 5.2.6: Localisation of GFP-tagged C- terminal OCRL1 in Caco-2 
cells 
 
                        GFP-OCRL1 C-term                      ZO-1 
 
Figure 5.2.6 legend: Cells were transfected with 0.4µg GFP-OCRL1-carboxy 
terminus DNA and left for 24 hours. Cells were then fixed with 4% 
paraformaldehyde, permeabilised and processed for ZO-1 immunostaining. 
Images were then taken with a Leica confocal microscope. White arrows 
indicate where ZO-1 positive segments of the periphery co-stained for GFP. 
Single confocal section. Scale bar (10µm).   158 
Figure 5.2.7: Localisation of GFP-tagged INPP5B in Caco-2 cells 
 
 
                            GFP-INPP5B                               ZO-1 
 
Figure 5.2.7 legend: Cells were transfected with 0.4µg GFP-INPP5B DNA 
and left for 24 hours. Cells were then fixed with 4% paraformaldehyde, 
permeabilised and processed for ZO-1 immunostaining. Images were then 
taken with a Leica confocal microscope. The white arrow indicates where a 
ZO-1 positive segment of the periphery co-stained for GFP. Single confocal 
section. Scale bar (10µm). 
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5.3: OCRL1 and ZO-1 co-immunoprecipitate 
 
Given the partial colocalisation of OCRL1 and ZO-1 (Figure 5.1 and Figure 
5.2) we decided to test a potential interaction between the two proteins. We 
undertook endogenous immunoprecipitations from two different polarised 
epithelial cell types, MDCK and Caco-2. When Caco-2 cells were grown at 
high density an interaction between OCRL1 and ZO-1 was not evident (Figure 
5.3.1). However, when immunoprecipitating endogenous OCRL1 at lower 
densities we began to detect an interaction with ZO-1. Interestingly this 
interaction was best observed when cells were plated so that very few were in 
contact with one another (Figure 5.3.2). Interestingly the interaction was only 
observed when cells were plated at low confluency, in agreement with our 
immunofluorescence results showing colocalisation only when cells were at 
low confluency (Figures 5.1.1-5.1.3).  
 
Given that GFP-OCRL1 was detected at tight junctions by 
immunofluorescence, we transfected Caco-2 cells with this construct, and 
immunoprecipitated it using antibodies to GFP (Figure 5.3.3). In this 
experiment, we found that a greater amount of ZO-1 than was 
immunoprecipitated by GFP-OCRL1 than in experiments relying on 
immunoprecipitation of endogenous OCRL1, suggesting over-expression of 
OCRL1 may increase the amount of ZO-1 interacting with it. This observation 
might tie in with the frequently detected syncytial polynuclear cells upon GFP-
OCRL1 over-expression (Figure 5.2.2), if the increased formation of   160 
complexes containing both OCRL1 and ZO-1 were to augment tight junction 
turnover.  
 
In the reverse experiment of immunoprecipitating ZO-1 and Western blotting 
for OCRL1 in MDCK and Caco-2 cells, a stronger OCRL1 positive band was 
observed where anti-ZO-1 antibody was used compared to control 
immunoglobulin (Figure 5.3.4). Consistently however, the control rabbit IgG 
lanes were not as clean as the sheep IgG control used when 
immunoprecipitating OCRL1 (Figure 5.3.4). A future experiment to further 
prove the density-dependent manner of the ZO-1/OCRL1 interaction would be 
to undergo a series of pull-downs with varying confuencies in parallel with one 
another. This will be the focus of future studies. 
 
Given that OCRL1 targets to early and recycling endosomes and these 
organelles are critical for primordial “belt-like” adherens junction formation, 
these data suggest that OCRL1 may facilitate vesicular traffic of junctional 
proteins. Recent work published by the Kroschewski lab has revealed key 
insights into the mechanism of initial cell-cell junction formation with MDCK 2-
cell aggregates. In this study, evidence is shown demonstrating that junctional 
and polarity proteins are delivered to the plasma membrane via apical 
recycling endosomes 
164. Given that Rab GTPases (specifically OCRL1-
binding partners Rab 8  and Rab 1 3) control the trafficking of tight junction 
proteins, these data suggest OCRL1 may function within this pathway 
109-112.    161 
Figure 5.3.1: Immunoprecipitation of OCRL1 at high confluency fails to 
bring down tight junction protein ZO-1 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1: Western blot for ZO-1. Caco-2 cells lysates were pre-cleared, 
and then mixed with beads carrying the indicated antibodies. In each case, 
30% of precipitated proteins were separated by SDS-PAGE, along with a 
proportion (equivalent to 1%) of the unbound supernatant. Arrow indicates 
full-length ZO-1, which runs as a doublet.  
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Figure 5.3.2: Immunoprecipitation of OCRL1 at low confluency brings 
down tight junction protein ZO-1 
 
 
 
 
 
 
 
 
 
Figure 5.3.2 legend: Western blot for ZO-1. Caco-2 cells lysates were pre-
cleared, and then mixed with beads carrying the indicated antibodies. In each 
case, 30% of precipitated proteins were separated by SDS-PAGE, along with 
a proportion (equivalent to 1%) of the unbound supernatant. Arrow indicates 
full-length ZO-1, which runs as a doublet. 
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Figure 5.3.3: Immunoprecipitation of GFP-OCRL1 brings down tight 
junction protein ZO-1 
 
 
 
 
 
 
 
Figure 5.3.3 legend: Western blot for ZO-1. Caco-2 cells were transfected 
with GFP-OCRL1 and lysates were prepared 24 hours after. Lysates were 
pre-cleared, and then mixed with beads carrying the indicated antibodies. In 
each case, 30% of precipitated proteins were separated by SDS-PAGE, along 
with a proportion (equivalent to 1%) of the unbound supernatant. Arrow 
indicates full-length ZO-1, which runs as a doublet.  
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Figure 5.3.4: Immunoprecipitation of ZO-1 brings down OCRL1 
 
 
 
 
 
 
 
 
Figure 5.3.4 legend: Western blot for OCRL1. Prior to lysis, Caco-2 and 
MDCK cells were treated with the chemical cross-linker DSP for 30 minutes, 
followed by three 15 minute washes in blocking solution (see Materials and 
Methods). Lysates were then made, pre-cleared, and mixed with beads 
carrying the indicated antibodies. In each case, 30% of precipitated proteins 
were separated by SDS-PAGE. Arrow indicates full-length OCRL1 determined 
from the position of OCRL1 in the supernatant (lane not shown). 
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5.4: Effects of OCRL1 loss in polarised cell types 
 
As Lowe Syndrome arises from the loss of OCRL1, we chose to test for a 
functional effect by depleting it from Caco-2 cells, using siRNA 
oligonucleotides. We were able to consistently achieve an 80-90% reduction 
in OCRL1 levels, with two applications of siRNA over a period of 3 days 
(Figure 5.4.1). This depletion of OCRL1 was also easily detected at the level 
of immunofluorescence (Figure 5.4.2). We noticed from our 
immunofluorescence studies that as cells depleted of OCRL1 contacted one 
another in culture they covered a much larger area than control siRNA treated 
cells. To characterise this difference, we chose to immunostain for proteins 
that target intercellular junctions such as ZO-1 and E-cadherin. By doing so, 
we could assess any changes in the staining pattern of both proteins but also 
it served to delineate the cell-cell boundaries, allowing us to measure the area 
covered by the cells.  
 
Importantly, we noticed that the localisation of ZO-1 to cell edges was 
unaltered upon OCRL1 depletion (Figure 5.4.3). However, specific localization 
of ZO-1 to apical membranes, shown by imaging XZ sections, was greatly 
disturbed (Figure 5.4.4). XZ sections of cells treated with OCRL1 siRNA 
revealed that not only were the cells smaller, but the localisation of ZO-1 was 
more basal and less uniform than cells treated with control, non-targetting 
siRNA. For E-cadherin, its distribution at intercellular junctions seemed to be 
very similar to that of control siRNA treated cells (Figure 5.4.5). However, we 
noticed a greater number of internal E-cadherin “flecks” upon OCRL1   166 
depletion. As the recruitment of ZO-1 to cell edges was unaffected by OCRL1 
loss, we used the ZO-1 immunostain to measure the area of the cells. Pooling 
results from two independent knock-down experiments, we found that cells 
lacking OCRL1 were approximately 2.5 times larger in area, and were 55% 
the height of control siRNA treated cells (Figure 5.4.6 and 5.4.7). We also 
tested the effect of OCRL1 depletion on another human polarised cell line, 
human corneal epithelial (HCE) cells. Again, upon contacting one another, 
HCE cells depleted of OCRL1 covered a much larger area on coverslips, and 
were much flatter than control siRNA treated cells (Figure 5.4.8) 
 
A change in the actin cytoskeleton has been seen previously in fibroblasts 
taken from Lowe Syndrome patients, but could not be observed when 
depleting OCRL1 in non-polarised cells such as HeLa or COS-7 cells (data 
not shown) 
66, 98. Interestingly, actin binds many components of intercellular 
junctions and the actin cytoskeleton is integral to cell-cell junction formation 
and maturation. We stained the actin in our Caco-2 cells with fluorescently 
labeled phalloidin, and upon depletion of OCRL1 we found a very similar 
phenotype to that seen in Lowe Syndrome fibroblasts. OCRL1 depleted cells 
displayed far fewer basal actin stress fibres than in cells treated with negative 
control siRNA (Figure 5.4.9). 
 
To further our understanding of the role of OCRL1 at intercellular junctions, 
we chose to test the trans-epithelial resistance across HCE cell monolayers 
during a calcium switch assay. We used HCE cells as they displayed the 
same cell flattening phenotype as Caco-2 cells, but grew better on the multi-  167 
well plates used for measuring trans-epithelial resistance. Overnight 
incubation of HCE cells in low calcium medium causes the dissociation of 
intercellular junctions. Re-addition of medium with regular levels of calcium 
causes the reformation of intercellular junctions, and by 6 hours most, if not all 
junctions should be reformed.  
 
We first carried out a calcium switch experiment and observed the localisation 
of OCRL1 and ZO-1 after overnight incubation and 6 hours post addition of 
medium containing regular calcium levels. We found that after incubation in 
low calcium medium, cells lost contact with one another and ZO-1 staining 
was cytoplasmic. OCRL1 displayed a strong perinuclear localisation, typical in 
HCE cells. 6 hours after addition of medium containing regular calcium levels, 
cells formed tight intercellular junctions, as shown by the return of ZO-1 
staining to the periphery. At neither time period did OCRL1 show localisation 
to tight junctions (Figure 5.4.10). This might still allow for OCRL1 recruitment 
to tight junctions in HCEs, but at an intermediate time during their formation – 
i.e. before 6 hours. 
 
We decided to repeat the same experiment with cells depleted of OCRL1. We 
followed the formation of intercellular junctions through immunocytochemistry 
and also by measuring the trans-epithelial resistance. Trans-epithelial 
resistance gives a read-out of junctional integrity as it measures across the 
apical–basolateral axis of the cell monolayer. In control and OCRL1 depleted 
cells, all junctions between cells were lost after overnight incubation in low 
calcium medium, as shown by ZO-1 immunostaining. 6 hours post addition of   168 
medium containing regular calcium levels, in both control and OCRL1 siRNA 
treated cells, ZO-1 recruitment was mostly recovered. However, we more 
readily found examples of failed ZO-1 recruitment to junctions in OCRL1 
depleted monolayers than control siRNA treated monolayers (Figure 5.4.11). 
The measurement of trans-epithelial resistance revealed only one minor 
difference over the 6 hour time period after cells were returned to regular 
calcium levels. In a repeated manner, the first hour of trans-epithelial 
resistance recovery was slower in OCRL1 depleted HCE cells than control 
siRNA treated cells. However, the transepithelial resistance was completely 
recovered in both control and OCRL1 siRNA treated monolayers by 6 hours 
(Figure 5.4.12). Repeatedly we found that the initial rate of TER recovery was 
slower in cells treated with OCRL1 siRNA, in comparison to those treated with 
control siRNA. Although in this experiment, TER is clearly increased at 6 
hours in OCRL1 siRNA cells this was not a typical result.  
 
In summary, these data suggest that OCRL1 plays a facilitating but not crucial 
role in junctional maturation, which may feed into the morphology of the cell. 
Similar phenotypes are seen when actin cytoskeletal rearrangement is 
inhibited but also when other junctional components are missing and so this 
phenotype does not immediately identify the target of OCRL1 
165, 166. Several 
lines of evidence point to roles for phosphoinositides in cell polarisation and 
junction formation
120, 123. A recent study also revealed that many PDZ 
domains interact with phosphoinositides 
132. Within the tested proteins ZO-1 
was found to bind phosphoinositides. Our preliminary results suggest that 
OCRL1 is linked to tight junction complexes and epithelial maturation.    169 
Figure 5.4.1: OCRL1 can be efficiently depleted from Caco-2 cells and 
detected by Western Blotting 
 
 
 
 
Figure 5.4.1 legend: Caco-2 cells were treated twice with non-targetting, 
negative control siRNA (lane A) or OCRL1 siRNA (lane B), over a period of 72 
hours. OCRL1 and β-actin expression levels were analysed by Western Blot. 
AIDA densitometry revealed that relative OCRL1 expression is reduced by 
90% in comparison to negative siRNA control.  
OCRL1 
Beta-actin 
A            B   170 
Figure 5.4.2: OCRL1 can be efficiently depleted from Caco-2 cells and 
detected by immunofluorescence 
 
 
 
 
 
Figure 5.4.2 legend: Immunofluorescence for OCRL1. Caco-2 cells were 
treated twice with OCRL1 siRNA or non-targetting, negative control siRNA, 
over a period of 72 hours. Cells were then fixed with 4% paraformaldehyde, 
permeabilised, blocked and processed for OCRL1 immunostaining. Images 
were then taken with a Leica confocal microscope. Single confocal section. 
Scale bar (10µm). 
Control siRNA  OCRL1 siRNA   171 
Figure 5.4.3: Effect of OCRL1 loss on ZO-1 localisation 
 
 
 
Figure 5.4.3 legend: Caco-2 cells were treated twice with OCRL1 siRNA or 
non-targetting, negative control siRNA, over a period of 72 hours. Cells were 
then fixed with 4% paraformaldehyde, permeabilised and processed for 
OCRL1 and ZO-1 immunostaining. Images were then taken with a Leica 
confocal microscope. Interestingly, the small number of cells treated with 
OCRL1 siRNA but still retaining OCRL1 expression (white stars) are smaller 
than most cells that lack OCRL1 expression. Compressed confocal sections. 
Control siRNA  OCRL1 siRNA 
OCRL1 
 ZO-1   172 
Figure 5.4.4: Effect of OCRL1 loss on ZO-1 localisation to apical 
membrane 
 
 
 
 
 
 
Figure 5.4.4 legend: Immunofluorescent stain of ZO-1. Caco-2 cells were 
treated twice with OCRL1 siRNA or non-targetting, negative control siRNA, 
over a period of 72 hours. Cells were then fixed with 4% paraformaldehyde, 
permeabilised, blocked and processed for ZO-1 immunostaining. XZ sections 
(1 micron distance per section) were then taken with a Leica confocal 
microscope. In the case of the OCRL1 siRNA treated sample, all cells in view 
were depleted of OCRL1. 
Control siRNA 
OCRL1 siRNA   173 
Figure 5.4.5: Effect of OCRL1 loss on E-cadherin localisation 
 
 
 
    
 
Figure 5.4.5 legend: Caco-2 cells were treated twice with OCRL1 siRNA or 
non-targetting, negative control siRNA, over a period of 72 hours. Cells were 
then fixed with 4% paraformaldehyde, permeabilised, blocked and processed 
for E-cadherin immunostaining. Images were then taken with a Leica confocal 
microscope. White arrows indicate sites of increased punctate staining, much 
of which is perinuclear. Multiple compressed confocal sections. Scale bar 
(10µm). 
Control siRNA  OCRL1 siRNA   174 
Figure 5.4.6: Quantification of effect of OCRL1 loss on cell area 
 
 
 
Figure 5.4.6 legend: Using the ZO-1 stain from two different sets of 
experiments, we measured the area covered of over 200 cells per experiment. 
Upon loss of OCRL1, cells cover approximately two and a half times the area 
of cells treated with non-targetting, negative control siRNA. This difference 
was statistically significant. Error bars represent standard error. * T-tests 
comparing siRNA treated cells with controls produce p values < 0.05. 
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Figure 5.4.7: Quantification of effect of OCRL1 loss on cell height 
 
 
 
Figure 5.4.7 legend: Using the ZO-1 stain from two different sets of 
experiments, we measured the height covered in three different regions of the 
Caco-2 monolayer. Upon loss of OCRL1, cells depleted of OCRL1 are 
approximately 55% the height of cells treated with non-targetting, negative 
control siRNA. This difference was statistically significant. Error bars 
represent standard error. * T-tests comparing siRNA treated cells with 
controls produce p values < 0.05. 
* 
*   176 
 
Figure 5.4.8: Effect of OCRL1 loss on ZO-1 localisation in HCE cells 
 
 
                   Control siRNA                      OCRL1 siRNA 
Figure 5.4.8 legend: HCE cells were treated twice with OCRL1 siRNA or 
non-targetting, negative control siRNA, over a period of 72 hours. Cells were 
then fixed with 4% paraformaldehyde, permeabilised, blocked and processed 
for OCRL1 and ZO-1 immunostaining. Images were then taken with a Leica 
confocal microscope. As with Caco-2 cells (Fig 6.4.3), HCE cells with higher 
residual OCRL1 tended to have smaller cross-sectional area. 3 compressed 
confocal sections. Scale bar (10µm).   177 
 
Figure 5.4.9: Effect of OCRL1 loss on the actin cytoskeleton 
 
 
             OCRL1                        Actin (apical)                     Actin (basal) 
 
Figure 5.4.9 legend: Caco-2 cells were treated twice with OCRL1 siRNA, 
over a period of 72 hours. Cells were then fixed with 4% paraformaldehyde, 
permeabilised, blocked and stained with TRITC-phalloidin. Images were then 
taken with a Leica confocal microscope. The right hand panel shows that 
while cells that retained OCRL1 (central cluster) are rich in basal actin stress 
fibres, most of the remaining cells in the same field that are depleted of 
OCRL1 have few or no stress fibres. Multiple compressed confocal sections. 
Scale bar (10µm).   178 
Figure 5.4.10: OCRL1 and ZO-1 localisation over the course of a calcium 
switch assay 
 
 
              OCRL1                              ZO-1 
 
Figure 5.4.10 legend: HCE cells were plated and allowed to grow to 100% 
confluency. Cells were then washed twice with PBS and placed in low calcium 
containing media overnight. After overnight incubation, cells were washed 
twice with PBS and regular calcium containing media was added to cells. 
After overnight incubation in low calcium containing media, and 6 hours after 
regular calcium, cells were then fixed with 4% paraformaldehyde. Cells were 
then permeabilised, blocked and immunostained for OCRL1 and ZO-1. 
Images were then taken with a Leica confocal microscope. 3 compressed 
confocal sections. Scale bar (10µm). 
Low calcium overnight 
Normal calcium 
(6 hrs after low calcium)   179 
Figure 5.4.11: Effect of OCRL1 loss on ZO-1 recruitment after a calcium 
switch assay 
 
 
               
            Control siRNA                         OCRL1 siRNA 
 
 
Figure 5.4.11 legend: HCE cells, after being treated with non-targetting, 
negative control or OCRL1 siRNA, were allowed to grow to 100% confluency. 
Cells were then washed twice with PBS and placed in low calcium containing 
media overnight. After overnight incubation, cells were washed twice with 
PBS and regular calcium containing media was added to cells. 6 hours after 
regular calcium, cells were then fixed with 4% paraformaldehyde. Cells were 
then permeabilised, blocked and immunostained for OCRL1 and ZO-1. 
Images were then taken with a Leica confocal microscope. 3 compressed 
confocal sections. Scale bar (10µm). 
OCRL1 
ZO-1   180 
Figure 5.4.12: Trans-epithelial resistance over the course of a calcium 
switch assay 
 
 
 
 
Figure 5.4.12 legend: HCE cells were plated into multi-well slides after being 
treated with control or OCRL1 siRNA and allowed to grow to 100% 
confluency. Cells were then washed twice with PBS and placed in low calcium 
containing media overnight. After overnight incubation, cells were washed 
twice with PBS and regular calcium containing media was added to cells. 
During the change of media, cell impedance was measured using an ECIS 
instrument. This measurement was then converted into trans-epithelial 
resistance. Measurements from wells in quadruplicate are averaged with error 
bars indicating standard error. Other repeat experiments showed a similar 
delay in initial speed of recovery. However, the elevated TER at 6 hours of 
OCRL1 siRNA treated cells, in comparison to controls, varied between 
experiments. 
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6: Discussion 
 
6.1: OCRL1 and localisation of phosphoinositides 
 
The preferred 5-phosphatase activity of OCRL1 upon the membrane lipid 
PI(4,5)P2 has been the focus of many studies driven at understanding the 
cellular basis of Lowe Syndrome. Many cellular events are regulated and 
affected by control of PI(4,5)P2 levels and localisation. Indeed, it has been 
shown that patients with Lowe Syndrome, lacking the OCRL1 enzyme, have 
elevated levels of PI(4,5)P2 
36. However, the site of this aberrant pool of 
PI(4,5)P2 has not yet been found. We decided to tackle this issue through a 
number of means: using existing GFP-tagged chimeras of PH domains known 
to have specific phosphoinositide binding ability, modifying one of these 
characterised modules to test our hypothesis and also visualising the 
endogenous localisation of a protein known to bind PI(4,5)P2.   
 
Our first hypothesis was that as OCRL1 resides predominantly at the trans-
Golgi network, the increased pool of PI(4,5)P2 upon OCRL1 loss would 
accumulate in its place. We could demonstrate repeatedly that depletion of 
OCRL1 using transient RNAi knock-down did not alter the localisation of the 
PH domain of PLCδ. We next moved on to check whether the localisation of 
PI(3,4,5)P3 was different upon OCRL1 depletion, as reported by the PH   183 
domains of AKT or Grp1 tagged to GFP. Our hypothesis was that excess 
PI(4,5)P2 may be converted to PI(3,4,5)P3 by PI3K family members in order 
to control PI(4,5)P2 levels. It was also possible that OCRL1 targeted a 
significant pool of PI(3,4,5)P3 
119. Again, no difference was observed upon 
transient OCRL1 knock-down.  
 
As no change in localisation upon OCRL1 depletion was observed using 
GFP-chimeras of AKT, Grp1 and PLCδ PH domains in HeLa cells, we 
attempted to tailor our GFP-reporter to the site of OCRL1 action. The major 
pool of PI(4,5)P2 exists at the plasma membrane, which is a relatively strong, 
anionic environment. Evolutionarily, many proteins that target and bind 
PI(4,5)P2 also prefer to reside within anionic environments and vice-versa 
167. 
For this reason, basic amino-acid residues surround the pockets of many PH 
domains that bind phosphoinositides. Furthermore, proteins with stretches of 
basic residues are sufficient to target the plasma membrane 
167. This 
mechanism of coincidence detection of the anionic plasma membrane and 
PI(4,5)P2 provides these proteins with greater membrane affinity and avidity. 
Coincidence detection is employed by a great number of proteins in the cell, 
as a means of targeting their desired organelle. The problem of this system 
comes when an experiment aims to use plasma membrane targeted domain 
that binds PI(4,5)P2 (PLCδ -PH), to seek out a (hypothesised) trans-Golgi 
network pool of PI(4,5)P2. It is this insight that led us to believe that the 
existing GFP-PH chimeras used to localise phosphoinositides were not 
suitable or tailored to our studies.   
   184 
The creation of GFP-POP-PH yielded very consistent, positive and 
encouraging initial results. This fusion of the mutated OSBP-PH domain and 
PLCδ-PH domain served to seek out internal, ARF1-positive pools of 
PI(4,5)P2 upon OCRL1 depletion. However, as we continued to do 
experiments with this reporter, experiments became less repeatable and were 
no longer statistically significant. Studies looking at the effect of expression of 
GFP-POP-PH alone in cells showed that after 24 hours OCRL1 was 
sequestered within a perinuclear site and the trans-Golgi network 
compartment as reported by TGN46 staining was disrupted. The reason for 
this finding may be that the ARF1 binding ability of GFP-POP-PH may have 
led to ARF1 being sequestered within the TGN, a phenotype that has been 
previously seen in other studies with overexpression of the OSBP-PH by our 
laboratory. This finding was disappointing but we believe it may be due to a 
side-effect of looking at the localisation of lipids using domains from proteins 
that work within the pathway being tested. For instance, all four PH domains 
often used to study the localisation of PI(3,4,5)P3 independently affect 
different downstream functions of the lipid 
154. Furthermore, we believe that 
the problems encountered with POP-PH are also related to gross over-
expression. For this reason we would like to create a POP-PH construct with 
a weaker promotor than the current CMV promoter used. On the evidence of 
our current results, we cannot say conclusively that there is an internal 
accumulation of PI(4,5)P2 reportable by POP-PH. Nevertheless, we would 
like to revisit our work with GFP-POP, possibly in another cell line where we 
can establish a role for OCRL1. Our studies using GFP-POP in HeLa cells 
were conducted very early in this project. Since then, our very recent work   185 
has centered on investigating the role of OCRL1 in Caco-2 cells.  As yet, we 
have not had time to test the effect of OCRL1 loss on GFP-POP localisation in 
Caco-2 cells.  
 
In summary, we failed to see any changes in phosphoinositide localisation 
upon OCRL1 knock-down as visualised with GFP-PH domains. Therefore, we 
still do not know, conclusively, where the elevated level of PI(4,5)P2 is 
localised. The best and most conclusive evidence we have is the negative 
data; the PLCδ-PH domain does not move from the plasma membrane upon 
OCRL1 knock-down. It could therefore be argued that the plasma membrane 
is the site we sought. This theory is supported by the endogenous localisation 
of OCRL1 in polarised cell lines and primary cells. In these cells, OCRL1 is 
readily seen at the plasma membrane, intercellular junctions and sometimes 
within the nucleus, all sites within the cell that have been shown to contain 
pools of PI(4,5)P2. Interestingly, many more protein domains are being 
discovered to interact with PI(4,5)P2. Our general theory of using a protein 
that binds PI(4,5)P2 and detects the co-incident site at which OCRL1 acts, 
may still prove to be rewarding in the hunt for the site of elevated PI(4,5)P2 in 
cells lacking OCRL1 function. Interesting sets of proteins, containing PDZ 
domains, have recently been shown to bind phosphoinositides 
132, 134. Many of 
these PDZ domains exist within proteins targeted to intercellular junctions, 
which makes them very attractive for future OCRL1 related studies. Through 
tagging GFP to the PDZ domains of proteins such as ZO-1 and syntenin-1, 
junctional pools of PI(4,5)P2 may be probed. It would be very interesting to 
characterise the binding site of these domains in order to specifically monitor   186 
levels of phosphoinositides. If we find and characterise PDZ domains of 
junctional proteins that specifically bind PI(4,5)P2, we could also try tandem 
dimers of these domains in an effort to more efficiently detect junctional 
PI(4,5)P2. The specificity of these reporters for PI(4,5)P2 could be tested by 
depleting PI(4,5)P2 from the plasma membrane of cells using the rapamycin 
system used by Varnai et al. in 2006. 
 
As mentioned above, PI(4,5)P2 has been shown to accumulate within the 
nucleus. Within the nucleus there is a complement of proteins that function to 
metabolise phosphoinositides, such as PLC, PI3K and phosphoinositide 
phosphatase families of proteins 
141, 168. Interestingly, the PDZ domain of 
Syntenin-2 has been shown to bind the PI(4,5)P2 within the nucleus 
21. Given 
that OCRL1 is found within the nucleus in some polarised cell types, and also 
that GFP-tagged C-terminal OCRL1 readily enters the nucleus, it would be 
interesting to see whether OCRL1 depletion would alter the localisation of this 
domain.  
 
Furthermore, given the finding that OCRL1 has a different localisation in 
polarised cells, it would be interesting to re-visit studies with PH domains of 
PLCδ, Grp1 and AKT in Caco-2 and MDCK cells. In particular, recent studies 
using 3D cultures of MDCK cells have shown that PI(4,5)P2 and PI(3,4,5)P3 
can be specifically detected at apical and basolateral membranes, 
respectively 
123, 142. It would be interesting to see whether OCRL1 depletion in 
a fully polarised model, especially the 3D model, would affect the 
characterised localisation of phosphoinositides. With regard to the 3D model   187 
of MDCK cyst formation, it was shown recently that the recruitment of Annexin 
A2 to the apical membrane of 3D MDCK cysts through binding to PI(4,5)P2 is 
integral to full epithelial polarisation, which makes this system well worth 
looking into further 
123. If a model organism for Lowe Syndrome were to be 
obtained, it would also be very interesting to undertake these experiments on 
the affected polarised epithelial tissue. 
 
Through endogenous staining of Annexin A2 in HeLa cells, we found a 
change in localisation with loss of OCRL1. Annexin A2 moved more towards 
limiting membranes, with less staining observed in the cytoplasm. This finding 
fits in nicely with previous published work published linking OCRL1 and actin 
dynamics 
66, 98. Annexin A2 has been demonstrated to have actin nucleating 
activity on vesicular actin rockets and on multivesicular bodies (Prof. Jean 
Gruenberg, Personal Communication). The redistribution of Annexin A2 also 
links in with a previous finding that Lowe Syndrome patient fibroblasts display 
a loss of actin stress fibres and an increase in punctate actin staining 
66. It is 
possible that Annexin A2, which can bind and bundle actin into cables, 
contributes to this phenotype. In the aforementioned study of Lowe Syndrome 
patient fibroblasts, other actin-modulating proteins such as gelsolin and α-
actinin, both of which have altered activity in the presence of PI(4,5)P2, also 
change their distribution 
169-171. Further experiments to fully correlate changes 
in actin dynamics, Annexin A2 localisation and levels and localisation of 
PI(4,5)P2 would be warranted. Interestingly, data published by our lab shows 
that in the Lowe Syndrome patient fibroblasts we use in this thesis, vesicular 
actin rocketing is readily seen in an unstimulated manner 
98. This links in with   188 
data in this thesis, as vesicular actin rocketing is a calcium and PI(4,5)P2-
dependent process.  
 
Not only did we observe an intracellular change in distribution of Annexin A2, 
but we also found Annexin A2 in the medium and on the exofacial leaflet of 
the plasma membrane. As mentioned above, Annexin A2 has been found to 
play a key role in the endocytic pathway in epithelial cells. It has been found 
that it functions to nucleate a small patch of actin on early endosomes, 
integral to their progression to multivesicular bodies (Personal 
communication, Prof. Jean Gruenberg). Furthermore, this process is highly 
dependent upon cholesterol levels. This nucleation may be an analagous 
process to the previously mentioned vesicular actin rocketing observed in 
Lowe Syndrome patient fibroblasts. One known mechanism for Annexin A2 
presence in the medium is through release of exosomes derived from 
multivesicular bodies 
152. If PI(4,5)P2 levels on late endosomes/multivesicular 
bodies increase upon OCRL1 depletion, recruitment of Annexin A2 may 
occur. This may explain the appearance of Annexin A2 in the medium and on 
the exofacial face of the plasma membrane.  
 
There are similar changes in Annexin A2 localisation upon loss of OCRL1 and 
CLCN5 function, which may reflect dysfunction of the same pathway. The 
activity of many ion channels and pumps has been shown to be affected by 
PI(4,5)P2. The changes in PI(4,5)P2 upon OCRL1 depletion may lead to 
dysregulation of the CLCN5 channel activity, an event that has been 
suggested previously 
87. Therefore changes in Annexin A2 localisation upon   189 
loss of function of CLCN5 or OCRL1 may reflect a difference in the ability to 
acidify endosomal compartments, which consequently may alter trafficking 
and possibly the orientation of Annexin A2 within the membrane. We do not 
know the exact mechanism by which Annexin A2 changes distribution, so this 
theory may be as likely as a theory in which Annexin A2 responds directly to 
changes in PI(4,5)P2 upon OCRL1 loss.  
 
Further to this, work from this study has revealed a potential shared 
mechanism for renal failure in Dent Disease patients and Lowe Syndrome 
patients. In cells expressing inactive CLCN5 and upon depletion of CLCN5, 
Annexin A2 changes its distribution in a similar fashion to cells depleted of 
OCRL1 
78. It has been proposed before that Annexin A2 at the extracellular 
face of the plasma membrane may provide a nucleus for calcium oxalate 
crystal binding, a known cause of renal Fanconi Syndrome. The renal 
dysfunction observed in Lowe Syndrome patients may however directly 
correlate with defects in endocytosis, a process highly regulated by PI(4,5)P2 
26, 172, 173. It is possible that a primarily endosomal defect could be consistent 
with a junctional defect in polarised cells. Endosomal proteins may be 
mistargetted through changes in the function and localisation of junctional 
proteins upon OCRL1 or CLCN5 loss, which often serve as scaffolds for 
trafficking events 
88. Conversely, if OCRL1 and CLCN5 do work within the 
same trafficking pathway, then it is possible that CLCN5 depletion may affect 
endocytosis or delivery of junctional proteins to desired membranes. For 
these reasons, it would also be interesting to assess the effect of CLCN5   190 
depletion and over-expression on the function and structure of the tight 
junction. 
 
Although GFP-POP-PH failed in its initial task, it proved to be extremely useful 
in detecting differences in yeast phosphoinositide levels. The reason for the 
difference in efficacy of PI(4,5)P2 detection of POP-PH between yeast and 
mammalian cells may lie in the balance between inositol lipids and inositol 
phosphates. In yeast, it is permissible for levels of inositol phosphates to be 
raised, as there is no IP3-dependent release of internal calcium stores. 
However, if IP3 levels were raised in mammalian cells, this would be 
catastrophic to the maintenance of cytosolic calcium levels, as the IP3-
receptor would be permanently engaged and open.  
 
In yeast, studies frequently use a dimer of the PLCδ-PH domain in order to 
visualise PI(4,5)P2, in order to maximise its signal at the plasma membrane. 
However, when used as a monomer, the domain binds to the relatively more 
abundant IP3 in the cytosol. This is because the PLCδ-PH domain binds both 
molecules, with a ten-fold greater affinity for IP3 
174. Therefore, the distinction 
between plasma membrane and cytosol is harder to visualise. In our 
experiments, cells were grown at 30 degrees, at which the PLCδ-PH domain 
was predominantly observed in the cytoplasm, and very infrequently at the 
plasma membrane. However, the POP-PH fusion was clearly seen at the 
plasma membrane. We attribute this to co-incident binding of POP-PH to 
PI(4,5)P2 (via PLCδ-PH) in the plasma membrane and a protein determinant 
we predict to be ARF-related (via mutated OSBP-PH), from previous studies.   191 
For this reason, POP is able to detect subtle changes in P(4,5)P2 at the 
plasma membrane upon inactivation of single synaptojanin-like proteins. 
 
We believe that the observed changes in GFP-POP distribution in yeast are 
representative of these changes in the ratio of PI(4,5)P2 and IP3. For 
example, it is possible that the removal of GFP-POP from the plasma 
membrane upon inactivation of synaptojanin-like proteins is due to increased 
levels of IP3 in the cytoplasm, due to over-activity of PLC1 upon elevated 
PI(4,5)P2 levels. Furthermore, these differences may be exacerbated if any of 
the synaptojanin-like proteins act to de-phosphorylate IP3 to IP2. Further 
studies will focus on elucidating the mechanism of this removal of POP-PH 
from the plasma membrane, through crossing PLC1 delete strains with the 
synaptojanin-like inactivated strains. These studies are important, as they 
reveal that each individual 5-phosphatase controls the specific regulation of 
PI(4,5)P2 levels. This reveals a difference in PI(4,5)P2 localisation and levels 
upon inactivation of just one of the synaptojanin-like proteins, previously 
unseen in the Stefan et al. study in 2002.  
 
In summary, current findings and our data suggest that in cells lacking OCRL1 
function, PI(4,5)P2 does build up on internal vesicles as shown through 
increased vesicular rocketing in Lowe Syndrome fibroblasts and relocalisation 
of Annexin A2 in HeLa cells. However, we have only been able to detect this 
indirectly through localisation of Annexin A2. It would be interesting to try 
different GFP-chimeras to PI(4,5)P2 binding modules. One potential avenue 
to test would be to mutate out the basic residues in the PLCδ-PH domain, in   192 
order to make the probe more PI(4,5)P2-specific and less attracted to anionic 
environments. Another would be to try other recently discovered PI(4,5)P2 
binding modules such as the Tubby domain, or some of the aforementioned 
PDZ domains, now known to bind PI(4,5)P2 
175. Furthermore, given that 
Annexin A2 reports differences in localisation upon OCRL1 loss, it may be 
profitable to elucidate the part of Annexin A2 sequence that binds PI(4,5)P2 
and use it to probe for phosphoinositide changes. 
 
These data also suggest that the changes in PI(4,5)P2 upon OCRL1 loss of 
function manifest themselves differently depending on the cell type used. 
Given these insights, we believe that it would be profitable to test the 
localisation of PI(4,5)P2 in these polarised 3D cell cultures lacking OCRL1, or 
in fully polarised epithelial tissue of a model organism for Lowe Syndrome.  
6.2: OCRL1 and calcium signalling 
 
Loss of OCRL1 function directly increases in the level of PI(4,5)P2 substrate 
for PLC family members. Our initial hypothesis was that a simple increase in 
PI(4,5)P2 levels may be sufficient to alter the regulation of cellular calcium 
handling. However, there are many ways in which an increase in PI(4,5)P2 
could affect calcium signalling.  
 
When transiently depleting OCRL1 from HeLa cells, we demonstrated that the 
elevated level of calcium in the cytoplasm of OCRL1 depleted cells comes 
from the extracellular medium. The shared sustained calcium response to 
both thapsigargin and histamine suggests that upon depletion of OCRL1 in   193 
HeLa cells, through an as yet unknown mechanism, there is increased 
calcium-induced calcium release. These data may be explained by changes in 
the function and/or activity of store operated calcium channels at the plasma 
membrane. For instance, OCRL1 may play a role in destabilising the 
conformational coupling of the IP3 receptor and store operated calcium 
channels, through ion channel endocytosis. Endocytosis of proteins involved 
in this pathway may also affect expression levels, if they are targeted for 
destruction. Furthermore, PI(4,5)P2 may have a positive, direct role in the 
activation of store-operated calcium channels. Upon OCRL1 depletion, an 
increase in the association of IP3 receptors and store operated channels, 
and/or increased activity of store operated calcium channels may be 
responsible for changes in cellular calcium handling. The identification of 
Orai1 and STIM-1 as the elusive components of the store operated calcium 
entry mechanism provides an avenue for further investigation, especially as 
these can form heterotrimeric complexes containing TRP-C channels that are 
regulated by PI(4,5)P2 
176-178.  
 
However, when looking at the Lowe Syndrome patient fibroblasts, we 
observed different phenotypes to those seen with OCRL1 depletion in HeLa 
cells. These differences may represent the many ways that changes in 
PI(4,5)P2 levels and localisation could impact calcium signalling. Upon 
OCRL1 depletion, some increase in basal levels of IP3 in the cytoplasm may 
occur through a corresponding increase in PLC family member activity upon 
its preferred substrate, PI(4,5)P2. Conversely, IP3 levels may be increased 
due to a direct influence of OCRL1 depletion upon IP3 metabolism. As   194 
mentioned earlier, it is possible that OCRL1 functions to dephosphorylate IP3 
to IP2. These possibilities can be investigated in a number of ways, such as 
direct measurement of IP3 levels in resting cells and upon stimulation with a 
G-protein coupled PLC stimulus such as histamine or ATP. This can be 
achieved through radioactive labelling of cells with tritiated inositol, which is 
readily incorporated into the PI(4,5)P2 precursor phosphatidylinositol 
179. Also, 
monitoring of changes in localisation of the C1 domain of PKC in resting and 
stimulated cells may reveal significant differences. PI(4,5)P2 is hydrolysed to 
IP3 and DAG, so changes in the kinetics of C1 domain binding of DAG at 
membranes upon stimulation may indirectly reflect changes in IP3 levels 
within the cell. Should a difference be found, this may also represent changes 
in PKC activity, which is known to be affected by the PLC/IP3 pathway 
157, 180.  
 
Another possibility can be proposed with the knowledge that the Golgi 
apparatus has been shown to be a bona fide IP3 sensitive calcium store. 
Work in this study and published data suggests that upon OCRL1 depletion in 
some cell types, especially Lowe Syndrome fibroblasts, PI(4,5)P2 
accumulates on internal membranes, as reported by the endogenous staining 
of Annexin A2. Should these internal membranes be directly verified as 
positive for PI(4,5)P2 and derived from the Golgi apparatus, an attractive 
model can be proposed. The hydrolysis of elevated PI(4,5)P2 at the Golgi 
apparatus by PLC family members may lead to local calcium transients. The 
increased use of the Golgi apparatus as an IP3-sensitive calcium store may 
lead to an increase in total Golgi calcium concentration through 
overcompensation. Excessive re-uptake of calcium ions into stores as a result   195 
of PI(4,5)P2 elevation at Golgi membranes may be responsible for the 
observed elevation in cytoplasmic calcium in OCRL1 depleted cells. The 
dynamics of ER and Golgi calcium stores can be efficiently monitored by 
aequorins targeted specifically to these organelles 
83, 84.  
 
Another appealing possibility can be found in work analysing the role of 
calcium and membrane traffic, which may provide an explanation for the 
redistribution of Annexin A2. Calcium transients in and around the Golgi 
apparatus have been shown to affect the secretory competence of cells and 
alter the function of the Golgi apparatus itself 
181. OCRL1 depletion may cause 
Golgi apparatus dysfunction leading to errors in organisation of the secretory 
pathway and membrane traffic as a whole. This potential mechanism may 
provide another explanation for the redistribution of Annexin A2 to 
membranes and its increased presence in the medium of OCRL1 depleted 
cells.  
 
The potential increase of cytosolic calcium levels upon stimulation as a result 
of OCRL1 depletion may be another contributing factor in the change of 
Annexin A2 localisation. Cells in the experiments presented in this report are 
grown in 10% foetal calf serum, which contains many different growth factors 
capable of eliciting IP3 responses. Annexin A2 binding to PI(4,5)P2 and 
membranes has been shown to be enhanced by elevated calcium 
75, 76. It is 
possible that the redistribution of Annexin A2 is due to a change in calcium 
levels within the cytoplasm, in combination with elevated PI(4,5)P2 at 
membranes. Experiments with the ratiometric calcium indicator Fura-2 have   196 
suggested that basal cytosolic calcium is unchanged in cells depleted of 
OCRL1 (data not shown). This does not however rule out the possibility of 
changes in the flux of calcium ions through the cytoplasm. The possibility 
exists that OCRL1 depleted cells leak calcium from stores and quickly 
respond by pumping it out of the cell or back into intracellular stores. Through 
a mechanism where calcium levels are continually oscillating, in combination 
with elevation of PI(4,5)P2, the redistribution of Annexin A2 may be explained. 
Interestingly BAPTA treatment in Lowe Syndrome fibroblasts caused loss of 
Annexin A2 dependent actin rocketing, known to be a calcium-dependent 
event. Furthermore, through butan-1-ol treatment, and subsequent reduction 
of PI(4,5)P2 synthesis, the number of cells displaying spontaneous actin 
rocketing was dramatically reduced. It could be argued that this experiment 
also provides support for a role for OCRL1 with phospholipase D. 
Interestingly, previous data have shown that Synaptojanin inhibits ARF-
activated PLD 
182. It is noteworthy that in this publication, they add an 
unpublished observation that OCRL1 also inhibits ARF-activated PLD. It 
would be interesting to follow up on this finding, especially considering there is 
also a characterised PI(4,5)P2 binding site in PLD1 and PLD2 
183. A feedback 
mechanism may exist, whereby OCRL1 reduces internal PI(4,5)P2 levels in 
order to reduce PLD activity. Without OCRL1, this means there may be no 
negative regulation upon PLD activity.  
 
Annexin A2 has been found to be an inhibitor of G-protein mediated PLC 
activation 
158. It is possible that a homeostatic mechanism may be in place 
whereby upon PI(4,5)P2 elevation, Annexin A2 binds and potentially   197 
sequesters PI(4,5)P2 from PLC family members. This possibility can be 
addressed by a double depletion of Annexin A2 and OCRL1 from cells and 
analysis of the ability of the cell to respond to histamine or ATP. It would also 
be interesting to monitor IP3-mediated calcium signalling of cells over-
expressing OCRL1. It would be expected that effects on calcium signalling 
through over-expression of OCRL1 would be similar to that shown for over-
expression of synaptojanin-1, another inositol polyphosphate 5-phosphatase 
85. 
 
Overall, clear differences in cellular calcium responses to various stimuli have 
been observed, however inconsistent. All of these differences may well be 
explained through variation in cell type and the way in which cells adapt to 
loss of OCRL1 function. Our data demonstrates variability in calcium 
response in cells lacking OCRL1, which is in line with published work. The 
recent calcium signalling study by Suchy et al. in 2009 also describes a great 
deal of variation in response to bradykinin between seven different Lowe 
Syndrome fibroblast lines 
184. Full and thorough characterisation is required 
for any clear conclusions to be drawn. The studies undertaken in this thesis 
were performed using the intensiometric calcium dye, Fluo-4. Although this 
dye is efficient in measuring changes in calcium levels and finding a 
phenotype in a population of cells, it does not provide any detail on how each 
single cell responds to a stimulus. These details may prove to be vital in 
understanding the mechanism of the phenotype we observe. Problems with 
the Fluo-4 dye and population measurement of calcium signalling lie with the 
way in which cells couple to one another. What seems to be a uniform   198 
response from a population of cells is actually a mean of many different 
responses, all inter-dependent upon one another. To continue these studies, 
we believe experiments using the ratiometric calcium dye, Fura-2 will be 
helpful in understanding the differences we observe upon OCRL1 loss of 
function. This dye can be used to measure actual calcium concentrations in 
single cells and we believe would be helpful in pinning down how and why 
OCRL1 affects calcium signalling. 
 
As mentioned above, in support of our finding of changes in calcium signalling 
in Lowe Syndrome fibroblasts and HeLa cells depleted of OCRL1, a paper 
has been published demonstrating a calcium phenotype, in a different set of 
Lowe Syndrome fibroblasts, upon stimulation with bradykinin 
184. Although this 
paper shows the same trend as our data, when comparing the responses 
provided in this study, there is no statistically significant difference in 
bradykinin responses between sets of control and Lowe Syndrome fibroblasts 
(p= 0.117). A calcium phenotype in cells lacking OCRL1 function may be very 
attractive, however, the variation in responses suggest that it is more likely to 
be wishful thinking rather than a significant and consistent difference.  
 
Given our findings and the phenotype of OCRL1 depletion in polarised cell 
types, it may be interesting to assess calcium signalling in MDCK and Caco-2 
cells upon depletion of OCRL1. Interestingly, phototransduction in the 
Drosophila eye occurs utilises the PLC signalling pathway. If an OCRL1 
knock-out fly model were to be created, changes in PI(4,5)P2/IP3 signalling 
would be easily probed for. Furthermore, the epithelial tissue and   199 
development of polarity in Drosophila is well characterised and many potential 
effects of OCRL1 in polarised living tissue could be examined. The draw-back 
of studies assessing the function of OCRL1 in Drosophila is that flies do not 
express INPP5B. Therefore a genetic model for Lowe Syndrome in this 
system may not be tractable to the human condition.  
 
6.3: OCRL1, intercellular junctions and polarised cell types 
 
The most striking of our findings came with the discovery that endogenous 
OCRL1 localises to very different sites in polarised cells. Given that the 
phenotype of OCRL1 loss in humans manifests itself in polarised cell types: 
the epithelial cells of the lens and kidney as well as highly polarised neurons, 
these findings raise multiple questions. What are the specific mechanisms by 
which OCRL1 targets the new sites we observe in polarised cells? Is there a 
specific role that OCRL1 plays in polarised cells, different to non polarised 
cells? For instance, are there subtle OCRL1-regulated changes in 
phosphoinositide levels at junctions and the nucleus, and what is the purpose 
of this regulation? Are there other binding partners for OCRL1 in polarised cell 
types? Does this new localisation provide us with an insight into cellular 
processes controlled by OCRL1 that have previously been overlooked?  
 
We have many clues to some of the answers to these questions. We have 
found, through over-expression of GFP-tagged chimeras of each terminus of 
OCRL1, that elements within the carboxyl-terminal bring OCRL1 to the tight 
junction. There are plenty of candidates that may be responsible for the   200 
molecular basis of this localisation. Interestingly, as discussed before, 
members of the Rab GTPase family, key organisers of membrane traffic, have 
been shown to localise and control trafficking pathways to and from 
intercellular junctions 
88, 107. The similarity to OCRL1 change of localisation 
between polarised and non-polarised cell types exhibited by some Rab 
GTPases, such as Rab 13, is something that we would like to follow up on. 
Furthermore, these differences may prove to be clinically important, especially 
considering that Rab 14 is a binding partner of OCRL1 but not its homologue, 
INPP5B 
44, 55. As INPP5B is likely to play a compensatory role upon OCRL1 
loss, this difference in Rab 14 binding may have some clinical importance and 
contribute to the phenotypes observed in neurons and epithelia of the lens 
and kidney. 
 
Another possibility is that OCRL1 targets intercellular junctions via its 
catalytically inactive Rho-GAP domain. In previous studies, looking at the 
RhoGAP domain of OCRL1 in isolation, it was found that stimulation of 
RhoGTPases caused its localisation to the plasma membrane ruffles 
47. The 
activity of RhoGTPases such as Rho, Rac and Cdc42 is integral to the 
formation of cortical and perijunctional actin, vital to development of polarised 
epithelia and intercellular junctions 
104, 105, 160-162. In addition, OCRL1 is a 
confirmed binding partner of both Rac and Cdc42 
42, 54. The capacity of the 
RhoGAP domain to target the plasma membrane suggests that it may 
contribute to the junctional localisation of OCRL1 in polarised cell types 
47. 
Recent studies have also shown the importance of PI(4,5)P2 levels at the   201 
apical membrane of polarised cells, a process highly dependent on Cdc42 
activity 
123. 
 
OCRL1 contains three stretches of proline rich amino-acid sequence, two in 
the N-terminal and one at the very far region of C-terminal OCRL1. The 
consensus PxxP motif of proline rich motifs binds to SH3 domains of 
proteins
185, 186. Interestingly, in this thesis we identify a new binding partner of 
OCRL1, in the tight junction protein ZO-1. It is possible that the interaction 
between the two proteins is direct through this method. Crystallographic 
studies of the C-terminus of OCRL1 reveal that the RhoGAP domain targets 
the membrane interface 
54. Through manipulation of this structure in Rasmol, 
we find that the prolines in the C-terminus are in an accessible region of 
OCRL1 structure and orientate into the membrane. There are many 
experiments to do to confirm this. If we were to knock-down OCRL1 and 
recover junctional localisation with a wobbled construct, then this possibility is 
easily probed for. If OCRL1 were to target and bind ZO-1 though its 
polyproline motifs, then this recovery of localisation would fail if the proline 
residues were mutagenised out to inert residues such as alanines.  
 
Something of which we have little clues to is the observed nuclear localisation 
of OCRL1 in primary porcine RPE and MDCK cells. The mechanism by which 
OCRL1 targets the nucleus in polarised cell types is unknown. Intriguingly, the 
potential of OCRL1 to target the nucleus is realised in all cell types when the 
C-terminus of OCRL1 or the RhoGAP domain of OCRL1 are over-expressed. 
In MDCK cells, this nuclear localisation is clearer at lower density, in   202 
monolayers that are yet to fully mature. During this period, there are many 
changes in transcriptional markers and proliferation. Whether the localisation 
of OCRL1 at these time points is significant or not, we do not know. There is a 
great deal of evidence for nuclear PI(4,5)P2, with many phosphoinositide 
metabolising proteins found to localise to a fairly novel sub-nuclear sites 
called nuclear speckles 
21, 139. Upon input of the C-terminal sequence into a 
bioinformatics database (Subnuclear Compartments Prediction System 
(Version 2.0)) capable of predicting the subnuclear localisation of proteins 
from primary sequence, we find that C-terminal OCRL1 is predicted to target 
these confirmed PI(4,5)P2 sites. Admittedly, we have not observed any 
evidence for OCRL1 in nuclear speckles, but the dynamics of these 
subnuclear organelles is yet to be established, and it may be that nuclear 
speckle localisation occurs in a stimulus-dependent manner. The nuclear and 
junctional localisation of OCRL1 opens up new ideas about OCRL1 biology. 
One potential mechanism by which the phenotype of OCRL1 loss occurs is 
through changes in proliferation and differentiation markers. There is a great 
amount of signalling to and from intercellular junctions and the nucleus 
135. 
OCRL1 activity may affect transcriptional activity of different proteins integral 
to the maturation and development of epithelial monolayers. It would be very 
interesting to study the signalling pathways derived from the junction, and this 
could be probed through analysis of the promotor activity of transcription 
factors such as ZONAB, β-catenin, AP-1 and myc.  
 
Given the new localisations of OCRL1 in polarised cell types, it would be very 
interesting to find how many more interaction partners OCRL1 has, in   203 
comparison to non-polarised cells such as HeLa or COS-7. It would also be 
interesting to find out whether the interaction between OCRL1 and ZO-1 is 
direct. It is possible that OCRL1 exists in a complex with other junctional 
proteins. For instance, the closely related ZO-2 protein shares much of the 
sequence of ZO-1, and displays similar nuclear and junctional localisation to 
OCRL1 in polarised epithelia. Further biochemical studies are required for full 
understanding of OCRL1 localisation and interactions in polarised cells.  
 
It has been found previously that OCRL1 interacts with ARF family GTPases, 
ARF1 and ARF6 
43. These proteins, like Rab GTPases, control many 
vesicular trafficking and signalling pathways. ARF6 has been shown to have 
roles in organising the actin cytoskeleton in polarised cells 
187. The ARF and 
Rho GTPase families of proteins may be responsible for the dramatic 
changes in the actin cytoskeleton upon OCRL1 loss in Caco-2 and HCE 
monolayers. The links between RhoGTPases and actin are well 
characterised, and OCRL1 loss may impact the regulation of them in many 
unpredictable ways. To get a grasp on the potential effect OCRL1 loss has 
upon RhoGTPase function, a study of their activity via effector domain 
immunoprecipitations of rhotekin and PAK could be undertaken. PI(4,5)P2 
alters the function of a wide number of actin modulating proteins, such as 
WASP, Annexin A2, gelsolin and profilin 
75, 76, 100, 129, 170, 188. If OCRL1 loss 
affects the ability of ARF6 to modulate PI(4,5)P2 levels through PI(4)P5K 
activity, the regulation of their effect on the actin cytoskeleton may be altered. 
One way of studying the role of OCRL1 in actin dynamics during epithelial   204 
polarisation would be to carry out a full biochemical study of the changes in 
pools of actin filaments, similar to that carried out by Zhang et al. in 2005 
102. 
 
The formation and development of junctions occurs alongside the maturation 
and development of the epithelial monolayer. Many of the junctional proteins 
such as ZO-1 and E-cadherin organise the actin cytoskeleton during 
development. Alongside these events, RhoGTPases also control actin 
polymerisation via WASP/SCAR signalling, in part through changes in 
PI(4,5)P2 metabolism 
100, 189. All these events can now be tied in with OCRL1 
biology. Due to the high number of proteins that OCRL1 interacts with, it will 
be hard to elucidate the molecular mechanism by which the actin phenotype 
in polarised cells occurs. The temporal dynamics of all of these interactions in 
polarised cells, alongside characterisation of the new interaction partners of 
OCRL1 will give a better understanding of how the changes in actin 
cytoskeletal elements and overall cell morphology occur. 
 
6.4:General discussion and overall summary 
 
In this study, we have investigated three distinct pathways related to depletion 
of OCRL1: localisation of PI(4,5)P2, calcium handling and development of 
junctions in polarised epithelia.  
 
The key finding from this thesis comes in the finding that OCRL1 exhibits a 
different cellular localisation and behaviour in a polarised context. Previous 
work has found that OCRL1 predominantly targets the trans-Golgi network   205 
and endosomes 
52. This localisation has always been perplexing, as the 
preferred substrate for OCRL1 is highly abundant at the plasma membrane. 
These studies place OCRL1 and its substrate at the same site, but only at 
specific time-points. In MDCK cells especially, the shift of endogenous 
OCRL1 localisation from the junction and nucleus to a more regular 
perinuclear, vesicular localisation, upon increased cellular density suggests 
that phosphoinositide levels are altered dynamically at different stages of 
epithelial maturation. Interestingly, the cellular phenotype we observed in 
Caco-2 cells upon knock-down of OCRL1 matches the monolayer morphology 
seen when OCRL1 best targets intercellular junctions i.e. the cells appear to 
be arrested at the stage where OCRL1 is normally targeted to junctions. To 
unify the findings from the two polarised cell lines we have used in this thesis, 
we need to reproduce our Caco-2 monolayer phenotype in MDCK cells, by 
design of oligonucleotides against canine OCRL1. If we can reproduce our 
phenotype in MDCKs, this would also answer any questions related to off 
target effects of our OCRL1 siRNA in Caco-2 cells. Also, we have performed 
knock-down and over-expression of OCRL1 in non-polarised cells such as 
HeLa and COS-7, with no evidence for any actin phenotype. However, there 
are many, as yet uncharacterised changes in the actin cytoskeleton upon 
these treatments in polarised cell types. We believe that the reason for the 
difference in effect of OCRL1 loss between polarised and non-polarised cells 
lies in the dynamics of the cross-talk between the actin cytoskeleton and 
intercellular junctions.  
   206 
There is one key experiment that is required to ensure our phenotype occurs 
purely due to loss of OCRL1. This is a recovery experiment, replacing the loss 
of OCRL1. We need to design a set of experiments where knock-down of 
OCRL1 is achieved. Given that epithelial maturation requires the concerted 
actions of many cells in contact with one another, it would be a good idea to 
aim for a blanket recovery of the knock-down phenotype using an siRNA 
resistant OCRL1 stable cell line. If this could be achieved, we will be able to 
plan for many different experiments testing the mechanism of our observed 
phenotype, such as mutagenesis of key residues and motifs in OCRL1. 
Furthermore, it would also be interesting to see whether over-expressed 
INPP5B compensates for OCRL1 loss. 
 
It is possible that the phenotype observed in Caco-2 cells is due to changes in 
polarised membrane traffic. In the future, we would like establish whether any 
changes in polarised traffic occur upon OCRL1 loss in Caco-2 cells. This can 
be achieved through staining for different markers of polarised traffic such as 
Na/K ATPase, transferrin receptor, and podocalyxin. Another possible cause 
for the phenotype we observe upon OCRL1 depletion is a change in cell 
proliferation. The recent data showing that the ASH domain of OCRL1 binds 
to APPL1 provides one possible avenue for investigation 
54. It has been 
shown that the nucleo-cytoplasmic shuttling of APPL1 can regulate the 
proliferative ability of the cell, via Rab 5 dependent trafficking 
124. If OCRL1 
loss affects the way in which APPL1 traffics in and out of the nucleus, the 
downstream events of its nuclear activity may be affected 
190.  
   207 
The cell biology of OCRL1 depletion presented in this study concurs with 
clinical data regarding Lowe Syndrome patients. Obvious defects within the 
polarised epithelia of the lens in Lowe Syndrome patients have previously 
been demonstrated 
191. The observed increase in stimulation dependent 
cytosolic calcium upon OCRL1 depletion has very close links with other 
conditions causing inherited cataract. Calcium handling in the lens is highly 
regulated and many erroneous cellular processes shown to cause cataract 
are proposed to be due to dysregulation of calcium handling in the lens 
192. 
Also, Annexin A2 and actin are very important in the differentiation of lens 
epithelial cells to lens fibre cells, which is integral in prevention of cataract 
148, 
193. Interestingly, it has been reported that Src family members play important 
roles in cataract formation 
194. Annexin A2 has been shown to be a major 
phosphorylation target of pp60 v-Src and therefore a link between Annexin A2 
and Src in cataract formation may exist 
195, 196.  
 
Interestingly, treatment of patients that suffer from manic depression with 
valproic acid (VPA), a drug that depletes the cell of IP3, leads to chronic renal 
Fanconi Syndrome 
197. This suggests that a general defect in inositol 
phosphate metabolism may explain both observations. This link suggests 
further evidence for PI(4,5)P2-dependent mechanisms playing a role in the 
pathology of Lowe Syndrome. If a defect in calcium signalling is responsible 
for the Lowe Syndrome renal disorder then it will be interesting to test if the 
mechanism of Dent Disease is similar by analysis of the histamine and 
thapsigargin response in CLCN5 depleted cells. A separate mechanism by 
which Dent disease might have altered calcium responses is via the   208 
endocytosis of vitamin D, which causes the release of IP3-sensitive calcium 
stores. Since Dent’s disease patients have defects in endocytosis of vitamin D 
198, 199, they will have lower release of these stores, which could be tested in 
the future as a continuation of the current work.  209 
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